



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 140623**

**TO: Janet Epps-Ford**  
**Location: REM-2C05/2C18**  
**Art Unit: 1635**  
**Thursday, December 16, 2004**  
**Case Serial Number: 08/901612**

**From: Paul Schulwitz**  
**Location: Biotech-Chem Library**  
**REM-1A65**  
**Phone: (571)272-2527**

**paul.schulwitz@uspto.gov**

### **Search Notes**

Examiner Epps-Ford,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz  
Technical Information Specialist  
STIC Biotech/Chem Library  
(571)272-2527



**THIS PAGE LEFT BLANK**

**Schulwitz, Paul**

---

**From:** Epps-Ford, Janet  
**Sent:** Tuesday, December 14, 2004 2:36 PM  
**To:** Schulwitz, Paul  
**Subject:** Question regarding 08/901612...

Applicants in this case have amended the claims to add new sequence identifiers. The newly added sequences are variants of sequences already in the claims for example: original SEQ ID NO: 7 in the claim has the sequence agagatgattaggcagaggt

newly added SEQ ID NO: 58 in the claim has the sequence  
agagatgauuaggcagaggt.

SEQ ID NO: 58 definitely has a similar structure as SEQ ID NO: 7, would the search for SEQ ID NO: 7 pick up hits that read on SEQ ID NO: 58?

*Thanks,*

*Janet L. Epps-Ford, Ph.D.*

*Art Unit 1635*

*Mailbox: Remsen 2C18*

*Office: Remsen 2C05*

*Phone: 571-272-0757*

*Fax: 571-273-0757*

**THIS PAGE LEFT BLANK**

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 15, 2004, 09:10:16 ; Search time 764 Seconds  
(without alignments)  
1237.950 Million cell updates/sec

Title: US-08-901-612A-7

Perfect score: 20

Sequence: 1 agagatgattagcgagagt 20

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database :

GenEmbl.\*

1: gb\_ba.\*

2: gb\_htg.\*

3: gb\_in.\*

4: gb\_om.\*

5: gb\_ov.\*

6: gb\_pat.\*

7: gb\_ph.\*

8: gb\_pl.\*

9: gb\_pr.\*

10: gb\_ro.\*

11: gb\_sta.\*

12: gb\_sy.\*

13: gb\_un.\*

14: gb\_vi.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20	100.0	20	6	AR027809 Sequence
2	20	100.0	27	6	AX147024 Sequence
3	20	100.0	30	6	AR027810 Sequence
4	20	100.0	30	6	AR027840 Sequence
5	20	100.0	87	6	AX151115 Sequence
6	20	100.0	93	14	HPBPRECA
7	20	100.0	99	14	HPBPRECA
8	20	100.0	99	14	HPBPRECA
9	20	100.0	99	14	HPBPRECC
10	20	100.0	99	14	HPBPRECD
11	20	100.0	99	14	HPBPRECE
12	20	100.0	99	14	HPBPRECF
13	20	100.0	99	14	HPBPRECH
14	20	100.0	99	14	HPBPRECI
15	20	100.0	99	14	HPBPRECK
16	20	100.0	99	14	HPBPRECL
17	20	100.0	99	14	HPBPRECM
18	20	100.0	99	14	HPBPRECM
19	20	100.0	129	6	AX151114 Sequence

C 20	20	100.0	150	14	AF528205	Hepatitis
C 21	20	100.0	150	14	AF528206	Hepatitis
C 22	20	100.0	150	14	AF528207	Hepatitis
C 23	20	100.0	150	14	AF528208	Hepatitis
C 24	20	100.0	150	14	AF528209	Hepatitis
C 25	20	100.0	150	14	AF528210	Hepatitis
C 26	20	100.0	150	14	AF528211	Hepatitis
C 27	20	100.0	150	14	AF528212	Hepatitis
C 28	20	100.0	150	14	AF528213	Hepatitis
C 29	20	100.0	150	14	AF528214	Hepatitis
C 30	20	100.0	150	14	AF528215	Hepatitis
C 31	20	100.0	150	14	AF528216	Hepatitis
C 32	20	100.0	150	14	AF528217	Hepatitis
C 33	20	100.0	150	14	AF528218	Hepatitis
C 34	20	100.0	150	14	AF528219	Hepatitis
C 35	20	100.0	150	14	AF528220	Hepatitis
C 36	20	100.0	150	14	AF528221	Hepatitis
C 37	20	100.0	150	14	AF528222	Hepatitis
C 38	20	100.0	150	14	AF528223	Hepatitis
C 39	20	100.0	150	14	AF528224	Hepatitis
C 40	20	100.0	150	14	AF528225	Hepatitis
C 41	20	100.0	150	14	AF528226	Hepatitis
C 42	20	100.0	150	14	AF528227	Hepatitis
C 43	20	100.0	150	14	AF528228	Hepatitis
C 44	20	100.0	150	14	AF528229	Hepatitis
C 45	20	100.0	150	14	AF528230	Hepatitis
C 46	20	100.0	150	14	AF528231	Hepatitis
C 47	20	100.0	150	14	AF528232	Hepatitis
C 48	20	100.0	150	14	AF528233	Hepatitis
C 49	20	100.0	150	14	AF528234	Hepatitis
C 50	20	100.0	150	14	AF528235	Hepatitis
C 51	20	100.0	150	14	AF528236	Hepatitis
C 52	20	100.0	150	14	AF528237	Hepatitis
C 53	20	100.0	150	14	AF528238	Hepatitis
C 54	20	100.0	150	14	AF528239	Hepatitis
C 55	20	100.0	150	14	AF528240	Hepatitis
C 56	20	100.0	150	14	AF528241	Hepatitis
C 57	20	100.0	150	14	AF528242	Hepatitis
C 58	20	100.0	150	14	AF528243	Hepatitis
C 59	20	100.0	150	14	AF528244	Hepatitis
C 60	20	100.0	150	14	AF528245	Hepatitis
C 61	20	100.0	150	14	AF528246	Hepatitis
C 62	20	100.0	150	14	AF528247	Hepatitis
C 63	20	100.0	150	14	AF528248	Hepatitis
C 64	20	100.0	150	14	AF528249	Hepatitis
C 65	20	100.0	150	14	AF528250	Hepatitis
C 66	20	100.0	150	14	AF528251	Hepatitis
C 67	20	100.0	150	14	AF528252	Hepatitis
C 68	20	100.0	150	14	AF528253	Hepatitis
C 69	20	100.0	150	14	AF528254	Hepatitis
C 70	20	100.0	150	14	AF528255	Hepatitis
C 71	20	100.0	150	14	AF528256	Hepatitis
C 72	20	100.0	150	14	AF528257	Hepatitis
C 73	20	100.0	150	14	AF528258	Hepatitis
C 74	20	100.0	150	14	AF528259	Hepatitis
C 75	20	100.0	150	14	AF528260	Hepatitis
C 76	20	100.0	150	14	AF528261	Hepatitis
C 77	20	100.0	150	14	AF528262	Hepatitis
C 78	20	100.0	150	14	AF528263	Hepatitis
C 79	20	100.0	150	14	AF528264	Hepatitis
C 80	20	100.0	150	14	AF528265	Hepatitis
C 81	20	100.0	150	14	AF528266	Hepatitis
C 82	20	100.0	150	14	AF528267	Hepatitis
C 83	20	100.0	150	14	AF528268	Hepatitis
C 84	20	100.0	150	14	AF528269	Hepatitis
C 85	20	100.0	150	14	AF528270	Hepatitis
C 86	20	100.0	150	14	AF528271	Hepatitis
C 87	20	100.0	150	14	AF528272	Hepatitis
C 88	20	100.0	150	14	AF528273	Hepatitis
C 89	20	100.0	150	14	AF528274	Hepatitis
C 90	20	100.0	150	14	AF528275	Hepatitis
C 91	20	100.0	150	14	AF528276	Hepatitis
C 92	20	100.0	150	14	AF528277	Hepatitis
C 93	20	100.0	150	14	AF528278	Hepatitis
C 94	20	100.0	150	14	AF528279	Hepatitis
C 95	20	100.0	150	14	AF528280	Hepatitis
C 96	20	100.0	150	14	AF528281	Hepatitis
C 97	20	100.0	150	14	AF528282	Hepatitis
C 98	20	100.0	150	14	AF528283	Hepatitis
C 99	20	100.0	150	14	AF528284	Hepatitis
C 100	20	100.0	150	14	AF528285	Hepatitis
C 101	20	100.0	150	14	AF528286	Hepatitis
C 102	20	100.0	150	14	AF528287	Hepatitis
C 103	20	100.0	150	14	AF528288	Hepatitis
C 104	20	100.0	150	14	AF528289	Hepatitis
C 105	20	100.0	150	14	AF528290	Hepatitis
C 106	20	100.0	150	14	AF528291	Hepatitis
C 107	20	100.0	150	14	AF528292	Hepatitis
C 108	20	100.0	150	14	AF528293	Hepatitis
C 109	20	100.0	150	14	AF528294	Hepatitis
C 110	20	100.0	150	14	AF528295	Hepatitis
C 111	20	100.0	150	14	AF528296	Hepatitis
C 112	20	100.0	150	14	AF528297	Hepatitis
C 113	20	100.0	150	14	AF528298	Hepatitis
C 114	20	100.0	150	14	AF528299	Hepatitis
C 115	20	100.0	150	14	AF528300	Hepatitis
C 116	20	100.0	150	14	AF528301	Hepatitis
C 117	20	100.0	150	14	AF528302	Hepatitis
C 118	20	100.0	150	14	AF528303	Hepatitis
C 119	20	100.0	150	14	AF528304	Hepatitis
C 120	20	100.0	150	14	AF528305	Hepatitis
C 121	20	100.0	150	14	AF528306	Hepatitis
C 122	20	100.0	150	14	AF528307	Hepatitis
C 123	20	100.0	150	14	AF528308	Hepatitis
C 124	20	100.0	150	14	AF528309	Hepatitis
C 125	20	100.0	150	14	AF528310	Hepatitis
C 126	20	100.0	150	14	AF528311	Hepatitis
C 127	20	100.0	150	14	AF528312	Hepatitis
C 128	20	100.0	150	14	AF528313	Hepatitis
C 129	20	100.0	150	14	AF528314	Hepatitis
C 130	20	100.0	150	14	AF528315	Hepatitis
C 131	20	100.0	150	14	AF528316	Hepatitis
C 132	20	100.0	150	14	AF528317	Hepatitis
C 133	20	100.0	150	14	AF528318	Hepatitis
C 134	20	100.0	150	14	AF528319	Hepatitis
C 135	20	100.0	150	14	AF528320	Hepatitis
C 136	20	100.0	150	14	AF528321	Hepatitis
C 137	20	100.0	150	14	AF528322	Hepatitis
C 138	20	100.0	150	14	AF528323	Hepatitis
C 139	20	100.0	150	14	AF528324	Hepatitis
C 140	20	100.0	150	14	AF528325	Hepatitis
C 141	20	100.0	150	14	AF528326	Hepatitis
C 142	20	100.0	150	14	AF528327	Hepatitis
C 143	20	100.0	150	14	AF528328	Hepatitis
C 144	20	100.0	150	14	AF528329	Hepatitis
C 145	20	100.0	150	14	AF528330	Hepatitis
C 146	20	100.0	150	14	AF528331	Hepatitis
C 147	20	100.0	150	14	AF528332	Hepatitis
C 148	20	100.0	150	14	AF528333	Hepatitis
C 149	20	100.0	150	14	AF528334	Hepatitis
C 150	20	100.0	150	14	AF528335	Hepatitis
C 151	20	100.0	150	14	AF528336	Hepatitis
C 152	20	100.0	150	14	AF528337	Hepatitis
C 153	20	100.0	150	14	AF528338	Hepatitis
C 154	20	100.0	150	14	AF528339	Hepatitis
C 155	20	100.0	150	14	AF528340	Hepatitis
C 156	20	100.0	150	14	AF528341	Hepatitis
C 157	20	100.0	150	14	AF528342	Hepatitis
C 158	20	100.0	150	14	AF528343	Hepatitis
C 159	20	100.0	150	14	AF528344	Hepatitis
C 160	20	100.0	150	14	AF528345	Hepatitis
C 161	20	100.0	150	14	AF528346	Hepatitis
C 162	20	100.0	150	14	AF528347	Hepatitis
C 163	20	100.0	150	14	AF528348	Hepatitis
C 164	20	100.0	150	14	AF528349	Hepatitis
C 165	20	100.0	150	14	AF528350	Hepatitis
C 166	20	100.0	150	14	AF528351	Hepatitis
C 167	20	100.0	150	14	AF528352	Hepatitis

C 93 20 100.0 150 14 AF528282 Hepatitis  
 C 94 20 100.0 150 14 AF528283 Hepatitis  
 C 95 20 100.0 150 14 AF528284 Hepatitis  
 C 96 20 100.0 150 14 AF528286 Hepatitis  
 C 97 20 100.0 150 14 AF528287 Hepatitis  
 C 98 20 100.0 150 14 AF528288 Hepatitis  
 C 99 20 100.0 150 14 AF528289 Hepatitis  
 C 100 20 100.0 150 14 AF528290 Hepatitis

## ALIGNMENTS

RESULT 1  
 LOCUS AR027809 20 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 7 from patent US 5856459.  
 ACCESSION AR027809  
 VERSION AR027809.1 GI:5938629  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Frank,B.L., Roberts,P.C., Goodchild,J., Craig,J.Charles. and Mills,J.S.  
 TITLE Oligonucleotides specific for hepatitis B virus  
 JOURNAL Patent: US 5856459-A 7 05-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 100.0%; Score 20; DB 6; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 17;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGTT 20  
 Db 1 AGAGATGATTAGGCAGGTT 20

RESULT 2  
 LOCUS AX147024/c 27 bp DNA linear PAT 08-JUN-2001  
 DEFINITION Sequence 18 from Patent WO0137291.  
 ACCESSION AX147024  
 VERSION AX147024.1 GI:14346295  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.

REFERENCE 1  
 AUTHORS Weindel,K., Riedling,M. and Geiger,A.  
 TITLE Magnetic glass particles, method for their preparation and uses thereof  
 JOURNAL Patent: WO 0137291-A 18 25-MAY-2001;  
 FEATURES Roche Diagnostics GmbH (DE)  
 source Location/Qualifiers  
 1..27  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:3630"  
 /note="Synthetic oligonucleotide primer (HBV reverse)"  
 modified\_base 27  
 /note="derivatization with a p-(t-butyl)benzyl-residue"  
 /mod\_base=OTHER

## ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 17;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGTT 20  
 Db 21 AGAGATGATTAGGCAGGTT 2

RESULT 3  
 LOCUS AR027810 30 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 8 from patent US 5856459.  
 ACCESSION AR027810  
 VERSION AR027810.1 GI:5938630  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)  
 AUTHORS Frank,B.L., Roberts,P.C., Goodchild,J., Craig,J.Charles. and Mills,J.S.  
 TITLE Oligonucleotides specific for hepatitis B virus  
 JOURNAL Patent: US 5856459-A 8 05-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..30  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 17;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGTT 20  
 Db 11 AGAGATGATTAGGCAGGTT 30

RESULT 4  
 LOCUS AR027840 30 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 38 from patent US 5856459.  
 ACCESSION AR027840  
 VERSION AR027840.1 GI:5938660  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)  
 AUTHORS Frank,B.L., Roberts,P.C., Goodchild,J., Craig,J.Charles. and Mills,J.S.  
 TITLE Oligonucleotides specific for hepatitis B virus  
 JOURNAL Patent: US 5856459-A 38 05-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..30  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 17;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGTT 20  
 Db 1 AGAGATGATTAGGCAGGTT 20

## RESULT 5

AX151115/c 87 bp DNA linear PAT 22-JUN-2001  
 LOCUS AX151115  
 DEFINITION Sequence 4 from Patent WO0138498.  
 ACCESSION AX151115  
 VERSION AX151115.1 GI:14533317  
 KEYWORDS

Cloned

SOURCE	synthetic construct
ORGANISM	synthetic construct artificial sequences.
REFERENCE	1
AUTHORS	Stuyver,L., Schinazi,R., de Gendt,S., van Geyt,C., Zoulim,F., Fried,M. and Rosaau,R.
TITLE	A new genotype Of hepatitis b virus
JOURNAL	Patent: WO 0138499-A 4 31-MAY-2001;
Pharmasset, Inc. (US) ; INNOGENETICS N.V. (BE)	
FEATURES	Location/Qualifiers
source	1..87
/organism=	"synthetic construct"
/mol_type=	"unassigned DNA"
/db_xref=	"taxon:32630"
ORIGIN	
Query Match	100.0%; Score 20; DB 6; Length 87;
Best Local Similarity	100.0%; Pred. No. 16;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy	1 AGAGATGATTAGGCACAGGT 20
Db	33 AGAGATGATTAGGCACAGGT 14
RESULT 6	
HPBPRECA/c	
LOCUS	HPBPRECAA 93 bp DNA linear VRL 24-JAN-2003
DEFINITION	Hepatitis B virus variant B3 genomic RNA, entire pre-C region.
ACCESSION	D30625 D01192
VERSION	D30625.1 GI:484048
KEYWORDS	.
SOURCE	
ORGANISM	Hepatitis B virus
Hepatitis B virus	
Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.	
REFERENCE	1 (bases 1 to 93)
AUTHORS	Galibert,F., Mandart,E., Fitoussi,F., Tiollais,P. and Charnay,P.
TITLE	Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli
JOURNAL	Nature 281 (5733), 646-650 (1979)
MEDLINE	81012091
PUBMED	399327
REFERENCE	2 (bases 1 to 93)
AUTHORS	Li,J., Tong,S., Vitvitski,L., Zoulim,F. and Trepo,C.
TITLE	Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region
JOURNAL	J. Gen. Virol. 71 (Pt 9), 1993-1998 (1990)
MEDLINE	91011344
PUBMED	2212990
FEATURES	Location/Qualifiers
source	1..93
/organism=	"Hepatitis B virus"
/mol_type=	"genomic DNA"
/db_xref=	"taxon:10407"
/note=	"HBVAg-negative HBV variant B3-pre-C region"
gene	1..93
/gene=	"pre-C/C"
CDS	1..>93
/gene=	"pre-C/C"
/codon_start=	1
/product=	"pre-C/C protein"
/protein_id=	"BAA06312.1"
/db_xref=	"GI:507810"
/translation=	"MQLFLHCLIIISCTPTQASKLGLGWGMND"
variation	25
/gene=	"pre-C/C"
/note=	"Base substitution has occurred at this position in E2"
variation	37
/replaces=	"aa or ac"
/gene=	"pre-C/C"
/note=	"Base substitution has occurred at this position in pre-C region"

```

variation
92
/gene="C"
/notes="g in wt; a in virus type 1 (creates internal stop
codon)"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 8
HPBPBREC/c
LOCUS
DEFINITION Hepatitis B virus type 2precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76688
VERSION M76688.1 GI:485343
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
2
/notes="c in wt; t in virus type 2"
10..93
/gene="C"
10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA45508.1"
/db_xref="GI:485344"
/translation="MQLFHLCLIIISCPTVQASKLCGLWL"
92
/gene="C"
/notes="g in wt; a in virus type 2 (creates internal stop
codon)"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 9
HPBPBREC/c
LOCUS
DEFINITION Hepatitis B virus type 3precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76689
VERSION M76689.1 GI:485345
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
6
/notes="c in wt; t in virus type 3"
10..93
/gene="C"
10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA45509.1"
/db_xref="GI:485346"
/translation="MQLFHLCLIIISCPTVQASKLCGLWL"
58
/gene="C"
/notes="g in wt; t in virus type 3 (val to phe)"
92
/gene="C"
/notes="g in wt; a in virus type 3 (creates internal stop
codon)"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 10
HPBPBREC/c
LOCUS
DEFINITION Hepatitis B virus type 4 precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76690
VERSION M76690.1 GI:485347
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"

```

```

VERSION M76689.1 GI:485345
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
6
/notes="c in wt; t in virus type 3"
10..93
/gene="C"
10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA45509.1"
/db_xref="GI:485346"
/translation="MQLFHLCLIIISCPTVQASKLCGLWL"
58
/gene="C"
/notes="g in wt; t in virus type 3 (val to phe)"
92
/gene="C"
/notes="g in wt; a in virus type 3 (creates internal stop
codon)"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 10
HPBPBREC/c
LOCUS
DEFINITION Hepatitis B virus type 4 precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76690
VERSION M76690.1 GI:485347
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"

```



```
/db_xref="taxon:10407"
10..93
/gene="C"
CDS
10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precore protein"
/protein_id="AAA45510.1"
/db_xref="GI:485348"
/translation="MQLFHLCLIISCSCTVQASKLCLGWL"
92
/variation
/gene="C"
/notes="g in wt; a in virus type 4 (creates internal stop codon)"
95
variation
/notes="g in wt; a in virus type 4 (gly to asp)"
95
ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
|||||
DB 42 AGAGATGATTAGGCAGAGGT 23
|||||

RESULT 12
HPBPREFC/c
LOCUS
DEFINITION
Hepatitis B virus type 4 (creates internal stop codon)
99 bp DNA linear VRL 11-MAY-1994
end.
ACCESSION M76692
VERSION M76692.1 GI:485351
KEYWORDS e antigen; precore protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
Location/Qualifiers
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
10..99
/gene="C"
gene
10..99
/misc_feature
10..99
/gene="C"
variation
11
/gene="C"
/notes="t in wt; c in virus type 6 (loss of start codon)"
ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
|||||
DB 42 AGAGATGATTAGGCAGAGGT 23
|||||

RESULT 13
HPBPREFC/c
LOCUS
DEFINITION
Hepatitis B virus type 7 precore protein (pre-C region, C) gene, 5' end.
ACCESSION M76693
VERSION M76693.1 GI:485352
KEYWORDS e antigen; precore protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
```

```

COMMENT      Original source text: Hepatitis B virus DNA.
FEATURES
  source
    1..99
    /organism="Hepatitis B virus"
    /mol_type="genomic DNA"
    /db_xref="taxon:10407"
  gene
    10..93
    /gene="C"
  misc_feature
    10..93
    /gene="C"
  variation
    /product="precure protein"
    /standard_name="pre-C region note: putative CDS"
  variation
    10
    /gene="C"
    /note="a in wt; t in virus type 7 (loss of start codon)"
  variation
    14
    /gene="C"
    /note="a in wt; g in virus type 7 (gln to arg)"
  variation
    92
    /gene="C"
    /note="g in wt; a in virus type 7 (creates internal stop codon)"
  ORIGIN
    Query Match      100.0%; Score 20; DB 14; Length 99;
    Best Local Similarity 100.0%; Pred. No. 16;
    Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

  Qy  1 AGAGATGATTAGGCAGAGGT 20
      |||||
  Db  42 AGAGATGATTAGGCAGAGGT 23

  RESULT 14
  HBPBREC/C
  LOCUS
  DEFINITION
    Hepatitis B virus type 8 precure protein (pre-C region, C) gene, 5'
  end.
  ACCESSION
    M76694.1 GI:485353
  VERSION
    M76694.1
  KEYWORDS
    e antigen; precure protein; tolerogen.
  SOURCE
    Hepatitis B virus
  ORGANISM
    Viruses; Retrovirdae; Hepadnaviridae; Orthohepadnavirus.
  REFERENCE
    1 (bases 1 to 99)
  AUTHORS
    Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and
    Will,H.
  TITLE
    Prevalence and type of pre-C HBV mutants in anti-HBe positive
    carriers with chronic liver disease in a highly endemic area
  JOURNAL
    Virology 183 (2), 840-844 (1991)
  MEDLINE
    91306476
  PUBMED
    1853582
  COMMENT
    Original source text: Hepatitis B virus DNA.
  FEATURES
    source
      Location/Qualifiers
        1..99
        /organism="Hepatitis B virus"
        /mol_type="genomic DNA"
        /db_xref="taxon:10407"
      gene
        10..93
        /gene="C"
      misc_feature
        10..93
        /gene="C"
      variation
        /product="precure protein"
        /standard_name="pre-C region note: putative CDS"
      variation
        13
        /gene="C"
        /note="C in wt; t in virus type 9 (creates internal stop
        codon)"
      variation
        92
        /gene="C"
        /note="g in wt; a in virus type 9 (creates internal stop
        codon)"
      variation
        95
        /note="g in wt; a in virus type 9 (gly to asp)"
  ORIGIN
    Query Match      100.0%; Score 20; DB 14; Length 99;
    Best Local Similarity 100.0%; Pred. No. 16;
    Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

  Qy  1 AGAGATGATTAGGCAGAGGT 20
      |||||
  Db  42 AGAGATGATTAGGCAGAGGT 23

  RESULT 16
  HBPBREC/C
  LOCUS
  DEFINITION
    Hepatitis B virus type 11 precure protein (pre-C region, C) gene,
    5' end.
  ACCESSION
    M76697.1 GI:485357
  VERSION
    M76697.1
  KEYWORDS
    e antigen; precure protein; tolerogen.
  SOURCE
    Hepatitis B virus
  ORGANISM
    Hepatitis B virus

```



```

Db      42 AGAGATGATTAGGCAGAGGT 23

RESULT 19
AX151114/c
LOCUS      AX151114      129 bp      DNA      linear      PAT 22-JUN-2001
DEFINITION Sequence 3 from Patent WO0138498.
ACCESSION  AX151114
VERSION     AX151114.1 GI:14533316
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Stuyver, L., Schinazi, R., de Gendt, S., van Geyt, C., Zoulim, F.,
            Fried, M. and Rosau, R.
TITLE       A new genotype of hepatitis b virus
JOURNAL     Patent: WO 0138498-A 3 31-MAY-2001;
            Pharmasset, Inc. (US) ; INNOGENETICS N.V. (BE)
FEATURES   Location/Qualifiers
            source
            1..129
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

ORIGIN

Query Match      100.0%; Score 20; DB 6; Length 129;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AGAGATGATTAGGCAGAGGT 20
        |||||
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 20
AF528205/c
LOCUS      AF528205      150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC1123 core antigen precursor, gene, partial
            cds.
ACCESSION  AF528205
VERSION     AF528205.1 GI:32810971
KEYWORDS   .
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
            Unpublished
JOURNAL
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1123"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87556.1"
            /db_xref="GI:32810971"
            /translation="MQLFHLCLIISCSCTPVQASKLCLGWLXG"

misc_feature
CDS

ORIGIN

Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AGAGATGATTAGGCAGAGGT 20
        |||||
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 22
AF528207/c
LOCUS      AF528207      150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC20 core antigen precursor, gene, partial cds.
ACCESSION  AF528207
VERSION     AF528207.1 GI:32810975
KEYWORDS   .
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
            Unpublished
JOURNAL
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1123"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87556.1"

misc_feature
CDS

```



```

SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC470"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            misc_feature <1..>150
            /note="contains partial basal core promoter"
            misc_feature 64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||||
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 26
AF528211/c
LOCUS      AF528211      150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC335 core antigen precursor, gene, partial cds.
ACCESSION  AF528211
VERSION     AF528211.1 GI:32810981
KEYWORDS   .
SOURCE     Hepatitis B virus
ORGANISM   Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC335"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            misc_feature <1..>150
            /note="contains partial basal core promoter"
            CDS      64..>150
            /note="contains complete precore region"

```

```

/codon_start=1
/product="core antigen precursor"
/protein_id="AAP87560.1"
/db_xref="GI:32810982"
/translation="MQLFHLCLIISCSCTPTVQASKLCIGWLWG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACAGATGATTAGGCAGAGGT 20
      |||||||
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 27
AF528212/c
LOCUS      AF528212      150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC343 core antigen precursor, gene, partial cds.
ACCESSION  AF528212
VERSION     AF528212.1 GI:32810983
KEYWORDS   .
SOURCE     Hepatitis B virus
ORGANISM   Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC343"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            misc_feature <1..>150
            /note="contains partial basal core promoter"
            CDS      64..>150
            /note="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87561.1"
            /db_xref="GI:32810984"
            /translation="MQLFHLCLIISCSCTPTQASKLCIGWLWG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||||
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 28
AF528213/c
LOCUS      AF528213      150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC404 core antigen precursor, gene, partial cds.
ACCESSION  AF528213
VERSION     AF528213.1 GI:32810985
KEYWORDS   .

```



misc_feature	/mol_type="genomic DNA" /isolate="ASC1061" /isolation_source="asymptomatic HBsAg carrier" /specific_host="Homo sapiens" /db_xref="taxon:10407" /country="India" <1..>150 /note="contains partial basal core promoter"	
misc_feature	64..>150 /note="contains complete precore region; nonfunctional core antigen precursor due to mutation"	
ORIGIN		
Query Match	100.0%; Score 20; DB 14; Length 150;	
Best Local Similarity	100.0%; Pred. No. 15;	
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 AGAGATGATTAGGCAGAGGT 20 	
DB	96 AGAGATGATTAGGCAGAGGT 77 	
RESULT 33		
LOCUS	AF528218 150 bp DNA linear VRL 31-JUL-2003	
DEFINITION	Hepatitis B virus ASC339 core antigen precursor, gene, partial cds.	
ACCESSION	AF528218	
VERSION	AF528218.1 GI:32810994	
KEYWORDS		
SOURCE	Hepatitis B virus	
ORGANISM	Hepatitis B virus	
REFERENCE	Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.	
AUTHORS	Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.	
TITLE	Comparative evaluation of HBV precore and basal core promoter mutants in Indian patients with diverse clinical manifestations	
JOURNAL	Unpublished	
AUTHORS	2 (bases 1 to 150)	
TITLE	Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.	
JOURNAL	Direct Submission	
FEATURES	Submitted (11-JUL-2002) Hepatitis Division, National Institute of Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India	
source	Location/Qualifiers	
	1..150	
	/organism="Hepatitis B virus"	
	/proviral	
	/mol_type="genomic DNA"	
	/isolate="ASC339"	
	/isolation_source="asymptomatic HBsAg carrier"	
	/specific_host="Homo sapiens"	
	/db_xref="taxon:10407"	
	/country="India"	
misc_feature	<1..>150 /note="contains partial basal core promoter"	
CDS	64..>150 /note="contains complete precore region" /codon_start=1 /product="core antigen precursor" /protein_id="AAP87586.1" /db_xref="GI:32810995" /translation="MQLFHLCLIIISCSOPTVQSKLCLGLWLG"	
ORIGIN		
Query Match	100.0%; Score 20; DB 14; Length 150;	
Best Local Similarity	100.0%; Pred. No. 15;	
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 AGAGATGATTAGGCAGAGGT 20 	
DB	96 AGAGATGATTAGGCAGAGGT 77 	
RESULT 34		



```

AF528219/c
LOCUS       AF528219               150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION   Hepatitis B virus ASC295 nonfunctional core antigen precursor,
             gene, partial sequence.
ACCESSION   AF528219
VERSION     AF528219.1  GI:32810996
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
            Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
AUTHORS     Direct Submission
TITLE       Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
JOURNAL     Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC295"
                     /isolation_source="asymptomatic HBsAg carrier"
                     /specific_host="Homo sapiens"
                     /db_xref="taxon:10407"
                     /country="India"
                     <1..>150
                     /note="contains partial basal core promoter"
     misc_feature     64..>150
     misc_feature     /note="contains complete precore region; nonfunctional
                     core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 35
AF528220/c
LOCUS       AF528220               150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION   Hepatitis B virus ASC1027 nonfunctional core antigen precursor,
             gene, partial sequence.
ACCESSION   AF528220
VERSION     AF528220.1  GI:32810997
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
            Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
AUTHORS     Direct Submission
TITLE       Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
JOURNAL     Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1027"

```

```

/isolation_source="asymptomatic HBsAg carrier"
/specific_host="Homo sapiens"
/db_xref="taxon:10407"
/country="India"
<1..>150
/note="contains partial basal core promoter"
64..>150
/note="contains complete precore region; nonfunctional
core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 36
AF528221/c
LOCUS       AF528221               150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION   Hepatitis B virus ASC1029 nonfunctional core antigen precursor,
             gene, partial sequence.
ACCESSION   AF528221
VERSION     AF528221.1  GI:32810998
KEYWORDS    .
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
            Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
AUTHORS     Direct Submission
TITLE       Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
JOURNAL     Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1029"
                     /isolation_source="asymptomatic HBsAg carrier"
                     /specific_host="Homo sapiens"
                     /db_xref="taxon:10407"
                     /country="India"
                     <1..>150
                     /note="contains partial basal core promoter"
                     /note="contains complete precore region; nonfunctional
                     core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 37
AF528222/c
LOCUS       AF528222               150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION   Hepatitis B virus ASC298 core antigen precursor, gene, partial cds.
ACCESSION   AF528222
VERSION     AF528222.1  GI:32810999

```

```

KEYWORDS
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
            Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
AUTHORS    Direct Submission
TITLE      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC298"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            /notes="contains partial basal core promoter"
            <1..>150
            64..>150
            /codon_start=1
            /notes="contains complete precore region"
            /product="core antigen precursor"
            /protein_id="AAP87567.1"
            /db_xref="GI:32811000"
            /translation="MQLFHLCLIIISGCTVQASKLCLGLWLG"

misc_feature
            <1..>150
            /notes="contains partial basal core promoter"
            64..>150

CDS
            64..>150
            /codon_start=1
            /notes="contains complete precore region"
            /product="core antigen precursor"
            /protein_id="AAP87567.1"
            /db_xref="GI:32811000"
            /translation="MQLFHLCLIIISGCTVQASKLCLGLWLG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGAGGT 20
    |||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 39
AF528225/c
LOCUS      AF528225
DEFINITION Hepatitis B virus ASC1036 nonfunctional core antigen precursor,
            gene, partial sequence.
ACCESSION  AF528225
VERSION     AF528225.1 GI:32811003
KEYWORDS   Hepatitis B virus
SOURCE     Hepatitis B virus
ORGANISM   Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE  1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
            Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
AUTHORS    Direct Submission
TITLE      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1036"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            /notes="contains partial basal core promoter"
            <1..>150
            64..>150
            /notes="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
            <1..>150
            /notes="contains partial basal core promoter"
            64..>150

misc_feature
            <1..>150
            /notes="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGAGGT 20
    |||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 40
AF528226/c
LOCUS      AF528226
DEFINITION Hepatitis B virus ASC1062 nonfunctional core antigen precursor,
            gene, partial sequence.
ACCESSION  AF528226
VERSION     AF528226.1 GI:32811004
KEYWORDS   Hepatitis B virus
SOURCE     Hepatitis B virus
ORGANISM   Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE  1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
            Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
AUTHORS    Direct Submission
TITLE      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC263"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"

```

```

SOURCE      Hepatitis B virus
ORGANISM     Hepatitis B virus
REFERENCE    1 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Comparative evaluation of HBV precore and basal core promoter
              mutants in Indian patients with diverse clinical manifestations
JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Direct Submission
JOURNAL      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
              Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES     Location/Qualifiers
              1..150
                /organism="Hepatitis B virus"
                /proviral
                /mol_type="genomic DNA"
                /isolate="ASC1062"
                /isolation_source="asymptomatic HBsAg carrier"
                /specific_host="Homo sapiens"
                /db_xref="taxon:10407"
                /country="India"
              <1..>150
                /note="contains partial basal core promoter"
              64..>150
                /note="contains complete precore region; nonfunctional
                core antigen precursor due to mutation"

              misc_feature
              misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
DB 96 AGAGATGATTAGGCAGAGGT 77
    |||||

RESULT 41
AF528227/c
LOCUS      Hepatitis B virus
DEFINITION Hepatitis B virus ASC1065 nonfunctional core antigen precursor,
            gene, partial sequence.
ACCESSION  AF528227
VERSION     AF528227.1 GI:32811005
KEYWORDS
SOURCE      Hepatitis B virus
ORGANISM     Hepatitis B virus
REFERENCE    1 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Comparative evaluation of HBV precore and basal core promoter
              mutants in Indian patients with diverse clinical manifestations
JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Direct Submission
JOURNAL      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
              Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES     Location/Qualifiers
              1..150
                /organism="Hepatitis B virus"
                /proviral
                /mol_type="genomic DNA"
                /isolate="ASC1065"
                /isolation_source="asymptomatic HBsAg carrier"
                /specific_host="Homo sapiens"
                /db_xref="taxon:10407"
                /country="India"
              <1..>150
                /note="contains partial basal core promoter"
              64..>150
                /note="contains complete precore region; nonfunctional
                core antigen precursor due to mutation"

              misc_feature
              misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
DB 96 AGAGATGATTAGGCAGAGGT 77
    |||||

RESULT 42
AF528228/c
LOCUS      Hepatitis B virus
DEFINITION Hepatitis B virus ASC1072 nonfunctional core antigen precursor,
            gene, partial sequence.
ACCESSION  AF528228
VERSION     AF528228.1 GI:32811006
KEYWORDS
SOURCE      Hepatitis B virus
ORGANISM     Hepatitis B virus
REFERENCE    1 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Comparative evaluation of HBV precore and basal core promoter
              mutants in Indian patients with diverse clinical manifestations
JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Direct Submission
JOURNAL      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
              Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES     Location/Qualifiers
              1..150
                /organism="Hepatitis B virus"
                /proviral
                /mol_type="genomic DNA"
                /isolate="ASC1072"
                /isolation_source="asymptomatic HBsAg carrier"
                /specific_host="Homo sapiens"
                /db_xref="taxon:10407"
                /country="India"
              <1..>150
                /note="contains partial basal core promoter"
              64..>150
                /note="contains complete precore region; nonfunctional
                core antigen precursor due to mutation"

              misc_feature
              misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
DB 96 AGAGATGATTAGGCAGAGGT 77
    |||||

RESULT 43
AF528229/c
LOCUS      Hepatitis B virus
DEFINITION Hepatitis B virus ASC1074 nonfunctional core antigen precursor,
            gene, partial sequence.
ACCESSION  AF528229
VERSION     AF528229.1 GI:32811007
KEYWORDS
SOURCE      Hepatitis B virus
ORGANISM     Hepatitis B virus
REFERENCE    1 (bases 1 to 150)
AUTHORS      Gandhi,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.

```



```

TITLE Direct Submission
JOURNAL Submitted (11-JUL-2002) Hepatitis Division, National Institute of
Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES
  source
    1..150
    /organism="Hepatitis B virus"
    /proviral
    /mol_type="genomic DNA"
    /isolate="ASC262"
    /isolation_source="asymptomatic HBsAg carrier"
    /specific_host="Homo sapiens"
    /db_xref="taxon:10407"
    /country="India"
  misc_feature
    <1..>150
    /note="contains partial basal core promoter"
  misc_feature
    64..>150
    /note="contains complete precore region; nonfunctional
    core antigen precursor due to mutation"
  ORIGIN
    Query Match 100.0%; Score 20; DB 14; Length 150;
    Best Local Similarity 100.0%; Pred. No. 15;
    Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  QY 1 AGAGATGATTAGGCAGAGGT 20
    |||||
  Db 96 AGAGATGATTAGGCAGAGGT 77
    |||||

RESULT 47
AF528234/c
LOCUS
DEFINITION Hepatitis B virus ASC1109 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION AF528234
VERSION AF528234.1 GI:32811012
SOURCE
  ORGANISM
    Hepatitis B virus
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
  REFERENCE
    1 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Comparative evaluation of HBV precore and basal core promoter
    mutants in Indian patients with diverse clinical manifestations
    Unpublished
  JOURNAL
    2 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Direct Submission
  TITLE
    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
    Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
  FEATURES
    source
      1..150
      /organism="Hepatitis B virus"
      /proviral
      /mol_type="genomic DNA"
      /isolate="ASC1109"
      /isolation_source="asymptomatic HBsAg carrier"
      /specific_host="Homo sapiens"
      /db_xref="taxon:10407"
      /country="India"
    misc_feature
      <1..>150
      /note="contains partial basal core promoter"
    misc_feature
      64..>150
      /note="contains complete precore region; nonfunctional
      core antigen precursor due to mutation"
    ORIGIN
      Query Match 100.0%; Score 20; DB 14; Length 150;
      Best Local Similarity 100.0%; Pred. No. 15;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
    QY 1 AGAGATGATTAGGCAGAGGT 20
      |||||
  Db 96 AGAGATGATTAGGCAGAGGT 77
      |||||

RESULT 49
AF528236/c
LOCUS
DEFINITION Hepatitis B virus ASC1274 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION AF528236
VERSION AF528236.1 GI:32811015
SOURCE
  ORGANISM
    Hepatitis B virus
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
  REFERENCE
    1 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Comparative evaluation of HBV precore and basal core promoter
    mutants in Indian patients with diverse clinical manifestations
    Unpublished
  JOURNAL
    2 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Direct Submission
  TITLE
    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
    Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
  FEATURES
    source
      1..150
      /organism="Hepatitis B virus"
      /proviral
      /mol_type="genomic DNA"
      /isolate="ASC1109"
      /isolation_source="asymptomatic HBsAg carrier"
      /specific_host="Homo sapiens"
      /db_xref="taxon:10407"
      /country="India"
    misc_feature
      <1..>150
      /note="contains partial basal core promoter"
    misc_feature
      64..>150
      /note="contains complete precore region; nonfunctional
      core antigen precursor due to mutation"
    ORIGIN
      Query Match 100.0%; Score 20; DB 14; Length 150;
      Best Local Similarity 100.0%; Pred. No. 15;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
    QY 1 AGAGATGATTAGGCAGAGGT 20
      |||||
  Db 96 AGAGATGATTAGGCAGAGGT 77
      |||||

```

```

Db 96 AGAGATGATTAGGCAGAGGT 77
  RESULT 48
  AF528235/c
  LOCUS
  DEFINITION Hepatitis B virus ASC1275 core antigen precursor, gene, partial
  cds.
  ACCESSION AF528235
  VERSION AF528235.1 GI:32811013
  KEYWORDS
  SOURCE
    Hepatitis B virus
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
  REFERENCE
    1 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Comparative evaluation of HBV precore and basal core promoter
    mutants in Indian patients with diverse clinical manifestations
    Unpublished
  JOURNAL
    2 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Direct Submission
  TITLE
    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
    Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
  FEATURES
    source
      1..150
      /organism="Hepatitis B virus"
      /proviral
      /mol_type="genomic DNA"
      /isolate="ASC1275"
      /isolation_source="asymptomatic HBsAg carrier"
      /specific_host="Homo sapiens"
      /db_xref="taxon:10407"
      /country="India"
    misc_feature
      <1..>150
      /note="contains partial basal core promoter"
    CDS
      64..>150
      /note="contains complete precore region"
      /product="core antigen precursor"
      /protein_id="AAP87568.1"
      /db_xref="GI:32811014"
      /translation="MQLFHLCLIFSCSPTIQASKLCLGLWLG"
    ORIGIN
      Query Match 100.0%; Score 20; DB 14; Length 150;
      Best Local Similarity 100.0%; Pred. No. 15;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
    QY 1 AGAGATGATTAGGCAGAGGT 20
      |||||
  Db 96 AGAGATGATTAGGCAGAGGT 77
      |||||

RESULT 49
AF528236/c
LOCUS
DEFINITION Hepatitis B virus ASC1274 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION AF528236
VERSION AF528236.1 GI:32811015
SOURCE
  ORGANISM
    Hepatitis B virus
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
  REFERENCE
    1 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Comparative evaluation of HBV precore and basal core promoter
    mutants in Indian patients with diverse clinical manifestations
    Unpublished
  JOURNAL
    2 (bases 1 to 150)
    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
    Direct Submission
  TITLE
    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
    Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
  FEATURES
    source
      1..150
      /organism="Hepatitis B virus"
      /proviral
      /mol_type="genomic DNA"
      /isolate="ASC1274"
      /isolation_source="asymptomatic HBsAg carrier"
      /specific_host="Homo sapiens"
      /db_xref="taxon:10407"
      /country="India"
    misc_feature
      <1..>150
      /note="contains partial basal core promoter"
    CDS
      64..>150
      /note="contains complete precore region"
      /product="core antigen precursor"
      /protein_id="AAP87568.1"
      /db_xref="GI:32811014"
      /translation="MQLFHLCLIFSCSPTIQASKLCLGLWLG"
    ORIGIN
      Query Match 100.0%; Score 20; DB 14; Length 150;
      Best Local Similarity 100.0%; Pred. No. 15;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
    QY 1 AGAGATGATTAGGCAGAGGT 20
      |||||
  Db 96 AGAGATGATTAGGCAGAGGT 77
      |||||

```

JOURNAL Submitted (11-JUL-2002) Hepatitis Division, National Institute of Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India

FEATURES

Source 1..150 /organism="Hepatitis B virus" /proviral /mol\_type="genomic DNA" /isolate="ASC1274" /isolation\_source="asymptomatic HBsAg carrier" /specific\_host="Homo sapiens" /db\_xref="taxon:10407" /country="India" <1..>150 /note="contains partial basal core promoter" 64..>150 /note="contains complete precore region; nonfunctional core antigen precursor due to mutation"

misc\_feature

misc\_feature

ORIGIN

Query Match 100.0%; Score 20; DB 14; Length 150; Best Local Similarity 100.0%; Pred.No.15; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20

Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 50

AF528237/c

LOCUS

DEFINITION Hepatitis B virus ASC1090 core antigen precursor, gene, partial cds. 150 bp DNA linear VRL 31-JUL-2003

ACCESSION AF528237

VERSION AF528237.1

KEYWORDS GI:32811016

SOURCE

ORGANISM Hepatitis B virus

Hepatitis B virus

REFERENCE 1 (bases 1 to 150)

AUTHORS Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.

TITLE Comparative evaluation of HBV precore and basal core promoter mutants in Indian patients with diverse clinical manifestations

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 150)

AUTHORS Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.

TITLE Direct Submission

JOURNAL Submitted (11-JUL-2002) Hepatitis Division, National Institute of Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India

FEATURES

Source 1..150 /organism="Hepatitis B virus" /proviral /mol\_type="genomic DNA" /isolate="ASC1090" /isolation\_source="asymptomatic HBsAg carrier" /specific\_host="Homo sapiens" /db\_xref="taxon:10407" /country="India" <1..>150 /note="contains partial basal core promoter" 64..>150 /note="contains complete precore region" /codon\_start=1 /product="core antigen precursor" /protein\_id="AAP87569.1" /db\_xref="GI:32811017" /translation="MQFLHLCIIISCSOPTVQASKLCIGMLWG"

misc\_feature

CDS

ORIGIN

Query Match 100.0%; Score 20; DB 14; Length 150; Best Local Similarity 100.0%; Pred.No.15; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Search completed: December 15, 2004, 16:04:28  
Job time : 764 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 15, 2004, 09:10:16 ; Search time 181 Seconds  
(without alignments)  
580.047 Million cell updates

**Title:** US-08-901-612A-7

Perfect score: 2

Sequence: 1 agagatgattagqcaagqgt 20

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4134886 segs. 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB geo length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match of

100% processing: Minimum Match 0%  
Maximum Match 100%

**Listing first 100 summaries**

Database :

Database : N Genesec 23Sep04:\*

```
1: _ geneseqn1980s:*
```

2: geneseqn1990s:\*

3: geneseqn2008:\*

4: geneseqn2001as:\*

5: geneseqn2001bs:\*

6: geneseqn2002as:\*

7: geneseqn2002bs:\*

8: geneseqn2003as:\*

9: geneseqn2003bs:\*

10: geneseqn2003cs:

11: geneseqn2003ds:

12: geneseqn2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Query			DB	ID	Description
	Score	Match	Length			
1	20	100.0	20	2	AAT72560	Hepatitis
2	20	100.0	20	2	AAT72561	Hepatitis
3	20	100.0	25	3	AA88131	SP6 RNA p
4	20	100.0	27	4	AAT25416	Reverse P
5	20	100.0	30	2	AAT72562	Hepatitis
6	20	100.0	30	2	AAT72614	Hepatitis
7	20	100.0	30	2	AAT72563	Hepatitis
8	20	100.0	30	2	AAT72615	Hepatitis
9	20	100.0	39	10	ADC64742	Hepatitis
10	20	100.0	64	3	AA88130	SP6 RNA p
11	20	100.0	87	4	AAD09094	Hepatitis
12	20	100.0	129	4	AAD09093	Hepatitis
13	20	100.0	250	6	ABK29867	Wild type
14	20	100.0	639	6	AD27422	Hepatitis
15	20	100.0	639	6	AD31509	Hepatitis
16	20	100.0	646	12	ADL56756	Hepatitis
17	20	100.0	655	2	AAQ47014	HBV (adw)
18	20	100.0	655	2	AAH75649	Precore/c
19	20	100.0	655	4	AAH77569	HBV genot
20	20	100.0	655	4	AAH77568	HBV genot
21	20	100.0	655	4	AAH77574	HBV genot

C 95 19 95.0 22 2 AAT73885  
 C 96 19 95.0 87 2 AAT05545  
 C 97 19 95.0 94 2 AAT73892  
 C 98 19 95.0 94 2 AAT73890  
 C 99 19 95.0 94 2 AAT73887  
 C 100 19 95.0 94 2 AAT73889

## ALIGNMENTS

RESULT 1  
 AAT72560  
 ID AAT72560 standard; DNA; 20 BP.  
 XX AC  
 XX AC  
 XX AC  
 DT 03-SEP-1997 (first entry)  
 DE Hepatitis B virus RNA antisense oligonucleotide HBV43a.  
 XX KW  
 XX KW  
 XX OS  
 XX Synthetic.

Key Location/Qualifiers  
 misc\_feature 1..20  
 /tag= a  
 /note= "Internucleotide linkages are phosphorothioate"

WO9639502-A1.  
 12-DEC-1996.

04-JUN-1996; 96WO-EP002432.

06-JUN-1995; 95US-00467397.

(HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 (HYBR-) HYBRIDON INC.

Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;  
 Roberts NA, Roberts PC, Slade A;  
 WPI; 1997-043124/04.

Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -  
 used in the detection and treatment of HBV infection.

Claim 1; Page 12; 81pp; English.

The present sequence represents a synthetic oligonucleotide HBV43a which  
 is complementary to a portion of the hepatitis B virus (HBV) RNA. The  
 antisense oligonucleotide may be used to detect the presence of HBV in a  
 sample. The antisense oligonucleotide, and oligonucleotides containing a  
 sequence which is complementary to at least two non-contiguous regions  
 of an HBV nucleic acid, may be used for inhibiting HBV replication in a  
 cell or for the treatment of HBV infection.

Sequence 20 BP; 7 A; 1 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 5.8;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACAGATGATTAGCAGAGGT 20  
 DB 1 ACAGATGATTAGCAGAGGT 20

RESULT 2  
 AAT72561  
 ID AAT72561 standard; DNA; 20 BP.

XX AAT72561;  
 AC 03-SEP-1997 (first entry)  
 DT Hepatitis B virus RNA antisense oligonucleotide HBV43Ma.  
 DE HBV; HBV infection; inhibition; replication; ss.  
 XX KW  
 XX KW  
 XX OS  
 XX Synthetic.  
 PH Key Location/Qualifiers  
 FT misc\_feature 1..20  
 /tag= a  
 /note= "Internucleotide linkages are phosphorothioate"  
 FT misc\_RNA 1..10  
 /tag= b  
 /note= "2'-OME RNA"  
 FT modified\_base 1  
 /tag= c  
 /mod\_base= OTHER  
 /note= "2'-O-methyladenosine"  
 FT modified\_base 2  
 /tag= d  
 /mod\_base= gm  
 FT modified\_base 3  
 /tag= e  
 /mod\_base= OTHER  
 /note= "2'-O-methyladenosine"  
 FT modified\_base 4  
 /tag= f  
 /mod\_base= gm  
 FT modified\_base 5  
 /tag= g  
 /mod\_base= OTHER  
 /note= "2'-O-methyladenosine"  
 FT modified\_base 6  
 /tag= h  
 /mod\_base= um  
 FT modified\_base 7  
 /tag= i  
 /mod\_base= gm  
 FT modified\_base 8  
 /tag= j  
 /mod\_base= OTHER  
 /note= "2'-O-methyladenosine"  
 FT modified\_base 9  
 /tag= k  
 /mod\_base= um  
 FT modified\_base 10  
 /tag= l  
 /mod\_base= um  
 PN WO9639502-A1.  
 XX 12-DEC-1996.  
 PD 04-JUN-1996; 96WO-EP002432.  
 PF 06-JUN-1995; 95US-00467397.  
 PR (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 PA (HYBR-) HYBRIDON INC.  
 PI Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;  
 PI Roberts NA, Roberts PC, Slade A;  
 XX WPI; 1997-043124/04.  
 DR Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -  
 used in the detection and treatment of HBV infection.  
 XX Claim 1; Page 12; 81pp; English.



XX The present sequence represents a synthetic oligonucleotide HBV43Ma which  
CC is complementary to a portion of the hepatitis B virus (HBV) RNA. The  
CC antisense oligonucleotide may be used to detect the presence of HBV in a  
CC sample. The antisense oligonucleotide, and oligonucleotides containing a  
CC sequence which is complementary to at least two non-contiguous regions  
CC of an HBV nucleic acid, may be used for inhibiting HBV replication in a  
CC cell or for the treatment of HBV infection  
XX  
SQ Sequence 20 BP; 7 A; 1 C; 8 G; 1 T; 3 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 20;  
Best Local Similarity 85.0%; Pred. No. 5.8;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
Db 1 AGAGAUGAUUAGGCAGAGGT 20

RESULT 3  
AAA88131  
ID AAA88131 standard; RNA; 25 BP.

XX  
AC AAA88131;  
XX  
DT 15-SEP-2003 (revised)  
DT 13-DEC-2000 (first entry)  
XX  
DE SP6 RNA polymerase promoter sequence SEQ ID NO:3.  
XX  
KW Hepatitis B virus; HBV; detection; probe; promoter; ss.

XX Enterobacteria phage SP6.

XX US6100024-A.

PN PD 08-AUG-2000.

XX PF 08-FEB-1991; 91US-00652888.

XX PR 08-FEB-1991; 91US-00652888.

XX (PROM-) PROMEGA CORP.

PA Hudson GR, Dimond RL, Schumm JW;

PI WPI; 2000-542420/49.

XX Single-stranded DNA probe comprising an anti-target nucleic acid, a (-)-  
PT promoter segment linked to the anti-target segment and a reporter  
PT segment, useful for detecting a target nucleic acid, e.g. hepatitis B  
PT virus, in a sample.

XX Example 3; Col 19-20; 18pp; English.

XX The present invention describes a single-stranded DNA probe (I)  
CC comprising in 3'-5' order, an anti-target nucleic acid segment, a (-)-  
CC promoter segment functionally linked to the anti-target segment, and a  
CC nucleic acid reporter segment. The probe is useful for testing a sample  
CC of a nucleic acid for the presence of a target nucleic acid segment or  
CC for detecting a target nucleic acid segment in a sample. The probe may  
CC also be used for the detection of hepatitis B virus (HBV). The present  
CC sequence represents a bacteriophage SP6 RNA polymerase promoter sequence  
CC which is used in an example from the present invention. (Updated on 15-  
CC SEP-2003 to standardise OS field)

XX Sequence 25 BP; 10 A; 1 C; 10 G; 0 T; 4 U; 0 Other;

Query Match 100.0%; Score 20; DB 3; Length 25;  
Best Local Similarity 80.0%; Pred. No. 5.9;  
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
Db 1 AGAGAUGAUUAGGCAGAGGT 20  
RESULT 4  
AAH25416/c  
ID AAH25416 standard; DNA; 27 BP.  
XX  
AC AAH25416;  
XX  
DT 22-AUG-2001 (first entry)  
XX  
DE Reverse PCR primer used to amplify a HBV DNA fragment.  
XX  
KW Magnetic glass particle; nucleic acid purification; PCR primer; ss.  
XX  
OS Hepatitis B virus.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 27  
FT /tag= a  
FT /note= "derivatisation with a p-(t-butyl)benzyl-residue"  
XX  
PN WO200137291-A1.  
XX  
XX 25-MAY-2001.  
XX  
PP 17-NOV-2000; 2000WO-EP011459.  
XX  
PR 17-NOV-1999; 99EP-00122853.  
PR 12-MAY-2000; 2000EP-00110165.  
XX  
PA (HOFF) ROCHE DIAGNOSTICS GMBH.  
XX  
PI Weindel K, Riedling M, Geiger A;  
XX  
XX WPI; 2001-381247/40.  
XX  
PT Novel composition of magnetic glass particles for purification of DNA or  
XX RNA in automated processes.  
XX  
PS Example 7; Page 99; 105pp; English.

XX The specification describes a composition of magnetic glass particles,  
CC which contain at least one magnetic object with a mean diameter between 5  
CC -500 nm. The composition is useful for the purification of nucleic acids.  
CC The composition can be used to process large quantities of nucleic acid  
CC samples, because it does not involve the particles being centrifuged or  
CC the fluids being drawn through glass fiber filters. PCR primers AAH25415-  
CC 16 were used to amplify HBV DNA fragments. The amplified fragment can be  
CC purified using the method of the invention  
XX  
SQ Sequence 27 BP; 5 A; 10 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 4; Length 27;  
Best Local Similarity 100.0%; Pred. No. 6;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
Db 21 AGAGATGATTAGGCAGAGGT 2

RESULT 5  
AAT72562  
ID AAT72562 standard; DNA; 30 BP.  
XX  
AC AAT72562;

XX  
DT 03-SEP-1997 (first entry)  
XX  
DE Hepatitis B virus RNA antisense oligonucleotide HBV88b.

```

XX HBV; HBV infection; inhibition; replication; ss.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..30
XX /*tag= a
XX /note= "Internucleotide linkages are phosphorothioate"
XX
XX WO9639502-A1.
XX
XX 12-DEC-1996.
XX
XX 04-JUN-1996; 96WO-EP002432.
XX
XX 06-JUN-1995; 95US-00467397.
XX
XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX (HYBR-) HYBRIDON INC.
XX
XX Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;
XX Roberts NA, Roberts PC, Slade A;
XX WPI; 1997-043124/04.
XX
XX Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -
XX used in the detection and treatment of HBV infection.
XX
XX Claim 1; Page 12; 81pp; English.
XX
XX The present sequence represents a synthetic oligonucleotide HBV88b which
XX is complementary to a portion of the hepatitis B virus (HBV) RNA. The
XX antisense oligonucleotide may be used to detect the presence of HBV in a
XX sample. The antisense oligonucleotide, and oligonucleotides containing a
XX sequence which is complementary to at least two non-contiguous regions
XX of an HBV nucleic acid, may be used for inhibiting HBV replication in a
XX cell or for the treatment of HBV infection
XX
XX Sequence 30 BP; 12 A; 3 C; 10 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 2; Length 30;
XX Best Local Similarity 100.0%; Pred. No. 6;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AGAGATGATTAGGCAGAGGT 20
XX Db 11 AGAGATGATTAGGCAGAGGT 30
XX
XX RESULT 6
XX AAT72614
XX ID AAT72614 standard; DNA; 30 BP.
XX
XX AC AAT72614;
XX
XX XX
XX DT 04-SEP-1997 (first entry)
XX
XX DE Hepatitis B virus RNA antisense oligonucleotide HBV-87b.
XX
XX KW HBV; HBV infection; inhibition; replication; ss.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..30
XX /*tag= a
XX /note= "Internucleotide linkages are phosphorothioate"
XX
XX WO9639502-A1.
XX
XX 12-DEC-1996.
XX
XX

```

```

PF 04-JUN-1996; 96WO-EP002432.
XX
XX 06-JUN-1995; 95US-00467397.
XX
XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX (HYBR-) HYBRIDON INC.
XX
XX Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;
XX Roberts NA, Roberts PC, Slade A;
XX WPI; 1997-043124/04.
XX
XX Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -
XX used in the detection and treatment of HBV infection.
XX
XX Claim 5; Page 15; 81pp; English.
XX
XX The present sequence represents a synthetic oligonucleotide HBV-87b which
XX contains a sequence which is complementary to at least two non-contiguous
XX regions of a hepatitis B virus (HBV) nucleic acid. The antisense
XX oligonucleotide may be used to detect the presence of HBV in a sample.
XX The antisense oligonucleotide, and oligonucleotides complementary to a
XX portion of the HBV RNA, may be used for inhibiting HBV replication in a
XX cell or for the treatment of HBV infection
XX
XX Sequence 30 BP; 10 A; 2 C; 12 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 2; Length 30;
XX Best Local Similarity 100.0%; Pred. No. 6;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AGAGATGATTAGGCAGAGGT 20
XX Db 1 AGAGATGATTAGGCAGAGGT 20
XX
XX RESULT 7
XX AAT72563
XX ID AAT72563 standard; DNA; 30 BP.
XX
XX AC AAT72563;
XX
XX XX
XX DT 03-SEP-1997 (first entry)
XX
XX DE Hepatitis B virus RNA antisense oligonucleotide HBV88Mb.
XX
XX KW HBV; HBV infection; inhibition; replication; ss.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..30
XX /*tag= a
XX /note= "Internucleotide linkages are phosphorothioate"
XX
XX misc_RNA 1..20
XX /*tag= b
XX /note= "2'-Ome RNA"
XX
XX modified_base 1
XX /*tag= c
XX /mod_base= gm
XX
XX modified_base 2
XX /*tag= d
XX /mod_base= OTHER
XX
XX modified_base 3
XX /note= "2'-O-methyladenosine"
XX
XX modified_base 4
XX /*tag= e
XX /mod_base= cm
XX
XX modified_base 5
XX /*tag= f
XX /mod_base= OTHER
XX
XX modified_base 5
XX /note= "2'-O-methyladenosine"
XX
XX /*tag= g
XX

```



```

FT modified_base 10
FT FT /*tag= 1
XX FT /mod_base= um
XX PN
XX WO9639502-A1.
XX
XX 12-DEC-1996.
XX
XX 04-JUN-1996; 96WO-EP002432.
XX
XX 06-JUN-1995; 95US-00467397.
XX
XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX (HYBR-) HYBRIDON INC.
XX
XX Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;
XX Roberts NA, Roberts PC, Slade A;
XX
XX WPI; 1997-043124/04.
XX
XX Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -
XX used in the detection and treatment of HBV infection.
XX
XX Claim 5; Page 15; 81pp; English.
XX
XX The present sequence represents a synthetic oligonucleotide HBV-87Mb
XX which contains a sequence which is complementary to at least two non-
XX contiguous regions of a hepatitis B virus (HBV) nucleic acid. The
XX antisense oligonucleotide may be used to detect the presence of HBV in a
XX sample. The antisense oligonucleotide, and oligonucleotides complementary
XX to a portion of the HBV RNA, may be used for inhibiting HBV replication
XX in a cell or for the treatment of HBV infection
XX
XX Sequence 30 BP; 10 A; 2 C; 12 G; 3 T; 3 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 2; Length 30;
XX Best Local Similarity 85.0%; Pred. NO. 6;
XX Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AGAGATGATTAGGCAGAGGT 20
DB |||||:|||||
1 AGAGAUGAUUAGGCAGAGGT 20
RESULT 9
ADC64742/c
ID ADC64742 standard; RNA; 39 BP.
XX
XX ADC64742;
XX
XX 18-DEC-2003 (first entry)
XX
XX Hepatitis B virus DNA polymerase related RNA oligonucleotide.
XX
XX screening; antiviral; hepatitis B virus; HBV; DNA polymerase; ss.
XX
XX Synthetic.
XX
XX Hepatitis B virus.
XX
XX KR2002007891-A.
XX
XX 29-JAN-2002.
XX
XX 19-JUL-2000; 2000KR-00041420.
XX
XX 19-JUL-2000; 2000KR-00041420.
XX
XX (MOGA-) MOGAM BIOTECHNOLOGY INST.
XX (VIRO-) VIROGEN CO LTD.
XX
XX Ji HJ, Jung SI, Kim YC, Min MG, Ryu WS, Yoon GS;
XX WPI; 2003-309015/30.

```

```

XX
XX Screening of antiviral agents by protein-priming activity of hepatitis B
XX virus DNA polymerase.
XX
XX Disclosure; Page 12; 13pp; Korean.
XX
XX The present invention describes a method of screening for an antiviral
XX agent by the protein-priming activity of hepatitis B virus (HBV) DNA
XX polymerase. Also described is developing an antiviral agent with a high
XX selectivity to HBV which can be used for high-throughput screening. The
XX present sequence represents an RNA oligonucleotide which is used in the
XX exemplification of the present invention.
XX
XX Sequence 39 BP; 5 A; 13 C; 3 G; 0 T; 18 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 10; Length 39;
XX Best Local Similarity 100.0%; Pred. No. 6.2;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AGAGATGATTAGGCAGAGGT 20
DB |||||:|||||
27 AGAGATGATTAGGCAGAGGT 8
RESULT 10
AAA88130/c
ID AAA88130 standard; DNA; 64 BP.
XX
XX AAA88130;
XX
XX 15-SEP-2003 (revised)
XX 13-DEC-2000 (first entry)
XX
XX SP6 RNA polymerase promoter sequence SEQ ID NO:2.
XX
XX Hepatitis B virus; HBV; detection; probe; promoter; ds.
XX
XX Enterobacteria phage SP6.
XX
XX US6100024-A.
XX
XX 08-AUG-2000.
XX
XX 08-FEB-1991; 91US-00652888.
XX
XX 08-FEB-1991; 91US-00652888.
XX
XX (PROM-) PROMEGA CORP.
XX
XX Hudson GR, Dimond RL, Schumm JW;
XX WPI; 2000-542420/49.
XX
XX Single-stranded DNA probe comprising an anti-target nucleic acid, a (-)-
XX promoter segment linked to the anti-target segment and a reporter
XX segment, useful for detecting a target nucleic acid, e.g. hepatitis B
XX virus, in a sample.
XX
XX Example 3; Col 19-20; 18pp; English.
XX
XX The present invention describes a single-stranded DNA probe (I)
XX comprising in 3'-5' order, an anti-target nucleic acid segment, a (-)-
XX promoter segment functionally linked to the anti-target segment, and a
XX nucleic acid reporter segment. The probe is useful for testing a sample
XX of a nucleic acid for the presence of a target nucleic acid segment or
XX for detecting a target nucleic acid segment in a sample. The probe may
XX also be used for the detection of hepatitis B virus (HBV). The present
XX sequence represents a bacteriophage SP6 RNA polymerase promoter sequence
XX which is used in an example from the present invention. (Updated on 15-
XX SEP-2003 to standardise OS field)
XX
XX Sequence 64 BP; 14 A; 22 C; 4 G; 24 T; 0 U; 0 Other;
XX

```

Query Match 100.0%; Score 20; DB 3; Length 64;  
 Best Local Similarity 100.0%; Pred. No. 6.6;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 23 AGAGATGATTAGGCAGAGGT 4  
 |||||

RESULT 11  
 AAD09094/c  
 ID AAD09094 standard; DNA; 87 BP.  
 XX  
 AC AAD09094;  
 XX  
 DT 04-SEP-2001 (first entry)  
 XX  
 DE Hepatitis B virus FRI strain genotype G HBeAg DNA fragment.  
 XX  
 KW HBV genotype G; precore; HbPol; polymerase; envelope protein; preS1;  
 KW preS2; surface antigen; HBeAg; HBx protein; vaccine; HBeAg;  
 KW liver disease; hepatitis; liver cancer; HBeAg; core antigen; ds.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO200138498-A2.  
 XX  
 PD 31-MAY-2001.  
 XX  
 PF 21-NOV-2000; 2000WO-US032108.  
 XX  
 PR 24-NOV-1999; 99US-0167206P.  
 XX  
 PA (PHAR-) PHARMASSET INC.  
 PA (INNO-) INNOGENETICS NV.  
 XX  
 PI Stuyver L, Schinazi R, De Gendt S, Van Geyt C, Zoulim F, Fried M;  
 PI Rossau R;  
 XX  
 DR WPI; 2001-367676/38.  
 XX  
 PT Novel hepatitis B virus genotype G, nucleic acids encoding virus,  
 PT polypeptides encoded by nucleic acids, useful for preparing vaccine to  
 PT treat or prevent the hepatitis B virus genotype G infection in a subject.  
 XX  
 PS Claim 6; Page 57; 84pp; English.  
 XX  
 CC The present invention relates to hepatitis B virus (HBV) strain FRI,  
 CC genotype G DNA encoding PreCore/Core protein, HbPol, envelope (PreS1,  
 CC PreS2 and surface antigen HBeAg) and HBx proteins. HBV genotype G nucleic  
 CC acids and polypeptides are useful for diagnosing, prognosing and treating  
 CC infections caused by HBV genotype G. They can be used in a vaccine to  
 CC treat or prevent HBV genotype G infection. The HBV genotype G derived  
 CC nucleic acids and antibodies are useful for detecting HBV genotype G in a  
 CC sample or diagnosis of HBV genotype G infection. The presence of HBV  
 CC genotype G statistically correlates with the presence of liver damage  
 CC and/or liver cancer in the subject. The HBV genotype G core insert  
 CC peptide encoding nucleic acid is useful for designing monitoring assays  
 CC to study and predict the evolution of anti-HBe and anti-HBc antibodies  
 CC and HBsAg (genotype G e antigen) in patients infected with HBV. The  
 CC antibodies or antigens of HBV genotype G are useful for identifying a  
 CC stage of liver disease caused by HBV genotype G. The present sequence is  
 CC a hepatitis B virus (HBV) strain FRI, genotype G DNA fragment encoding e  
 CC antigen (HBeAg)  
 XX  
 SQ Sequence 87 BP; 14 A; 24 C; 17 G; 32 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 4; Length 87;  
 Best Local Similarity 100.0%; Pred. No. 6.8;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||

RESULT 12  
 AAD09093/c  
 ID AAD09093 standard; DNA; 129 BP.  
 XX  
 AC AAD09093;  
 XX  
 DT 04-SEP-2001 (first entry)  
 XX  
 DE Hepatitis B virus FRI strain genotype G DNA fragment #1.  
 XX  
 KW HBV genotype G; precore; HbPol; polymerase; envelope protein; preS1;  
 KW preS2; surface antigen; HBeAg; HBx protein; vaccine; liver disease;  
 KW hepatitis; liver cancer; HBeAg; core antigen; ds.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO200138498-A2.  
 XX  
 PD 31-MAY-2001.  
 XX  
 PF 21-NOV-2000; 2000WO-US032108.  
 XX  
 PR 24-NOV-1999; 99US-0167206P.  
 XX  
 PA (PHAR-) PHARMASSET INC.  
 PA (INNO-) INNOGENETICS NV.  
 XX  
 PI Stuyver L, Schinazi R, De Gendt S, Van Geyt C, Zoulim F, Fried M;  
 PI Rossau R;  
 XX  
 DR WPI; 2001-367676/38.  
 XX  
 PT Novel hepatitis B virus genotype G, nucleic acids encoding virus,  
 PT polypeptides encoded by nucleic acids, useful for preparing vaccine to  
 PT treat or prevent the hepatitis B virus genotype G infection in a subject.  
 XX  
 PS Claim 5; Page 57; 84pp; English.  
 XX  
 CC The present invention relates to hepatitis B virus (HBV) strain FRI,  
 CC genotype G DNA encoding PreCore/Core protein, HbPol, envelope (PreS1,  
 CC PreS2 and surface antigen HBeAg) and HBx proteins. HBV genotype G nucleic  
 CC acids and polypeptides are useful for diagnosing, prognosing and treating  
 CC infections caused by HBV genotype G. They can be used in a vaccine to  
 CC treat or prevent HBV genotype G infection. The HBV genotype G derived  
 CC nucleic acids and antibodies are useful for detecting HBV genotype G in a  
 CC sample or diagnosis of HBV genotype G infection. The presence of HBV  
 CC genotype G statistically correlates with the presence of liver damage  
 CC and/or liver cancer in the subject. The HBV genotype G core insert  
 CC peptide encoding nucleic acid is useful for designing monitoring assays  
 CC to study and predict the evolution of anti-HBe and anti-HBc antibodies  
 CC and HBsAg (genotype G e antigen) in patients infected with HBV. The  
 CC antibodies or antigens of HBV genotype G are useful for identifying a  
 CC stage of liver disease caused by HBV genotype G. The present sequence is  
 CC a hepatitis B virus (HBV) strain FRI, genotype G DNA fragment  
 XX  
 SQ Sequence 129 BP; 25 A; 32 C; 26 G; 46 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 4; Length 129;  
 Best Local Similarity 100.0%; Pred. No. 7.1;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||

RESULT 13  
 ABK29867/c  
 ID ABK29867 standard; DNA; 250 BP.  
 XX

AC ABK29867;  
 XX  
 XX  
 XX 23-APR-2002 (first entry)  
 XX  
 XX Wild type hepatitis B virus core promoter.  
 DE  
 XX Cyclin D1 promoter; CD40L promoter; hepatitis B virus promoter;  
 KW HBV promoter; vancomycin-resistant enterococci promoter; VRE promoter;  
 KW vanH promoter; androgen receptor promoter; AR promoter;  
 KW human epidermal growth factor receptor 2 promoter; her2 promoter;  
 KW beta lactamase promoter; Bla promoter; transgene; cancer; breast cancer;  
 KW colon cancer; immunological disorder; prostate cancer; cytostatic;  
 KW autoimmune disease; HBV pre-S promoter; HBV-X promoter;  
 KW Enterococcus infection; immunosuppressive; antibacterial; antiviral;  
 KW gene expression modulator; multiple sclerosis; MS;  
 KW chronic hepatic insufficiency; cirrhosis; hepatocellular carcinoma;  
 KW systematic lupus erythematosus; SLE; graft-vs-host disease; GVHD;  
 KW familial adenomatous polyposis; rheumatoid arthritis; PCR; primer;  
 KW transgenic; ds.  
 XX  
 XX Hepatitis B virus.  
 XX  
 XX  
 XX Key Location/Qualifiers  
 FH misc\_binding 61..72  
 FT /\*tag= a  
 FT /bound\_moiety= "HNF4"  
 FT /notes="Hepatocyte nuclear factor 4"  
 FT misc\_binding 80..90  
 FT /\*tag= b  
 FT /bound\_moiety= "HNF3-1"  
 FT /notes="Hepatocyte nuclear factor 3-1"  
 FT misc\_binding 115..126  
 FT /\*tag= c  
 FT /bound\_moiety= "HNF3-2"  
 FT /notes="Hepatocyte nuclear factor 3-2"  
 XX  
 PN WO200194600-A2.  
 XX  
 XX 13-DEC-2001.  
 XX  
 XX 06-JUN-2001; 2001WO-US018343.  
 XX  
 XX 06-JUN-2000; 2000US-0209549P.  
 XX  
 XX (GENE-) GENELABS TECHNOLOGIES INC.  
 XX  
 XX Kim JP, Starr DB, Tam AW, Laurance ME, Michelotti EF;  
 PI Velligan MD, Latour DR, Thomas RL, Kongpachith A, Sheppard LT;  
 PI Lim MY, Bruice TW;  
 XX  
 XX WPI; 2002-130595/17.  
 DR  
 XX  
 XX New nucleic acid regulatory sequences, which are able to regulate  
 PT expression of a gene operably linked to a promoter, useful for regulating  
 PT the expression of transgenes and for treating e.g., cancer and  
 PT immunological diseases.  
 XX  
 XX Disclosure; Fig 1A; 95pp; English.  
 PS  
 XX  
 XX The invention describes an isolated nucleic acid regulatory sequence for  
 CC a cyclin D1 promoter, a CD40L promoter, vancomycin-resistant enterococci  
 CC (VRE) promoter, an HBV promoter, androgen receptor (AR) promoter, Human  
 CC epidermal growth factor receptor 2 (HER2) promoter, or a beta lactamase  
 CC (Bla) promoter. Transcription regulatory sequences may be used to  
 CC regulate expression of the endogenous, autologous or heterologous genes  
 CC operably linked to the promoter, and may be incorporated into  
 CC heterologous nucleic acid constructs for use in regulated expression of  
 CC transgenes. Regulated expression of cyclin D1 can be used in cancer  
 CC therapies, such as breast, colon or pancreatic cancers and familial  
 CC adenomatous polyposis. Regulation of the activity of CD40L gene promoter  
 CC may be used in the treatment of immunological disorders, such as  
 CC autoimmune diseases e.g. multiple sclerosis (MS), systematic lupus  
 CC erythematosus (SLE), graft-vs-host disease (GVHD) and rheumatoid

CC arthritis. Regulated expression of genes under the control of the HBV  
 CC (hepatitis B)-specific core, pre-S and X promoters can be used in the  
 CC therapy of HBV disease, chronic hepatic insufficiency, cirrhosis,  
 CC hepatocellular carcinoma, and in the regulated expression of liver cell-  
 CC specific genes. Regulated expression of the vanH gene promoter can be  
 CC used in treatment of Enterococcus infection, while regulated expression  
 CC of the androgen receptor gene can be used in the treatment of prostate  
 CC cancer. This sequence represents the hepatitis B virus core promoter the  
 CC regulatory regions of which are described in the method of the invention  
 XX  
 SQ Sequence 250 BP; 66 A; 59 C; 62 G; 63 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 6; Length 250;  
 Best Local Similarity 100.0%; Pred. No. 7.6;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGATGATTAGGCAGAGGT 20  
 Db 248 AGAGATGATTAGGCAGAGGT 229  
 RESULT 14  
 AAD27422/c  
 ID AAD27422 standard; DNA; 639 BP.  
 XX  
 AC AAD27422;  
 XX  
 DT 18-APR-2002 (first entry)  
 XX  
 DE Hepatitis B virus (HBV) core antigen (HBcAg) encoding DNA #1.  
 KW Hepatitis B virus; HBV; core antigen; HBcAg; immune system; typhoid;  
 KW prophylactic; gene therapy; vaccine; hepatitis A virus; HAV; herpes;  
 KW hepatitis C virus; HCV; influenza; foot-and-mouth disease; diarrhoea;  
 KW tuberculosis; polio; rabies; acquired immunodeficiency syndrome; AIDS;  
 KW dengue fever; yellow fever; malaria; whooping cough; salmonellosis;  
 KW food poisoning; meningitis; gonorrhea; antiviral; antibacterial;  
 KW antiprotozoal; ds.  
 XX  
 OS Hepatitis B virus.  
 FH  
 XX Key Location/Qualifiers  
 FT CDS 1..639  
 FT /\*tag= a  
 FT /product= "HBcAg"  
 XX  
 XX WO200198333-A2.  
 PN  
 XX 27-DEC-2001.  
 PD  
 XX  
 XX 22-JUN-2001; 2001WO-GB002817.  
 XX  
 XX 22-JUN-2000; 2000GB-00015308.  
 PR  
 PR 06-OCT-2000; 2000GB-00024544.  
 XX  
 XX (CELL-) CELLS TECH PHARM LTD.  
 PA  
 XX  
 XX Page M, Li J, Pumpens P;  
 PI  
 XX WPI; 2002-098223/13.  
 DR  
 DR P-PSDS; AAE17018.  
 XX  
 XX New proteins comprising a modified hepatitis B core antigen, useful as a  
 PT vaccine in prophylactic or therapeutic vaccination of the human or animal  
 PT body, particularly against hepatitis B virus infection.  
 XX  
 XX Disclosure; Page 38-39; 40pp; English.  
 PS  
 XX The invention relates to modified proteins comprising hepatitis B virus  
 CC (HBV) core antigen (HBcAg) wherein one or more of the four arginine  
 CC repeats has been deleted and the protein comprising the C-terminal  
 CC cysteine of HBcAg. The deleted region may be replaced by an epitope from  
 CC a protein other than HBcAg, in which case the HBcAg acts as a carrier to

CC present the epitope to the immune system. This chimeric protein or its  
 CC nucleic acid is useful as a vaccine or in a method of prophylactic or  
 CC therapeutic vaccination of the human or animal body, particularly against  
 CC HBV. The nucleic acid encoding the protein may be used in gene therapy or  
 CC DNA vaccination protocols. The chimeric protein or its nucleic acid may  
 CC also be used as the basis of a prophylactic vaccine against a range of  
 CC diseases, e.g. HBV, hepatitis A virus (HAV), hepatitis C virus (HCV),  
 CC influenza, foot-and-mouth disease, polio, herpes, rabies, acquired  
 CC immunodeficiency syndrome (AIDS), dengue fever, yellow fever, malaria,  
 CC tuberculosis, whooping cough, salmonellosis, typhoid, food poisoning,  
 CC diarrhoea, meningitis or gonorrhea. The present sequence is a DNA  
 CC encoding Hepatitis B virus core antigen (HBcAg)

SQ Sequence 639 BP; 147 A; 161 C; 141 G; 190 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 6; Length 639;  
 Best Local Similarity 100.0%; Pred. No. 8.4;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 15  
 AAD31509/c  
 ID AAD31509 standard; DNA; 639 BP.

XX AAD31509;

DT 18-JUN-2002 (first entry)

DE Hepatitis B virus core antigen (HBcAg) encoding DNA.

KW Hepatitis B virus core antigen; HBcAg; prophylactic; viral hepatitis;  
 KW therapeutic; vaccine; acquired immune deficiency syndrome; influenza;  
 KW polio; herpes; rabies; AIDS; foot-and-mouth disease; ds.

OS Hepatitis B virus.

FH Key Location/Qualifiers

FT CDS 1..639

FT /\*tag= a /product= "Hbc protein"

FT sig\_peptide 1..87

FT /\*tag= b

FT mat\_peptide 88..636

FT /\*tag= c /product= "Mature Hbc protein"

FT WO200177158-A1.

PN 18-OCT-2001.

XX 09-APR-2001; 2001WO-GB001607.

XX 07-APR-2000; 2000EP-00107118.

XX (MEDE-) MEDEVA EURO LTD.

XX Gehin A, Gilbert R, Stuart D, Rowlands D;

XX WPI; 2002-239995/29.

XX P-PSDB; AAE19793.

XX Hepatitis B (HB) core antigen fusion proteins, useful as vaccines for the  
 PT prophylactic or therapeutic treatment of humans or animals against e.g.  
 PT HB virus, viral hepatitis, hepatitis C virus, influenza, or foot-and-  
 PT mouth disease.

XX Disclosure; Page 23-24; 27pp; English.

CC The present invention relates to hepatitis B virus (HBV) core antigen

CC (HBcAg) fusion proteins and polynucleotides encoding such proteins.  
 CC Sequences of the invention are useful in methods of prophylactic or  
 CC therapeutic vaccination or to manufacture medicaments for prophylactic or  
 CC therapeutic vaccination of the human or animal body against HBV, e.g.  
 CC against viral hepatitis. They are also useful as a prophylactic vaccine  
 CC against e.g. hepatitis C virus, influenza, polio, herpes, rabies,  
 CC acquired immune deficiency syndrome (AIDS) or foot-and-mouth disease. The  
 CC present sequence is a DNA encoding hepatitis B virus core antigen (HBcAg)

SQ Sequence 639 BP; 147 A; 161 C; 141 G; 190 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 6; Length 639;

Best Local Similarity 100.0%; Pred. No. 8.4;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20

|||||

Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 16

ADL56756/c

ID ADL56756 standard; DNA; 646 BP.

XX ADL56756;

DT 17-JUN-2004 (first entry)

DE HBV precore/core DNA.

XX ds; precore/core; cancer; genetic disease; arthritis; AIDS.

XX Hepatitis B virus.

PN US2004063652-A1.

PD 01-APR-2004.

XX 29-MAR-2001; 2001US-00821662.

XX 21-MAR-1988; 88US-00170515.

XX 18-AUG-1989; 89US-00395932.

XX 10-AUG-1990; 90US-00565606.

XX 21-SEP-1990; 90US-00586603.

XX 29-NOV-1991; 91US-00800328.

XX 04-FEB-1992; 92US-00830417.

XX 22-OCT-1992; 92US-00965084.

XX 17-MAR-1993; 93US-00032385.

XX 04-AUG-1993; 93US-00102132.

XX 09-AUG-1993; 93US-00104424.

XX 15-SEP-1993; 93US-00122791.

XX 18-NOV-1993; 93US-00155944.

XX 25-NOV-1997; 97US-00978293.

XX (JOLL/) JOLLY D J.

PA (MONT/) MONTISANO D.

XX Jolly DJ, Montisano D;

XX WPI; 2004-282522/26.

XX Introducing nucleic acid molecules to an animal or human, useful for

PT treating diseases including cancer, genetic diseases, arthritis or AIDS  
 PT comprises administering a composition comprising two or more gene  
 PT delivery vehicles.  
 XX Disclosure; SEQ ID NO 23; 72pp; English.  
 XX The invention relates to a method of introducing nucleic acid molecules  
 CC to an animal which comprises administering a composition comprising two  
 CC or more gene delivery vehicles to an animal at the same time and same  
 CC site via a single administration device. The method is useful for  
 CC introducing nucleic acid molecules to an animal, preferably humans for

CC treating diseases including cancer, genetic diseases, arthritis or AIDS.  
 CC The method can also be administered to plants using traditional methods.  
 CC The introduction of multiple or more than one nucleic acid molecule at  
 CC one time provide significant advantages because multiple nucleic acid  
 CC molecules can provide complementary substances or activities to a single  
 CC organ or joint. The difficulty, cost and time to engineer multiple  
 CC nucleic acid molecules is much less than engineering a single molecule.  
 CC With the use of multiple molecules, there is less chance that one  
 CC substance or activity will sterically hinder or otherwise interfere with  
 CC another substance or activity. The use of multiple molecules also permits  
 CC the expression of different substances or activities from expression  
 CC systems subject to differing activating events, thus permitting better  
 CC control of differential expression of the different substances or  
 CC activities. The present sequence represents the HBV precore/core DNA.  
 CC  
 XX

SQ Sequence 646 BP; 154 A; 170 C; 137 G; 185 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 12; Length 646;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 DB 43 AGAGATGATTAGGCAGAGGT 24

RESULT 17  
 AAQ47014/c  
 ID AAQ47014 standard; DNA; 655 BP.  
 AC AAQ47014;  
 XX  
 DT 27-AUG-2003 (revised)  
 DT 25-MAR-2003 (revised)  
 DT 31-JAN-1994 (first entry)  
 XX  
 DE HBV (adw) corrected precore/core sequence.  
 XX  
 KW Precore; core; coding region; hepatitis B; virus; HBV; plasmid; KSII+;  
 KW KSII+HBpc/c; pM6; deletion; frameshift; PCR; overlap extension; SK+ Hbe;  
 KW primers; mutation; hepatocellular carcinomas; class-I;  
 KW cytotoxic T-lymphocyte; CTL; hepatitis C; infection; ss.  
 XX  
 OS Hepatitis B virus.  
 XX

FH Key Location/Qualifiers  
 FT mutation 334  
 FT /\*tag= a  
 FT /note= "Nucleotide which is deleted in plasmid pM6"  
 XX  
 PN WO9315207-A2.  
 XX  
 PD 05-AUG-1993.  
 XX  
 PF 04-FEB-1993; 93WO-US001009.  
 XX  
 PR 04-FEB-1992; 92US-00830417.  
 XX  
 PA (VIAG-) VIAGENE INC.  
 XX

PI Jolly DJ, Chang SMW, Lee WT, Townsland K, Odeja J;  
 XX WPI; 1993-258682/32.  
 DR  
 XX Treatment of hepatitis B and C, and associated carcinoma(s) - using a  
 PT vector construct directing the expression of part of hepatitis B or C  
 PT antigen.  
 XX  
 PS Example 2; Fig 2; 110pp; English.  
 XX

CC This sequence represents the entire precore/core coding region of  
 CC hepatitis B virus (HBV) isolated from the plasmid KSII+HBpc/c. This  
 CC plasmid was created by ligating a 1.8 kb fragment of plasmid pM6

CC containing the entire precore/core region, into the BamHI site of KSII+.  
 CC The precore/core region of plasmid KSII+HBpc/p was sequenced and was  
 CC found to contain a single base pair deletion which causes a frameshift at  
 CC codon 79 which results in two consecutive in-frame TAG codons. This  
 CC deletion was corrected by PCR overlap extension in plasmid SK+ Hbe using  
 CC the primer sequences given in AAQ47015-18 in four separate reactions. The  
 CC mutation may also be corrected using the primers given in AAQ47019-23 in  
 CC a separate series of reactions. The isolated HBV precore/core region may  
 CC be used in a method to induce potent class-I restricted protective and  
 CC therapeutic cytotoxic T-lymphocyte (CTL) response, and a humoral response  
 CC for the treatment of hepatitis B and C infections, as well as a humoral response  
 CC hepatocellular carcinomas. (Updated on 25-MAR-2003 to correct PN field.)  
 CC (Updated on 27-AUG-2003 to correct OS field.)  
 XX

SQ Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 655;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 DB 43 AGAGATGATTAGGCAGAGGT 24

RESULT 18  
 AAT35649/c  
 ID AAT35649 standard; cDNA; 655 BP.  
 AC AAT35649;  
 XX

DT 27-AUG-2003 (revised)  
 DT 25-FEB-1997 (first entry)  
 XX  
 DE Precore/core region of HBV.  
 XX  
 KW Precore; core region; HBV; hepatitis B virus; gene delivery vehicle; GDV;  
 KW immunogen; HBV antigen; hepatitis C carcinoma cell; HBV infection;  
 KW gene expression; non-tumorigenic tumour associated antigen; therapy;  
 KW altered ras gene; altered p53 gene; altered mucin; ss.  
 XX  
 OS Hepatitis B virus.  
 XX

FH Key Location/Qualifiers  
 FT misc\_feature 10..97  
 FT /\*tag= a  
 FT /note= "precure region"  
 FT misc\_feature 98..655  
 FT /\*tag= b  
 FT /note= "core region"  
 XX  
 PN WO9621015-A2.  
 XX  
 PD 11-JUL-1996.  
 XX  
 PF 22-DEC-1995; 95WO-US016964.  
 XX  
 PR 30-DEC-1994; 94US-00368210.  
 XX

PA (CHIR ) CHIRON VIAGENE INC.  
 XX  
 PI Jolly DJ, Montisano D;  
 XX WPI; 1996-333990/33.  
 DR  
 XX Introduction of nucleic acid molecules to an animal - comprises  
 PT administration of two or more gene delivery vehicles comprising  
 PT heterologous nucleic acid.  
 XX

PS Disclosure; Page 131; 161pp; English.  
 XX

CC This sequence represents the precore/core region of the hepatitis B virus

CC (HBV) genome. This sequence can be included in a gene delivery vehicle



CC (GDV) of the invention, and is used as an immunogenic portion of a HBV  
 CC antigen. The GDVs can be used in the method of the invention, for  
 CC introducing nucleic acids into an animal, by administration of a  
 CC composition comprising two or more GDVs, in combination with a carrier or  
 CC diluent. Each GDV contains a nucleic acid molecule not naturally  
 CC contained within the GDV, or directs expression of at least one substance  
 CC (or biologically active nucleic acid) in host cells containing the GDV.  
 CC The two GDVs collectively direct the expression of at least two different  
 CC substances, or direct the expression of at least one substance, where the  
 CC GDVs differ in one or more biological functions. The GDVs can be used for  
 CC destroying hepatitis C carcinoma cells, for treating HBV (when a GDV  
 CC contains an immunogenic HBV fragment such as this sequence). The GDVs can  
 CC also be used for directing expression of non-tumorigenic, tumour  
 CC associated antigens (such as altered ras gene), altered p53 gene, and  
 CC altered mucin. (Updated on 27-AUG-2003 to correct OS field.)

XX Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;  
 SQ Query Match 100.0%; Score 20; DB 2; Length 655;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 43 AGAGATGATTAGGCAGAGGT 24

RESULT 19  
 AAH77569/c  
 ID AAH77569 standard; DNA; 655 BP.  
 AC AAH77569;  
 DT 19-OCT-2001 (first entry)  
 XX HBV genotype G strain US1 preCore/Core DNA.

XX Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;  
 KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBCAg;  
 KW HBeAg; ds.

OS Hepatitis B virus.

XX WO200140279-A2.

PN 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.

XX 03-DEC-1999; 99EP-00870252.

PR 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

PI Stuyver L, Van Geyt C, De Gendt S;

XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and  
 PT polynucleotide sequences that are phylogenetically different from HBV  
 PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
 PT therapy.

PS Claim 3; Fig 7; 94pp; English.

XX The invention relates to the complete nucleic acid sequence of a new  
 CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
 CC This genotype was found with a high prevalence in patients chronically  
 CC infected with HBV and residing in Europe and the USA. The invention  
 CC relates to a fully defined sequence of 3248 nucleotides as given in  
 CC specification, a sequence with 92% identity to the given sequence, or  
 CC sequence that is degenerate to the mentioned sequences. These  
 CC polynucleotides are useful for HBV genotyping. The proteins encoded by

CC the polynucleotides are useful for detecting antibodies in a biological  
 CC sample. Ligands that bind to the proteins and antibodies directed against  
 CC the proteins are useful for detecting the proteins and for detecting  
 CC HBeAg and HBeAg (precursor proteins). They are also useful for  
 CC preparing a vaccine or medicament for treating HBV infections. The  
 CC present sequence is provided in an alignment of preCore/Core sequences of  
 CC an HBV genotype A strain (HBVXCPS) and 7 strains (PRI, FR2, US1, US3,  
 CC US6, US7, US9, US10) of HBV genotype G

SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;

Query Match 100.0%; Score 20; DB 4; Length 655;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 20  
 AAH77568/c  
 ID AAH77568 standard; DNA; 655 BP.

AC AAH77568;

DT 19-OCT-2001 (first entry)

XX HBV genotype G strain FR2 preCore/Core DNA.

XX Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;  
 KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBCAg;  
 KW HBeAg; ds.

OS Hepatitis B virus.

XX WO200140279-A2.

PN 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.

XX 03-DEC-1999; 99EP-00870252.

PR 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

PI Stuyver L, Van Geyt C, De Gendt S;

XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and  
 PT polynucleotide sequences that are phylogenetically different from HBV  
 PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
 PT therapy.

PS Claim 3; Fig 7; 94pp; English.

XX The invention relates to the complete nucleic acid sequence of a new  
 CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
 CC This genotype was found with a high prevalence in patients chronically  
 CC infected with HBV and residing in Europe and the USA. The invention  
 CC relates to a fully defined sequence of 3248 nucleotides as given in  
 CC specification, a sequence with 92% identity to the given sequence, or  
 CC sequence that is degenerate to the mentioned sequences. These  
 CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
 CC the polynucleotides are useful for detecting antibodies in a biological  
 CC sample. Ligands that bind to the proteins and antibodies directed against  
 CC the proteins are useful for detecting the proteins and for detecting  
 CC HBeAg and HBeAg (precursor proteins). They are also useful for  
 CC preparing a vaccine or medicament for treating HBV infections. The  
 CC present sequence is provided in an alignment of preCore/Core sequences of  
 CC an HBV genotype A strain (HBVXCPS) and 7 strains (PRI, FR2, US1, US3,

```
CC US6, US7, US9, US10) of HBV genotype G
XX
SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;
Query Match 100.0%; Score 20; DB 4; Length 655;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 21
AAH77574/c
ID AAH77574 standard; DNA; 655 BP.
XX
AC AAH77574;
XX
DT 19-OCT-2001 (first entry)
XX
DE HBV genotype G strain US10 preCore/Core DNA.
XX
KW Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW HBeAg; ds.
XX
OS Hepatitis B virus.
XX
PN WO200140279-A2.
XX
PD 07-JUN-2001.
XX
PF 20-NOV-2000; 2000WO-EP011526.
XX
PR 03-DEC-1999; 99EP-00870252.
PR 07-DEC-1999; 99US-0169287P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L, Van Geyt C, De Gendt S;
XX
DR WPI; 2001-374785/39.
XX
PT Novel isolated and/or purified hepatitis B virus polypeptide and
PT polynucleotide sequences that are phylogenetically different from HBV
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT therapy.
XX
PS Claim 3; Fig 7; 94pp; English.
XX
CC The invention relates to the complete nucleic acid sequence of a new
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC This genotype was found with a high prevalence in patients chronically
CC infected with HBV and residing in Europe and the USA. The invention
CC relates to a fully defined sequence of 3248 nucleotides as given in
CC specification, a sequence with 92% identity to the given sequence, or
CC sequence that is degenerate to the mentioned sequences. These
CC polynucleotides are useful for HBV genotyping. The proteins encoded by
CC the polynucleotides are useful for detecting antibodies in a biological
CC sample. Ligands that bind to the proteins and antibodies directed against
CC the proteins are useful for detecting the proteins and for detecting
CC HBcAg and HBeAg (precursor proteins). They are also useful for
CC preparing a vaccine or medicament for treating HBV infections. The
CC present sequence is provided in an alignment of preCore/Core sequences of
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC US6, US7, US9, US10) of HBV genotype G
XX
SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;
Query Match 100.0%; Score 20; DB 4; Length 655;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 22
AAH77573/c
ID AAH77573 standard; DNA; 655 BP.
XX
AC AAH77573;
XX
DT 19-OCT-2001 (first entry)
XX
DE HBV genotype G strain US7 preCore/Core DNA.
XX
KW Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW HBeAg; ds.
XX
OS Hepatitis B virus.
XX
PN WO200140279-A2.
XX
PD 07-JUN-2001.
XX
PF 20-NOV-2000; 2000WO-EP011526.
XX
PR 03-DEC-1999; 99EP-00870252.
PR 07-DEC-1999; 99US-0169287P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L, Van Geyt C, De Gendt S;
XX
DR WPI; 2001-374785/39.
XX
PT Novel isolated and/or purified hepatitis B virus polypeptide and
PT polynucleotide sequences that are phylogenetically different from HBV
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT therapy.
XX
PS Claim 3; Fig 7; 94pp; English.
XX
CC The invention relates to the complete nucleic acid sequence of a new
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC This genotype was found with a high prevalence in patients chronically
CC infected with HBV and residing in Europe and the USA. The invention
CC relates to a fully defined sequence of 3248 nucleotides as given in
CC specification, a sequence with 92% identity to the given sequence, or
CC sequence that is degenerate to the mentioned sequences. These
CC polynucleotides are useful for HBV genotyping. The proteins encoded by
CC the polynucleotides are useful for detecting antibodies in a biological
CC sample. Ligands that bind to the proteins and antibodies directed against
CC the proteins are useful for detecting the proteins and for detecting
CC HBcAg and HBeAg (precursor proteins). They are also useful for
CC preparing a vaccine or medicament for treating HBV infections. The
CC present sequence is provided in an alignment of preCore/Core sequences of
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC US6, US7, US9, US10) of HBV genotype G
XX
SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;
Query Match 100.0%; Score 20; DB 4; Length 655;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 23
AAH77574/c
ID AAH77574 standard; DNA; 655 BP.
XX
AC AAH77574;
XX
DT 19-OCT-2001 (first entry)
XX
DE HBV genotype G strain US10 preCore/Core DNA.
XX
KW Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW HBeAg; ds.
XX
OS Hepatitis B virus.
XX
PN WO200140279-A2.
XX
PD 07-JUN-2001.
XX
PF 20-NOV-2000; 2000WO-EP011526.
XX
PR 03-DEC-1999; 99EP-00870252.
PR 07-DEC-1999; 99US-0169287P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L, Van Geyt C, De Gendt S;
XX
DR WPI; 2001-374785/39.
XX
PT Novel isolated and/or purified hepatitis B virus polypeptide and
PT polynucleotide sequences that are phylogenetically different from HBV
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT therapy.
XX
PS Claim 3; Fig 7; 94pp; English.
XX
CC The invention relates to the complete nucleic acid sequence of a new
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC This genotype was found with a high prevalence in patients chronically
CC infected with HBV and residing in Europe and the USA. The invention
CC relates to a fully defined sequence of 3248 nucleotides as given in
CC specification, a sequence with 92% identity to the given sequence, or
CC sequence that is degenerate to the mentioned sequences. These
CC polynucleotides are useful for HBV genotyping. The proteins encoded by
CC the polynucleotides are useful for detecting antibodies in a biological
CC sample. Ligands that bind to the proteins and antibodies directed against
CC the proteins are useful for detecting the proteins and for detecting
CC HBcAg and HBeAg (precursor proteins). They are also useful for
CC preparing a vaccine or medicament for treating HBV infections. The
CC present sequence is provided in an alignment of preCore/Core sequences of
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC US6, US7, US9, US10) of HBV genotype G
XX
SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;
Query Match 100.0%; Score 20; DB 4; Length 655;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
AAH77570/c
ID AAH77570 standard; DNA; 655 BP.
XX
AC AAH77570;
XX
DT 19-OCT-2001 (first entry)
XX
DE HBV genotype G strain US3 preCore/Core DNA.
XX
KW Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBx; HBPol;
KW HBeAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW HBeAg; ds.
XX
OS Hepatitis B virus.
XX
PN WO200140279-A2.
XX
PD 07-JUN-2001.
XX
PF 20-NOV-2000; 2000WO-EF011526.
XX
PR 03-DEC-1999; 99EP-00870252.
PR 07-DEC-1999; 99US-0169287P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L, Van Geyt C, De Gendt S;
XX WPI; 2001-374785/39.
XX
PT Novel isolated and/or purified hepatitis B virus polypeptide and
PT polynucleotide sequences that are phylogenetically different from HBV
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT therapy.
XX
PS Claim 3; Fig 7; 94pp; English.
XX
CC The invention relates to the complete nucleic acid sequence of a new
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC This genotype was found with a high prevalence in patients chronically
CC infected with HBV and residing in Europe and the USA. The invention
CC relates to a fully defined sequence of 3248 nucleotides as given in
CC specification, a sequence with 92% identity to the given sequence, or
CC the polynucleotides are useful for HBV genotyping. The proteins encoded by
CC the polynucleotides are useful for detecting antibodies in a biological
CC sample. Ligands that bind to the proteins and antibodies directed against
CC HBcAg and HBeAg (precursor proteins). They are also useful for
CC preparing a vaccine or medicament for treating HBV infections. The
CC present sequence is provided in an alignment of preCore/Core sequences of
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC US6, US7, US9, US10) of HBV genotype G
XX
SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;
Query Match 100.0%; Score 20; DB 4; Length 655;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
DB 33 AGAGATGATTAGGCAGAGGT 14
|||||
RESULT 24
AAH77571/c
ID AAH77571 standard; DNA; 655 BP.
XX
AC AAH77571;
XX
DT 19-OCT-2001 (first entry)
XX
DE HBV genotype G strain US3 preCore/Core DNA.
XX
KW Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBx; HBPol;
KW HBeAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW HBeAg; ds.
XX
OS Hepatitis B virus.
XX
PN WO200140279-A2.
XX
PD 07-JUN-2001.
XX
PF 20-NOV-2000; 2000WO-EF011526.
XX
PR 03-DEC-1999; 99EP-00870252.
PR 07-DEC-1999; 99US-0169287P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L, Van Geyt C, De Gendt S;
XX WPI; 2001-374785/39.
XX
PT Novel isolated and/or purified hepatitis B virus polypeptide and
PT polynucleotide sequences that are phylogenetically different from HBV
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT therapy.
XX
PS Claim 3; Fig 7; 94pp; English.
XX
CC The invention relates to the complete nucleic acid sequence of a new
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC This genotype was found with a high prevalence in patients chronically
CC infected with HBV and residing in Europe and the USA. The invention
CC relates to a fully defined sequence of 3248 nucleotides as given in
CC specification, a sequence with 92% identity to the given sequence, or
CC the polynucleotides are useful for HBV genotyping. The proteins encoded by
CC the polynucleotides are useful for detecting antibodies in a biological
CC sample. Ligands that bind to the proteins and antibodies directed against
CC HBcAg and HBeAg (precursor proteins). They are also useful for
CC preparing a vaccine or medicament for treating HBV infections. The
CC present sequence is provided in an alignment of preCore/Core sequences of
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC US6, US7, US9, US10) of HBV genotype G
XX
SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;
Query Match 100.0%; Score 20; DB 4; Length 655;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
DB 33 AGAGATGATTAGGCAGAGGT 14
|||||
RESULT 25
AAH77571/c
ID AAD21244 standard; DNA; 655 BP.
XX
AC AAD21244;
XX
DT 15-JAN-2002 (first entry)
XX
DE Hepatitis B virus adw strain precore/core mutant DNA.
XX
KW Hepatitis B; hepatitis C; immunogen; HBV; HCV; hepatocellular carcinoma;
KW HCC; gene therapy; virucide; hepatotropic; antiinflammatory; cytostatic;
KW mutant; ds.
XX
OS Hepatitis B virus.
```

```

XX Key Location/Qualifiers
FH misc_feature 11..97
FT /*tag= a
FT /note= "Precore region"
FT misc_feature 98..655
FT /*tag= b
FT /note= "Core region"
FT mutation replace(332..334, CC)
FT /*tag= c
FT mutation replace(338..340, CAA)
FT /*tag= d
XX US6297048-B1.
XX 02-OCT-2001.
XX 07-JUN-1995; 95US-00483511.
XX 04-FEB-1992; 92US-00830417.
XX 17-MAR-1993; 93US-00032385.
XX 04-AUG-1993; 93US-00102132.
XX 05-AUG-1994; 94US-00286829.
XX 13-JAN-1995; 95US-00374414.
XX (CHIR ) CHIRON CORP.
XX Jolly DJ, Chang SMW, Lee WTL, Townsend K, O'dea J;
XX WPI; 2001-647290/74.
XX
XX New vectors that direct the (co-)expression of one or more immunogenic
XX portions of the hepatitis B or C virus antigen(s), useful in gene
XX therapy, e.g. for treating or preventing hepatitis B or C infections, or
XX hepatocellular carcinomas.
XX
XX Example 2; Fig 2; 64pp; English.
XX
XX The present invention relates to a method for treating hepatitis B or C
XX infections. The method involves administering a vector construct that
XX directs the expression of at least one immunogenic portion of hepatitis B
XX virus (HBV) antigen, containing HBeAg, HbAg, HsAg, S, Pre-S1, Pre-S2,
XX open reading frame (ORF) 5, ORF 6, HBV pol or HbAg or co-expression of
XX at least one immunogenic portion of a HBV antigen and at least one
XX immunogenic portion of a hepatitis C virus (HCV) antigen. The vectors are
XX useful in gene therapy, particularly for treating or preventing hepatitis
XX B and hepatitis C infections, as well as hepatocellular carcinomas (HCC).
XX The present sequence is a PCR primer used for amplifying Hepatitis B
XX virus adw strain precore/core mutant DNA
XX
XX Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 4; Length 655;
XX Best Local Similarity 100.0%; Pred. No. 8.5;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AGAGATGATTAGGCAGAGGT 20
XX Db 43 AGAGATGATTAGGCAGAGGT 24
XX
XX RESULT 26
XX ABX80077/c
XX ID ABX80077 standard; DNA; 655 BP.
XX AC ABX80077;
XX XX
XX XX 22-APR-2003 (first entry)
XX DE Hepatitis B virus precore/core DNA.
XX
XX Hepatitis B virus; hepatitis C virus; hepatitis C infection; poliovirus;
XX hepatitis B infection; hepatitis C antigen; polyprotein antigen; SV40;

```

```

KW rhinovirus; pox virus; canary pox virus; vaccinia virus; influenza virus;
KW adenovirus; parvovirus; adeno-associated virus; herpes virus; measles;
KW corona virus; HIV; human immunodeficiency virus; Sindbis virus; virucide;
KW hepatotropic; ds; precore/core DNA.
XX Hepatitis B virus.
XX OS
XX US2002141974-A1.
XX PN
XX 03-OCT-2002.
XX PD
XX 24-JUL-2001; 2001US-00912679.
XX PF
XX 04-FEB-1992; 92US-00830417.
XX PR
XX 17-MAR-1993; 93US-00032385.
XX PR
XX 04-AUG-1993; 93US-00102132.
XX PR
XX 05-AUG-1994; 94US-00286829.
XX PR
XX 19-JAN-1995; 95US-00374414.
XX PR
XX 07-JUN-1995; 95US-00483511.
XX
XX (JOLLY) JOLLY D J.
XX (CHAN/) CHANG S M W.
XX (LEEW/) LEE W T L.
XX (TOWN/) TOWNSEND K.
XX (ODEA/) O'DEA J.
XX
XX Jolly DJ, Chang SMW, Lee WTL, Townsend K, O'dea J;
XX WPI; 2003-174125/17.
XX
XX Treating hepatitis C infections in a warm-blooded animal by administering
XX a vector construct, which directs the expression of an immunogenic
XX portion of a hepatitis C antigen, and alternatively, with an
XX immunomodulatory cofactor.
XX
XX Example 2; Fig 2; 70pp; English.
XX
XX The invention relates to a method for treating hepatitis C infections in
XX a warm-blooded animal comprising administering a vector construct which
XX directs the expression of at least one immunogenic portion of a hepatitis
XX C antigen, where an immune response is generated, and alternatively, in
XX combination with an immunomodulatory cofactor. The invention also relates
XX to a vector construct which directs the co-expression of at least one
XX immunogenic portion of a hepatitis B antigen and at least one immunogenic
XX portion of a hepatitis C antigen, an immunogenic portion of the
XX polypeptide antigen, or an immunoregulatory cofactor A recombinant virus carrying the vector
XX construct is selected from poliovirus, rhinovirus, pox virus, canary pox
XX virus, vaccinia virus, influenza virus, adenovirus, parvovirus, adeno-
XX associated virus, herpes virus, SV40, HIV, measles, corona virus or
XX Sindbis virus. This sequence represents hepatitis B virus precore/core
XX DNA used in the method of the invention
XX
XX Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 9; Length 655;
XX Best Local Similarity 100.0%; Pred. No. 8.5;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AGAGATGATTAGGCAGAGGT 20
XX Db 43 AGAGATGATTAGGCAGAGGT 24
XX
XX RESULT 27
XX ABX96938/c
XX ID ABX96938 standard; DNA; 655 BP.
XX XX
XX AC ABX96938;
XX XX
XX XX 15-MAY-2003 (first entry)
XX DT
XX DE Hepatitis B virus (HBV) DNA.

```

XX Human; HBV; HCV; gene; ds; hepatitis B virus; hepatitis C virus;  
 KW intracellular infection; HSV; HIV; viral infection; herpes simplex virus;  
 KW human immunodeficiency virus; FIV; feline immunodeficiency virus;  
 KW parasitic infection; rickettsia; malaria; leishmaniasis; tuberculosis;  
 KW bacterial disease; legionella; chlamydia.  
 OS Hepatitis B virus.  
 XX US2002165172-A1.  
 PN 07-NOV-2002.  
 XX 17-DEC-1999; 99US-00466035.  
 XX 16-SEP-1997; 97US-00931031.  
 PR (SALL/) SALLBERG M.  
 PA (MILI/) MILICH D R.  
 PA (LEEW/) LEE W T L.  
 XX Sallberg M, Milich DR, Lee WTL;  
 DR WPI; 2003-288144/28.  
 XX Treating intracellular infections, e.g. viral, parasitic and bacterial  
 PT diseases, comprises administering a vector construct which directs the  
 PT expression of an immunogenic portion of an antigen from an intracellular  
 PT pathogen.  
 XX Disclosure; Page 44-45; 69pp; English.  
 XX The invention relates to a method for treating intracellular infections  
 CC within warm-blooded animals comprising administering to a warm-blooded  
 CC animal a vector construct which directs the expression of at least one  
 CC immunogenic portion of an antigen derived from an intracellular pathogen,  
 CC and a protein having the immunogenic portion of the antigen to generate  
 CC an immune response. The method is useful for treating intracellular  
 CC infections or diseases including viral infections (e.g. hepatitis B virus  
 CC (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), human  
 CC immunodeficiency virus (HIV) or feline immunodeficiency virus (FIV)),  
 CC parasitic infections (e.g. rickettsia, leishmaniasis or malaria) and  
 CC certain bacterial diseases (e.g. legionella, tuberculosis or chlamydia).  
 CC This sequence represents hepatitis B virus DNA used in the method of the  
 CC invention  
 XX Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;  
 SQ Query Match 100.0%; Score 20; DB 10; Length 655;  
 Best Local Similarity 100.0%; Pred. NO. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGATGATTAGGCAGAGT 20  
 DB 43 AGAGATGATTAGGCAGAGT 24  
 RESULT 28  
 AAN91081/c  
 ID AAN91081 standard; DNA; 660 BP.  
 XX AAN91081;  
 AC AAN91081;  
 XX 25-MAR-2003 (revised)  
 DT 14-JUL-1990 (first entry)  
 XX DNA sequence of subclones encompassing the core (C) and precore (preC)  
 DE antigens (Ag) of an adv serotype hepatitis B (HB) virus.  
 XX Hepatitis B virus; core gene; precore gene; antigen; vaccine;  
 KW polypeptide expression sequence; ACNPV transfer vector pACYM1;  
 KW pACYM1Ktpc; pACYM1KTC; recombinant baculovirus; YMK1Kpc; YMK1KTC.

OS Hepatitis B virus.  
 XX Key Location/Qualifiers  
 FH CDS 2..658  
 FT /\*tag= e  
 FT misc\_feature 2..100  
 FT /\*tag= c  
 FT /note= "This is labelled 'preCore'"  
 FT 14..82  
 FT /\*tag= a  
 FT /product= "Precore antigen"  
 FT 83..659  
 FT /\*tag= d  
 FT /note= "This labelled 'Core'"  
 FT 101..658  
 FT /\*tag= b  
 FT /product= "Core Antigen"  
 FT 169  
 FT /\*tag= f  
 FT /note= "Differs from the HB virus adv sequence published  
 FT by Ono and associates (1983)"  
 FT 181..182  
 FT /\*tag= g  
 FT /note= "As above"  
 FT 217  
 FT /\*tag= h  
 FT /note= "As above"  
 FT 274  
 FT /\*tag= i  
 FT /note= "As above"  
 FT 329  
 FT /\*tag= j  
 FT /note= "As above"  
 FT 346  
 FT /\*tag= k  
 FT /note= "As above"  
 XX WO8901518-A.  
 XX 23-FEB-1989.  
 XX 11-AUG-1988; 88WO-GB000663.  
 XX 12-AUG-1987; 87GB-00019108.  
 XX 12-JUL-1988; 88GB-00016084.  
 XX (NATU-) NATURAL ENVIRON RES.  
 PA Bishop DH, Emery VC;  
 PI WPI; 1989-068873/09.  
 DR P-PSDB; AAP90702.  
 XX New plasmid replicon for inserting several genes into vector - contg. two  
 PT polypeptide expression structures, and derived viral vectors for  
 PT infecting insect cells.  
 XX Disclosure; Page ?; 74pp; English.  
 XX The coding sequences of the preC and C Ags of HB virus were inserted into  
 CC Autograph californica nuclear polyhedrosis virus (ACNPV) transfer vector  
 CC pACYM1. The derived recombinant transfer vectors were called pACYM1Ktpc  
 CC and pACYM1KTC. Following cotransfection with infectious ACNPV DNA,  
 CC recombinant baculoviruses were obtained - YMK1KTC and YMK1Kpc. It was  
 CC determined that all the HBcAg and HBpAg was cell associated and that the  
 CC yield of purified HBcAg was of the order of 5 mg per liter of 1x10<sup>9</sup>  
 CC infected cells. Such Ag may be useful in vaccines. (Updated on 25-MAR-  
 CC 2003 to correct PR field.)  
 XX Sequence 660 BP; 156 A; 171 C; 143 G; 189 T; 0 U; 1 Other;  
 SQ Query Match 100.0%; Score 20; DB 1; Length 660;  
 Best Local Similarity 100.0%; Pred. NO. 8.5;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGT 20  
 DB 46 AGAGATGATTAGGCAGAGT 27

RESULT 29  
 AAH77572/c  
 ID AAH77572 standard; DNA; 664 BP.  
 XX AC AAH77572;  
 XX DT 19-OCT-2001 (first entry)  
 XX DE HBV genotype G strain US6 preCore/Core DNA.  
 XX KW Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;  
 XX KW HBeAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBeAg;  
 XX KW HBeAg; ds.  
 XX OS Hepatitis B virus.  
 XX PN WO200140279-A2.  
 XX PD 07-JUN-2001.  
 XX PF 20-NOV-2000; 2000WO-EP011526.  
 XX PR 03-DEC-1999; 99EP-00870252.  
 XX PR 07-DEC-1999; 99US-0169287P.  
 XX PA (INNO-) INNOGENETICS NV.  
 XX PI Stuyver L, Van Geyt C, De Gendt S;  
 XX DR WPI; 2001-374785/39.  
 XX PT Novel isolated and/or purified hepatitis B virus polypeptide and  
 PT polynucleotide sequences that are phylogenetically different from HBV  
 PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
 PT therapy.  
 XX Claim 3; Fig 7; 94pp; English.  
 XX The invention relates to the complete nucleic acid sequence of a new  
 CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
 CC This genotype was found with a high prevalence in patients chronically  
 CC infected with HBV and residing in Europe and the USA. The invention  
 CC relates to a fully defined sequence of 3248 nucleotides as given in  
 CC specification, a sequence with 92% identity to the given sequence, or  
 CC sequence that is degenerate to the mentioned sequences. These  
 CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
 CC the polynucleotides are useful for detecting antibodies in a biological  
 CC sample. Ligands that bind to the proteins and antibodies directed against  
 CC the proteins are useful for detecting the proteins and for detecting  
 CC HBeAg and HBeAg (precursor protein). They are also useful for  
 CC preparing a vaccine or medicament for treating HBV infections. The  
 CC present sequence is provided in an alignment of preCore/Core sequences of  
 CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,  
 CC US6, US7, US9, US10) of HBV genotype G  
 XX SQ Sequence 664 BP; 146 A; 160 C; 144 G; 208 T; 0 U; 6 Other;

Query Match 100.0%; Score 20; DB 4; Length 664;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGT 20  
 DB 33 AGAGATGATTAGGCAGAGT 14

RESULT 30  
 ADO07220/c  
 ID ADO07220 standard; DNA; 669 BP.  
 XX AC ADO07220;  
 XX DT 15-JUL-2004 (first entry)  
 XX DE Hepatitis B virus core antigen DNA.  
 XX KW HBeAg; immunomodulator; vaccine; gene; ss.  
 XX OS Hepatitis B virus.  
 XX FH Key  
 XX CDS Location/Qualifiers  
 XX 10..669  
 XX /tag= a  
 XX /product= "HBeAg"  
 XX /partial  
 XX /note= "No start codon"  
 XX PN WO2004035007-A2.  
 XX PD 29-APR-2004.  
 XX PF 17-OCT-2003; 2003WO-US033178.  
 XX PR 17-OCT-2002; 2002US-0419279P.  
 XX PA (ORAG-) ORAGEN CORP.  
 XX PI Michaels F;  
 XX DR WPI; 2004-348329/32.  
 XX DR P-FSDB; ADO07221.  
 XX PT Modulating a systemic immune response to a peptide in a mammal comprises  
 PT transmuscosally administering a macromolecular aggregate of the peptide.  
 PS Disclosure; SEQ ID NO 1; 81pp; English.  
 XX The present sequence is the DNA sequence of the hepatitis B virus core  
 CC antigen (HBeAg) gene from HBV serotype ayw. A peptide comprising a HBV  
 CC protein can be used in claimed methods of the invention for modulating an  
 CC immune response in a mammal. A method of inducing a systemic immune  
 CC response to a peptide in a mammal comprises transmuscosally administering  
 CC to the mammal a macromolecular aggregate of the peptide. The  
 CC macromolecular aggregate comprises at least 10 peptide subunits, may have  
 CC a molecular weight of over 1,000 kDa, and is preferably at least 5 nm in  
 CC diameter. It is resistant to digestive degradation, being stabilised in  
 CC aggregate form by chemical treatment and/or by recombinant protein  
 CC engineering of the peptide. The peptide preferably comprises a HBV  
 CC protein selected from HBV surface protein, nucleocapsid protein or  
 CC envelope protein. Transmuscosal administration to a mammal of a  
 CC macromolecular aggregate of a HBV surface protein engenders a systemic  
 CC immune response in the mammal. A method of suppressing an immune response  
 CC in a mammal involves transmuscosally administering a monomolecular peptide  
 CC that is resistant to digestive degradation and which may be stabilised by  
 CC chemical treatment or protein engineering, and which may be derived from  
 CC a HBV protein. A monomolecular peptide is useful for the induction of  
 CC oral tolerance when induction of systemic immunity is undesirable, e.g.  
 CC in cases of chronic infections.

Sequence 669 BP; 155 A; 170 C; 148 G; 196 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 12; Length 669;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGT 20  
 DB 63 AGAGATGATTAGGCAGAGT 44

CC stage of liver disease caused by HBV genotype G. The present sequence is  
 CC hepatitis B virus (HBV) strain FRI, genotype G DNA fragment encoding  
 CC PreCore/Core antigen (HBcAg) protein  
 XX  
 SQ Sequence 673 BP; 148 A; 165 C; 146 G; 214 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 4; Length 673;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 33 AGAGATGATTAGGCAGAGGT 14  
 RESULT 32  
 AAH77563/c  
 ID AAH77563 standard; DNA; 675 BP.  
 XX  
 AC AAH77563;  
 DT 19-OCT-2001 (first entry)  
 XX  
 DE HBV preCore/Core gene.  
 XX  
 KW Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBx; HBPol;  
 KW HBSAg; antiviral; vaccine; genotype G; genotyping; HBcAg; HBeAg; ds.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO200140279-A2.  
 PD 07-JUN-2001.  
 XX  
 PF 20-NOV-2000; 2000WO-EP011526.  
 XX  
 PR 03-DEC-1999; 99EP-00870252.  
 PR 07-DEC-1999; 99US-0169287P.  
 XX  
 PA (INNO-) INNOGENETICS NV.  
 XX  
 PI Stuyver L, Van Geyt C, De Gendt S;  
 XX  
 DR WPI; 2001-374785/39.  
 XX  
 PT Novel isolated and/or purified hepatitis B virus polypeptide and  
 PT polynucleotide sequences that are phylogenetically different from HBV  
 PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
 PT therapy.  
 XX  
 PS Claim 4; Fig 2; 94pp; English.  
 CC  
 CC The invention relates to the complete nucleic acid sequence of a new  
 CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
 CC This genotype was found with a high prevalence in patients chronically  
 CC infected with HBV and residing in Europe and the USA. The invention  
 CC relates to a fully defined sequence of 3248 nucleotides as given in  
 CC specification, a sequence with 92% identity to the given sequence, or  
 CC sequence that is degenerate to the mentioned sequences. These  
 CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
 CC the polynucleotides are useful for detecting antibodies in a biological  
 CC sample. Ligands that bind to the proteins and antibodies directed against  
 CC the proteins are useful for detecting the proteins and for detecting  
 CC HBcAg and HBeAg (precore precursor proteins). They are also useful for  
 CC preparing a vaccine or medicament for treating HBV infections. The  
 CC present sequence is the complete coding sequence of the HBV preCore/Core  
 CC gene  
 XX  
 SQ Sequence 675 BP; 149 A; 165 C; 147 G; 214 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 4; Length 675;  
 Best Local Similarity 100.0%; Pred. No. 8.5;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 RESULT 31  
 AAD09092/c  
 ID AAD09092 standard; DNA; 673 BP.  
 XX  
 AC AAD09092;  
 DT 04-SEP-2001 (first entry)  
 XX  
 DE Hepatitis B virus FRI strain genotype G PreCore/HBcAg DNA.  
 XX  
 KW HBV genotype G; preCore; HBPol; polymerase; envelope protein; preS1;  
 KW preS2; surface antigen; HBSAg; HBx protein; vaccine; liver disease;  
 KW hepatitis; liver cancer; HBcAg; core antigen; ds.  
 XX  
 OS Hepatitis B virus.  
 XX  
 FH Key Location/Qualifiers  
 CDS 1..672  
 FT 1..672  
 FT /tag= a  
 FT /product= "PreCore/HBcAg core protein"  
 FT /transl\_except= (pos:4..6, aa:Xaa)  
 FT /transl\_except= (pos:82..84, aa:Xaa)  
 FT /note= "Xaa corresponds to in-frame stop codon; Does not  
 FT include stop codon"  
 FT /partial  
 FT 1..87  
 FT /tag= b  
 FT /note= "PreCore protein DNA"  
 FT 88..672  
 FT /tag= c  
 FT /note= "HBcAg core protein DNA"  
 FT 94..129  
 FT /tag= d  
 FT /note= "Core insert peptide DNA"  
 FT  
 XX  
 PN WO200138498-A2.  
 XX  
 PD 31-MAY-2001.  
 XX  
 PF 21-NOV-2000; 2000WO-US032108.  
 XX  
 PR 24-NOV-1999; 99US-0167206P.  
 XX  
 PA (PHAR-) PHARMASSET INC.  
 PA (INNO-) INNOGENETICS NV.  
 XX  
 PI Stuyver L, Schinazi R, De Gendt S, Van Geyt C, Zoulim F, Fried M;  
 PI Rossau R;  
 XX  
 DR WPI; 2001-367676/38.  
 DR P-PSDB; AAE04707.  
 XX  
 XX Novel hepatitis B virus genotype G, nucleic acids encoding virus,  
 PT polypeptides encoded by nucleic acids, useful for preparing vaccine to  
 PT treat or prevent the hepatitis B virus genotype G infection in a subject.  
 XX  
 PS Claim 4; Page 56-57; 84pp; English.  
 CC  
 CC The present invention relates to hepatitis B virus (HBV) strain FRI,  
 CC genotype G DNA encoding PreCore/Core protein, HBPol, envelope (PreS1,  
 CC PreS2 and surface antigen HBSAg) and HBx proteins. HBV genotype G nucleic  
 CC acids and polypeptides are useful for diagnosing, prognosing and treating  
 CC infections caused by HBV genotype G. They can be used in a vaccine to  
 CC treat or prevent HBV genotype G infection. The HBV genotype G derived  
 CC nucleic acids and antibodies are useful for detecting HBV genotype G in a  
 CC sample or diagnosis of HBV genotype G infection. The presence of HBV  
 CC genotype G statistically correlates with the presence of liver damage  
 CC and/or liver cancer in the subject. The HBV genotype G core insert  
 CC peptide encoding nucleic acid is useful for designing monitoring assays  
 CC to study and predict the evolution of anti-HBe and anti-HBc antibodies  
 CC and HBeAg (genotype G e antigen) in patients infected with HBV. The  
 CC antibodies or antigens of HBV genotype G are useful for identifying a

```

QY      1 AGAGATGATTAGGCAGAGGT 20
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 33
AAH77566/c
ID      AAH77566 standard; DNA; 681 BP.
XX
AC      AAH77566;
XX
KW      HBsAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBeAg;
KW      HBeAg; ds.
XX
DT      19-OCT-2001 (first entry)
XX
DE      HBV genotype A strain HBVXCPs preCore/Core DNA.
XX
KW      Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;
KW      HBeAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBeAg;
KW      HBeAg; ds.
XX
OS      Hepatitis B virus.
XX
PN      WO200140279-A2.
XX
PD      07-JUN-2001.
XX
PF      20-NOV-2000; 2000WO-EP011526.
XX
PR      03-DEC-1999; 99EP-00870252.
PR      07-DEC-1999; 99US-0169287P.
XX
PA      (INNO-) INNOGENETICS NV.
XX
PI      Stuyver L, Van Geyt C, De Gendt S;
XX      WPI; 2001-374785/39.
XX
PT      Novel isolated and/or purified hepatitis B virus polypeptide and
PT      polynucleotide sequences that are phylogenetically different from HBV
PT      genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT      therapy.
XX
PS      Example 2; Fig 7; 94pp; English.
XX
CC      The invention relates to the complete nucleic acid sequence of a new
CC      human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC      This genotype was found with a high prevalence in patients chronically
CC      infected with HBV and residing in Europe and the USA. The invention
CC      relates to a fully defined sequence of 3248 nucleotides as given in
CC      specification, a sequence with 92% identity to the given sequence, or
CC      sequence that is degenerate to the mentioned sequences. These
CC      polynucleotides are useful for HBV genotyping. The proteins encoded by
CC      the polynucleotides are useful for detecting antibodies in a biological
CC      sample. Ligands that bind to the proteins and antibodies directed against
CC      the proteins are useful for detecting the proteins and for detecting
CC      HBcAg and HBeAg (precursor proteins). They are also useful for
CC      preparing a vaccine or medicament for treating HBV infections. The
CC      present sequence is provided in an alignment of preCore/Core sequences of
CC      an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC      US6, US7, US9, US10) of HBV genotype G
XX
SQ      Sequence 681 BP; 151 A; 166 C; 139 G; 189 T; 0 U; 36 Other;

Query Match      100.0%; Score 20; DB 4; Length 681;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 34
AAH77567/c
ID      AAH77567 standard; DNA; 681 BP.
XX
AC      AAH77567;
XX
DT      19-OCT-2001 (first entry)
XX
DE      HBV genotype G strain FR1 preCore/Core DNA.
XX
KW      Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;
KW      HBeAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBeAg;
KW      HBeAg; ds.
XX
OS      Hepatitis B virus.
XX
PN      WO200140279-A2.
XX
PD      07-JUN-2001.
XX
PF      20-NOV-2000; 2000WO-EP011526.
XX
PR      03-DEC-1999; 99EP-00870252.
PR      07-DEC-1999; 99US-0169287P.
XX
PA      (INNO-) INNOGENETICS NV.
XX
PI      Stuyver L, Van Geyt C, De Gendt S;
XX      WPI; 2001-374785/39.
XX
PT      Novel isolated and/or purified hepatitis B virus polypeptide and
PT      polynucleotide sequences that are phylogenetically different from HBV
PT      genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT      therapy.
XX
PS      Claim 3; Fig 7; 94pp; English.
XX
CC      The invention relates to the complete nucleic acid sequence of a new
CC      human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC      This genotype was found with a high prevalence in patients chronically
CC      infected with HBV and residing in Europe and the USA. The invention
CC      relates to a fully defined sequence of 3248 nucleotides as given in
CC      specification, a sequence with 92% identity to the given sequence, or
CC      sequence that is degenerate to the mentioned sequences. These
CC      polynucleotides are useful for HBV genotyping. The proteins encoded by
CC      the polynucleotides are useful for detecting antibodies in a biological
CC      sample. Ligands that bind to the proteins and antibodies directed against
CC      the proteins are useful for detecting the proteins and for detecting
CC      HBcAg and HBeAg (precursor proteins). They are also useful for
CC      preparing a vaccine or medicament for treating HBV infections. The
CC      present sequence is provided in an alignment of preCore/Core sequences of
CC      an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC      US6, US7, US9, US10) of HBV genotype G
XX
SQ      Sequence 681 BP; 149 A; 165 C; 147 G; 214 T; 0 U; 6 Other;

Query Match      100.0%; Score 20; DB 4; Length 681;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 35
AAH80943/c
ID      AAH80943 standard; DNA; 750 BP.
XX
AC      AAH80943;
XX
DT      25-MAR-2003 (revised)
DT      19-NOV-1990 (first entry)

```



XX HBV core gene of plasmid pHBV-8.  
 XX Hepatitis B core antigen; virus; vaccine; immunoassay; ss.  
 KW Hepatitis B virus.  
 XX  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FT CDS 31..675 /\*tag= a "HBcAg"  
 FT /\*product= "HBcAg"  
 XX  
 XX EP272483-A.  
 XX  
 XX 29-JUN-1988.  
 XX  
 XX 25-NOV-1987; 87EP-00117370.  
 XX  
 XX 19-DEC-1986; 86US-00944645.  
 XX  
 XX (ABBO ) ABBOTT LAB.  
 XX  
 XX Andersen PR, Mushahwar IK, Mimms LT, Staller JM;  
 XX WPI; 1988-176639/26.  
 DR P-PSDB; AAP80961.  
 XX  
 XX Polynucleotide encoding HBEAG and HBCAG immuno-reactive polypeptide -  
 PT useful in immunoassays, for raising antibodies and as vaccine prods.  
 XX  
 XX Disclosure; Page ?; 32pp; English.  
 XX  
 XX The cloned HBV DNA can be used to engineer plasmids for HBcAg synthesis  
 CC in bacteria. The DNA may be fused to a gene for beta galactosidase. The  
 CC recombinant protein can be used for immuno- assays, to raise antibodies,  
 CC and in vaccines. See also AAN82265 and 66. (Updated on 25-MAR-2003 to  
 CC correct PI field.)  
 XX  
 XX Sequence 750 BP; 176 A; 192 C; 160 G; 222 T; 0 U; 0 Other;  
 SQ  
 Query Match 100.0%; Score 20; DB 1; Length 750;  
 Best Local Similarity 100.0%; Pred. No. 8.6;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 DB 63 AGAGATGATTAGGCAGAGGT 44  
 RESULT 36  
 AAH77169/c  
 ID AAH77169 standard; DNA; 909 BP.  
 XX  
 AC AAH77169;  
 XX  
 DT 23-JAN-2002 (first entry)  
 XX  
 DE Regulatory and coding region of the X15 component in the X-myc construct.  
 XX  
 KW Transgenic mouse; cancer; oncogene; bicistronic hepatitis B virus; HBV;  
 KW X15-c-myc transgene; hepatocellular carcinoma; malignant liver tumour;  
 KW X15; c-myc; murine; HBX; carcinogen; ds.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN US6274788-B1.  
 XX  
 PD 14-AUG-2001.  
 XX  
 PF 02-FEB-1999; 99US-00243282.  
 XX  
 XX 23-SEP-1998; 98IN-DE002858.  
 XX  
 XX  
 (ITGE-) INT CENT GENETIC ENG & BIOTECHNOLOGY.  
 (NAIM-) NAT INST IMMUNOLOGY.  
 PI Kumar V, Singh M, Totey S, Anand R;  
 XX WPI; 2002-009266/01.  
 XX  
 XX New bicistronic hepatitis B virus (HBV) X15-c-myc transgene, useful for  
 PT producing transgenic mouse model systems for human hepatocellular  
 PT carcinoma, comprises HBV X15 transgene and c-myc transgene.  
 XX  
 PS Claim 3; Fig 3; 12pp; English.  
 XX  
 XX This polynucleotide represents the sequence of the regulatory and coding  
 CC regions of the X15 component in the X-myc construct. The invention  
 CC relates to a bicistronic hepatitis B virus (HBV) X15-c-myc transgene,  
 CC comprising of the HBV X15 gene and c-myc gene. The myc gene is known to  
 CC be an activatable oncogene. The transgene encodes a truncated HBV X15  
 CC protein that has amino acids 58-154 of HBV X15 and a murine c-myc  
 CC protein, respectively. A transgenic mouse containing the transgene  
 CC construct is useful for screening a candidate substance (CS), to  
 CC determine whether CS promotes hepatocellular carcinoma. This is  
 CC determined by exposing a transgenic mouse to CS, and monitoring the mouse  
 CC for the development of hepatocellular carcinoma, where an increase in the  
 CC development of hepatocellular carcinoma in the transgenic mouse exposed  
 CC to CS compared to the development of hepatocellular carcinoma in a  
 CC transgenic mouse not exposed to CS, indicates that CS promotes  
 CC hepatocellular carcinoma. The transgenic mice can be employed as a source  
 CC for cell and tissue culture. The transgenic animal models comprising of  
 CC the HBV X15-c-myc transgene for hepatocellular carcinoma are superior to  
 CC any transgenic animal model system for hepatocellular carcinoma in that  
 CC the transgenic mice develop more aggressive and accelerated onset of  
 CC malignant liver tumours in all lobes causing death of the affected  
 CC animals in 20-22 weeks, that is faster than the time taken by the other  
 CC transgenic animals to even develop a tumour  
 XX  
 SQ Sequence 909 BP; 210 A; 236 C; 211 G; 252 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 6; Length 909;  
 Best Local Similarity 100.0%; Pred. No. 8.8;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 DB 851 AGAGATGATTAGGCAGAGGT 832  
 RESULT 37  
 AAV82691/c  
 ID AAV82691 standard; DNA; 1334 BP.  
 XX  
 AC AAV82691;  
 XX  
 DT 16-FEB-1999 (first entry)  
 XX  
 DE Fulminant hepatitis B virus genotype D variant FHBV12 sequence.  
 XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN W09845421-A2.  
 XX  
 PD 15-OCT-1998.  
 XX  
 XX 08-APR-1998; 98WO-EP002048.  
 XX  
 XX 09-APR-1997; 97GB-00007221.  
 XX  
 XX (UNIU ) UNIV GLASGOW.  
 PA Carman B;  
 PI

XX WPI; 1999-009329/01.  
XX New hepatitis B virus nucleic acid with combination of specific mutations  
PT - useful for, e.g. detection of binding interactions between host or  
PT viral proteins and HBV nucleic.  
XX  
PS Disclosure; Fig 5; 85pp; English.  
XX  
XX The present sequence represents part of the genome of a fulminant  
CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
CC a mutation (i.e. alteration from the normal nucleotide in any of the  
CC genotypes A to F) in at least two of the enhancer I region, the negative  
CC regulatory element region, the enhancer II/ core upstream regulatory  
CC sequence/ basal core promoter region, or a mutation which leads to an X-  
CC peptide amino acid change to Cys or Met. The HBV variants of the  
CC invention are used to detect binding interactions between host or viral  
CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
CC specified mutated regions are used to detect HBV-related disease, or  
CC especially fulminant infection, but also severe chronic infection, or  
CC serologically unusual forms of disease. Combinations of the specified  
CC mutations are associated with fulminant infections, probably because they  
CC reduce the ability to bind inhibitory proteins in the host cell  
XX  
SQ Sequence 1334 BP; 288 A; 363 C; 311 G; 372 T; 0 U; 0 Other;  
Query Match 100.0%; Score 20; DB 2; Length 1334;  
Best Local Similarity 100.0%; Pred. No. 9.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGAGATGATTAGGCAGAGGT 20  
DB 735 AGAGATGATTAGGCAGAGGT 716  
RESULT 39  
AAV82688/c  
ID AAV82688 standard; DNA; 1395 BP.  
XX  
AC AAV82688;  
XX  
XX 16-FEB-1999 (first entry)  
XX Fulminant hepatitis B virus genotype D variant FHBV5 sequence.  
DE  
XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
KW HBV-related disease; ss.  
XX  
OS Hepatitis B virus.  
XX  
XX WO9845421-A2.  
XX  
PD 15-OCT-1998.  
XX  
PF 08-APR-1998; 98WO-EP002048.  
XX  
PR 09-APR-1997; 97GB-00007221.  
XX  
XX (UNIU ) UNIV GLASGOW.  
XX  
XX Carman B;  
XX  
XX WPI; 1999-009329/01.  
XX  
XX New hepatitis B virus nucleic acid with combination of specific mutations  
PT - useful for, e.g. detection of binding interactions between host or  
PT viral proteins and HBV nucleic.  
XX  
PS Disclosure; Fig 5; 85pp; English.  
XX  
XX The present sequence represents part of the genome of a fulminant  
CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.

CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
CC a mutation (i.e. alteration from the normal nucleotide in any of the  
CC genotypes A to F) in at least two of the enhancer I region, the negative  
CC regulatory element region, the enhancer II/ core upstream regulatory  
CC sequence/ basal core promoter region, or a mutation which leads to an X-  
CC peptide amino acid change to Cys or Met. The HBV variants of the  
CC invention are used to detect binding interactions between host or viral  
CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
CC specified mutated regions are used to detect HBV-related disease, or  
CC especially fulminant infection, but also severe chronic infection, or  
CC serologically unusual forms of disease. Combinations of the specified  
CC mutations are associated with fulminant infections, probably because they  
CC reduce the ability to bind inhibitory proteins in the host cell  
XX  
SQ Sequence 1395 BP; 277 A; 387 C; 331 G; 398 T; 0 U; 2 Other;  
Query Match 100.0%; Score 20; DB 2; Length 1395;  
Best Local Similarity 100.0%; Pred. No. 9.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGAGATGATTAGGCAGAGGT 20  
DB 846 AGAGATGATTAGGCAGAGGT 827  
RESULT 39  
AAV82687/c  
ID AAV82687 standard; DNA; 1400 BP.  
XX  
AC AAV82687;  
XX  
XX 16-FEB-1999 (first entry)  
XX Fulminant hepatitis B virus genotype D variant FHBV4 sequence.  
DE  
XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
KW HBV-related disease; ss.  
XX  
OS Hepatitis B virus.  
XX  
XX WO9845421-A2.  
XX  
PD 15-OCT-1998.  
XX  
PF 08-APR-1998; 98WO-EP002048.  
XX  
PR 09-APR-1997; 97GB-00007221.  
XX  
XX (UNIU ) UNIV GLASGOW.  
XX  
XX Carman B;  
XX  
XX WPI; 1999-009329/01.  
XX  
XX New hepatitis B virus nucleic acid with combination of specific mutations  
PT - useful for, e.g. detection of binding interactions between host or  
PT viral proteins and HBV nucleic.  
XX  
PS Disclosure; Fig 5; 85pp; English.  
XX  
XX The present sequence represents part of the genome of a fulminant  
CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
CC a mutation (i.e. alteration from the normal nucleotide in any of the  
CC genotypes A to F) in at least two of the enhancer I region, the negative  
CC regulatory element region, the enhancer II/ core upstream regulatory  
CC sequence/ basal core promoter region, or a mutation which leads to an X-  
CC peptide amino acid change to Cys or Met. The HBV variants of the  
CC invention are used to detect binding interactions between host or viral  
CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
CC specified mutated regions are used to detect HBV-related disease, or  
CC especially fulminant infection, but also severe chronic infection, or  
CC serologically unusual forms of disease. Combinations of the specified

CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1400 BP; 287 A; 388 C; 332 G; 393 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 1400;  
 Best Local Similarity 100.0%; Pred. No. 9.2;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||

Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 40

AAV82692/c

ID AAV82692 standard; DNA; 1445 BP.

XX

AC AAV82692;

XX

DT 16-FEB-1999 (first entry)

XX

DE Fulminant hepatitis B virus genotype D variant FHBV13 sequence.

XX

KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;

XX

KW HBV-related disease; ss.

XX

OS Hepatitis B virus.

XX

PN WO9845421-A2.

XX

PD 15-OCT-1998.

XX

PF 08-APR-1998; 98WO-EP002048.

XX

PR 09-APR-1997; 97GB-00007221.

XX

PA (UNITU ) UNIV GLASGOW.

XX

PI Carman B;

XX

DR WPI; 1999-009329/01.

XX

PT New hepatitis B virus nucleic acid with combination of specific mutations

XX

PT - useful for, e.g. detection of binding interactions between host or

XX

PT viral proteins and HBV nucleic.

XX

PS Disclosure; Fig 5; 85pp; English.

XX

CC The present sequence represents part of the genome of a fulminant

XX

CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.

XX

CC The specification describes Hepatitis B virus (HBV) nucleic acid that has

XX

CC a mutation (i.e. alteration from the normal nucleotide in any of the

XX

CC genotypes A to F) in at least two of the enhancer I region, the negative

XX

CC regulatory element region, the enhancer II/ core upstream regulatory

XX

CC sequence/ basal core promoter region, or a mutation which leads to an X-

XX

CC peptide amino acid change to Cys or Met. The HBV variants of the

XX

CC invention are used to detect binding interactions between host or viral

XX

CC proteins and HBV nucleic acid. Probes that hybridise to any of the

XX

CC specified mutated regions are used to detect HBV-related disease,

XX

CC especially fulminant infection, but also severe chronic infection or

XX

CC serologically unusual forms of disease. Combinations of the specified

Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 41

AAV82685/c

ID AAV82685 standard; DNA; 1445 BP.

XX

AC AAV82685;

XX

DT 16-FEB-1999 (first entry)

XX

DE Fulminant hepatitis B virus genotype D variant FHBV2 sequence.

XX

KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;

XX

KW HBV-related disease; ss.

XX

OS Hepatitis B virus.

XX

PN WO9845421-A2.

XX

PD 15-OCT-1998.

XX

PF 08-APR-1998; 98WO-EP002048.

XX

PR 09-APR-1997; 97GB-00007221.

XX

PA (UNITU ) UNIV GLASGOW.

XX

PI Carman B;

XX

DR WPI; 1999-009329/01.

XX

PT New hepatitis B virus nucleic acid with combination of specific mutations

XX

PT - useful for, e.g. detection of binding interactions between host or

XX

PT viral proteins and HBV nucleic.

XX

PS Disclosure; Fig 5; 85pp; English.

XX

CC The present sequence represents part of the genome of a fulminant

XX

CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.

XX

CC The specification describes Hepatitis B virus (HBV) nucleic acid that has

XX

CC a mutation (i.e. alteration from the normal nucleotide in any of the

XX

CC genotypes A to F) in at least two of the enhancer I region, the negative

XX

CC regulatory element region, the enhancer II/ core upstream regulatory

XX

CC sequence/ basal core promoter region, or a mutation which leads to an X-

XX

CC peptide amino acid change to Cys or Met. The HBV variants of the

XX

CC invention are used to detect binding interactions between host or viral

XX

CC proteins and HBV nucleic acid. Probes that hybridise to any of the

XX

CC specified mutated regions are used to detect HBV-related disease,

XX

CC especially fulminant infection, but also severe chronic infection or

XX

CC serologically unusual forms of disease. Combinations of the specified

XX

CC mutations are associated with fulminant infections, probably because they

XX

CC reduce the ability to bind inhibitory proteins in the host cell

XX

SQ Sequence 1445 BP; 298 A; 393 C; 340 G; 414 T; 0 U; 0 Other;

XX

Query Match 100.0%; Score 20; DB 2; Length 1445;

Best Local Similarity 100.0%; Pred. No. 9.2;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 42

AAV82690/c

ID AAV82690 standard; DNA; 1445 BP.

XX

AC AAV82690;

XX

DT 16-FEB-1999 (first entry)

XX

XX

XX

XX

XX

XX

XX

DE Fulminant hepatitis B virus genotype D variant FHBV7 sequence.  
 XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO9845421-A2.  
 XX  
 XX 15-OCT-1998.  
 XX  
 XX  
 PF 08-APR-1998; 98WO-EP002048.  
 XX  
 PR 09-APR-1997; 97GB-00007221.  
 XX  
 XX (UNIU ) UNIV GLASGOW.  
 PA Carman B;  
 XX  
 PI WPI; 1999-009329/01.  
 DR  
 DR New hepatitis B virus nucleic acid with combination of specific mutations  
 XX - useful for, e.g. detection of binding interactions between host or  
 XX viral proteins and HBV nucleic.  
 XX  
 PS Disclosure; Fig 5; 85pp; English.  
 XX  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1445 BP; 293 A; 402 C; 340 G; 410 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1445;  
 Best Local Similarity 100.0%; Pred. No. 9.2;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 846 AGAGATGATTAGGCAGAGGT 827  
 RESULT 43  
 AAV82684/c  
 ID AAV82684 standard; DNA; 1445 BP.  
 XX  
 AC AAV82684;  
 XX  
 XX 16-FEB-1999 (first entry)  
 DT  
 XX Fulminant hepatitis B virus genotype D variant FHBV1 sequence.  
 DE  
 XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO9845421-A2.  
 XX  
 XX 15-OCT-1998.  
 PD  
 XX

PF 08-APR-1998; 98WO-EP002048.  
 XX  
 PR 09-APR-1997; 97GB-00007221.  
 XX  
 XX (UNIU ) UNIV GLASGOW.  
 PA Carman B;  
 XX  
 PI WPI; 1999-009329/01.  
 DR  
 DR New hepatitis B virus nucleic acid with combination of specific mutations  
 XX - useful for, e.g. detection of binding interactions between host or  
 XX viral proteins and HBV nucleic.  
 XX  
 PS Disclosure; Fig 5; 85pp; English.  
 XX  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1445 BP; 298 A; 400 C; 336 G; 411 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1445;  
 Best Local Similarity 100.0%; Pred. No. 9.2;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 846 AGAGATGATTAGGCAGAGGT 827  
 RESULT 44  
 AAV82695/c  
 ID AAV82695 standard; DNA; 1500 BP.  
 XX  
 AC AAV82695;  
 XX  
 XX 16-FEB-1999 (first entry)  
 DT  
 XX Fulminant hepatitis B virus genotype D variant CHBV2 sequence.  
 DE  
 XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO9845421-A2.  
 XX  
 XX 15-OCT-1998.  
 PD  
 XX  
 PF 08-APR-1998; 98WO-EP002048.  
 XX  
 PR 09-APR-1997; 97GB-00007221.  
 XX  
 XX (UNIU ) UNIV GLASGOW.  
 PA Carman B;  
 XX  
 PI WPI; 1999-009329/01.  
 DR  
 DR New hepatitis B virus nucleic acid with combination of specific mutations  
 XX

PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 XX  
 PS Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (HBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1500 BP; 308 A; 412 C; 347 G; 433 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 100.0%; Pred. No. 9.3;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGGCT 20  
 DB 846 AGAGATGATTAGGCAGGCT 827

RESULT 45  
 AA82683/C  
 ID AA82683 standard; DNA; 1500 BP.  
 XX  
 AC AA82683;  
 XX  
 DT 16-FEB-1999 (first entry)  
 XX  
 DE Fulminant hepatitis B virus genotype D variant AHBV1 sequence.

XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.

XX Hepatitis B virus.

XX WO9845421-A2.

XX 15-OCT-1998.

XX 08-APR-1998; 98WO-EP002048.

XX 09-APR-1997; 97GB-00007221.

XX (UNITU ) UNIV GLASGOW.

XX Carman B;

XX WPI; 1999-009329/01.

XX New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.

XX Disclosure; Fig 5; 85pp; English.

XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (HBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory

CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX

SQ Sequence 1500 BP; 305 A; 411 C; 354 G; 430 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 100.0%; Pred. No. 9.3;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGGCT 20  
 DB 846 AGAGATGATTAGGCAGGCT 827

RESULT 46  
 AA82694/C  
 ID AA82694 standard; DNA; 1500 BP.  
 XX  
 AC AA82694;  
 XX  
 DT 16-FEB-1999 (first entry)  
 XX  
 DE Fulminant hepatitis B virus genotype D variant HBVP2CSX sequence.

XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.

XX Hepatitis B virus.

XX WO9845421-A2.

XX 15-OCT-1998.

XX 08-APR-1998; 98WO-EP002048.

XX 09-APR-1997; 97GB-00007221.

XX (UNITU ) UNIV GLASGOW.

XX Carman B;

XX WPI; 1999-009329/01.

XX New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.

XX Disclosure; Fig 5; 85pp; English.

XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (HBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX

SQ Sequence 1500 BP; 305 A; 408 C; 349 G; 438 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 100.0%; Pred. No. 9.3;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 47  
 AAV82686/c  
 ID AAV82686 standard; DNA; 1500 BP.  
 XX AC AAV82686;  
 XX DT 16-FEB-1999 (first entry)  
 XX DE Fulminant hepatitis B virus genotype D variant FHBV3 sequence.  
 XX KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 XX KW HBV-related disease; ss.  
 XX OS Hepatitis B virus.  
 XX PN WO9845421-A2.  
 XX PD 15-OCT-1998.  
 XX PF 08-APR-1998; 98WO-EP002048.  
 XX PR 09-APR-1997; 97GB-00007221.  
 XX PA (UNIU ) UNIV GLASGOW.  
 XX PI Carman B;  
 XX DR WPI; 1999-009329/01.  
 XX PT New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 PS Disclosure; Fig 5; 85pp; English.  
 XX CC The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 846 AGAGATGATTAGGCAGAGGT 827

Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 100.0%; Pred. No. 9.3;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 48

AAV82706/c  
 ID AAV82706 standard; DNA; 1500 BP.  
 XX AC AAV82706;  
 XX DT 16-FEB-1999 (first entry)  
 XX DE Wild type hepatitis B virus genotype D nucleotides 1000-2500.  
 XX KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 XX KW HBV-related disease; ss.  
 XX OS Hepatitis B virus.  
 XX PN WO9845421-A2.  
 XX PD 15-OCT-1998.  
 XX PF 08-APR-1998; 98WO-EP002048.  
 XX PR 09-APR-1997; 97GB-00007221.  
 XX PA (UNIU ) UNIV GLASGOW.  
 XX PI Carman B;  
 XX DR WPI; 1999-009329/01.  
 XX PT New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 PS Disclosure; Fig 5; 85pp; English.  
 XX CC The present sequence represents part of the genome of wild type Hepatitis  
 CC B virus genotype D, nucleotides 1000 to 2500. Mutations occur in this  
 CC region in fulminant hepatitis B virus (FHBV) patients. The specification  
 CC describes Hepatitis B virus (HBV) nucleic acid that has a mutation (i.e.  
 CC alteration from the normal nucleotide in any of the genotypes A to F) in  
 CC at least two of the enhancer I region, the negative regulatory element  
 CC region, the enhancer II/ core upstream regulatory sequence/ basal core  
 CC promoter region, or a mutation which leads to an X-peptide amino acid  
 CC change to Cys or Met. The HBV variants of the invention are used to  
 CC detect binding interactions between host or viral proteins and HBV  
 CC nucleic acid. Probes that hybridise to any of the specified mutated  
 CC regions are used to detect HBV-related disease, especially fulminant  
 CC infection, but also severe chronic infection or serologically unusual  
 CC forms of disease. Combinations of the specified mutations are associated  
 CC with fulminant infections, probably because they reduce the ability to  
 CC bind inhibitory proteins in the host cell

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 846 AGAGATGATTAGGCAGAGGT 827

Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 100.0%; Pred. No. 9.3;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 49  
 AAV82689/c  
 ID AAV82689 standard; DNA; 1500 BP.  
 XX AC AAV82689;  
 XX DT 16-FEB-1999 (first entry)  
 XX DE Fulminant hepatitis B virus genotype D variant FHBV6 sequence.  
 XX KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;

```
KW HBV-related disease; ss.
XX
OS Hepatitis B virus.
XX
PN WO9845421-A2.
XX
PD 15-OCT-1998.
XX
XX
PF 08-APR-1998; 98WO-EF002048.
XX
PR 09-APR-1997; 97GB-00007221.
XX
PA (UNIU ) UNIV GLASGOW.
XX
XX Carman B;
XX WPI; 1999-009329/01.
XX
XX New hepatitis B virus nucleic acid with combination of specific mutations
PT - useful for, e.g. detection of binding interactions between host or
PT viral proteins and HBV nucleic.
XX
XX Disclosure; Fig 5; 85pp; English.
XX
XX The present sequence represents part of the genome of a fulminant
CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.
CC The specification describes Hepatitis B virus (HBV) nucleic acid that has
CC a mutation (i.e. alteration from the normal nucleotide in any of the
CC genotypes A to F) in at least two of the enhancer I region, the negative
CC regulatory element region, the enhancer II/ core upstream regulatory
CC sequence/ basal core promoter region, or a mutation which leads to an X-
CC peptide amino acid change to Cys or Met. The HBV variants of the
CC invention are used to detect binding interactions between host or viral
CC proteins and HBV nucleic acid. Probes that hybridise to any of the
CC specified mutated regions are used to detect HBV-related disease,
CC especially fulminant infection, but also severe chronic infection or
CC serologically unusual forms of disease. Combinations of the specified
CC mutations are associated with fulminant infections, probably because they
CC reduce the ability to bind inhibitory proteins in the host cell
XX
SQ Sequence 1500 BP; 302 A; 416 C; 353 G; 427 T; 0 U; 2 Other;
Query Match 100.0%; Score 20; DB 2; Length 1500;
Best Local Similarity 100.0%; Pred. No. 9.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGAGATGATTAGGCAGAGGT 20
DB 846 AGAGATGATTAGGCAGAGGT 827
RESULT 50
AAV82693/C
ID AAV82693 standard; DNA; 1500 BP.
XX
XX AAV82693;
XX
XX 16-FEB-1999 (first entry)
XX
XX Fulminant hepatitis B virus genotype D variant HBVP3CSX sequence.
XX
XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;
KW HBV-related disease; ss.
XX
XX Hepatitis B virus.
XX
XX WO9845421-A2.
XX
XX 15-OCT-1998.
XX
XX 08-APR-1998; 98WO-EF002048.
XX
XX 09-APR-1997; 97GB-00007221.
XX
```

THIS PAGE LEFT BLANK



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 15, 2004, 09:10:16 ; Search time 1339.5 Seconds  
(without alignments)  
544.080 Million cell updates/sec

Title: US-08-901-612A-7

Perfect score: 20

Sequence: 1 agagatgattaggcagaggt 20

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database :

EST:\*

1: gb\_est1:\*

2: gb\_est2:\*

3: gb\_hic:\*

4: gb\_est3:\*

5: gb\_est4:\*

6: gb\_est5:\*

7: gb\_est6:\*

8: gb\_gsa1:\*

9: gb\_gsa2:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	18.4	92.0	547	4	BG487106 dad25b04.
2	18.4	92.0	587	5	BQ5233985 NISC no02
3	18.4	92.0	612	7	CO359322 DR ATE_SU
4	18.4	92.0	689	7	CN090609 EC2BBA33C
5	18.4	92.0	731	7	CN095940 EC2CAA16B
6	18.4	92.0	794	7	CO799851 AGENCOURT
7	18.4	92.0	859	5	BX693640 BX693640
8	18.4	92.0	869	7	CR417260 CR417260
9	18.4	92.0	886	7	CO812154 AGENCOURT
10	18.4	92.0	896	7	CR445414 CR445414
11	18.4	92.0	910	5	BX699062 BX699062
12	18.4	92.0	913	5	BX683124 BX683124
13	18.4	92.0	914	5	BX694706 BX694706
14	18.4	92.0	914	2	AW342249 GthEST1 G
15	17.4	87.0	354	2	AW215253 up05g04.y
16	17.4	87.0	354	2	BQ315866 CM3-CT003
17	17.4	87.0	680	5	BG440037 GA_Ea000
18	17.4	87.0	741	8	BH039638 RPT-24-2
19	17.4	87.0	1032	8	BN030290K Tetraodon
20	17.4	87.0	1044	9	CNS027K3 Tetraodon
21	17.4	87.0	248	2	BB361792 BB361792
22	17.4	87.0	490	8	AQ355954 CIT91-E1
23	16.8	84.0	145	2	BF330446 MR2-BN036
24	16.8	84.0	146	2	BF330451 MR2-BN036

98 16 80.0 501 7 CN283739 CN283739 170004252  
 c 99 16 80.0 649 9 CC956922 CC956922 BO1CH02TR  
 c 100 16 80.0 682 8 BH972205 BH972205 odj23g10.

## ALIGNMENTS

RESULT 1  
 BG487106 547 bp mRNA linear EST 22-MAR-2001  
 LOCUS gda25b04.x1 Wellcome CRC PCS107 tropicalis St10-12 Xenopus  
 DEFINITION tropicalis cDNA clone IMAGE:4440511 3', mRNA sequence.  
 BG487106  
 VERSION BG487106.1 GI:13434683  
 KEYWORDS EST.  
 SOURCE Xenopus tropicalis (western clawed frog)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;  
 Xenopodinae; Xenopus; Silurana.  
 REFERENCE 1 (bases 1 to 547)  
 AUTHORS Clifton, S., Johnson, S.L., Blumberg, B., Song, J., Hillier, L.,  
 Pape, D., Martin, J., Wylie, R., Underwood, K., Theising, B., Bowers, Y.,  
 Person, B., Gibbons, M., Harvey, N., Ritter, E., Jackson, Y., McCann, R.,  
 Waterston, R., and Wilson, R.  
 TITLE Washu Xenopus EST project, 1999  
 JOURNAL Unpublished (1999)  
 COMMENT Contact: Sandy Clifton, Ph.D.  
 Washu Xenopus EST project, 1999  
 Washington University School of Medicine  
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA  
 Tel: 314 286 1800  
 Fax: 314 286 1810  
 Email: est@watson.wustl.edu  
 Library constructed by A. Zorn and J. Mason (Wellcome/CRC  
 Institute). DNA Sequencing by: Washington University Genome  
 Sequencing Center  
 Clone distribution: Xenopus clones from this library are available  
 through the I.M.A.G.E. Consortium/LLNL at: info@image.llnl.gov  
 Seq primer: -40UP from Gibco  
 High quality sequence stop: 507.

## FEATURES

Location/Qualifiers  
 1..547  
 /organism="Xenopus tropicalis"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:8364"  
 /clone="IMAGE:4440511"  
 /tissue\_type="whole embryo, stages 10-12"  
 /lab\_host="PH108 (phage-resistant)"  
 /clone\_lib="Wellcome CRC PCS107 tropicalis St10-12"  
 /note="Vector: pcMV-SF0R6.1; Site 1: NotI; Site 2: EcoRI; cDNAS  
 were oligo-dT primed and directionally cloned. Average  
 insert size 1.5 kb, range 0.5-4 kb. Library constructed by  
 A. Zorn and J. Mason (Wellcome/CRC Institute)."

## ORIGIN

Query Match 92.0%; Score 18.4; DB 4; Length 547;  
 Best Local Similarity 95.0%; Pred. No. 3.1e+02;  
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 234 AAAGATGATTAGGCAGAGGT 253

RESULT 2  
 BQ523985 587 bp mRNA linear EST 10-JUN-2002  
 LOCUS NISC nc02b04.x1 NICHG XCC\_Emb8 Xenopus tropicalis cDNA clone  
 DEFINITION IMAGE:5379775 3', mRNA sequence.  
 BQ523985  
 ACCESSION BQ523985  
 VERSION BQ523985.1 GI:21382854

## KEYWORDS

Xenopus tropicalis (western clawed frog)  
 Xenopus tropicalis  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;  
 Xenopodinae; Xenopus; Silurana.  
 REFERENCE 1 (bases 1 to 587)  
 AUTHORS NIH-XCG http://image.llnl.gov/image/html/xenopuslib\_info.shtml.  
 TITLE National Institute of Child Health and Human Development, National  
 Cancer Institute, Xenopus Gene Collection  
 JOURNAL Unpublished (2002)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Email: cgapbs-r@mail.nih.gov  
 CDNA Library Preparation:  
 DNA Library Arrayed by: The I.M.A.G.E. Consortium/LLNL  
 DNA Sequencing by: National Institutes of Health Intramural  
 Sequencing Center (NISC)  
 Clone distribution: NCI-CGAP clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 info@image.llnl.gov  
 Plate: LLAM1967 row: C column: 8  
 Seq primer: -21M13 forward primer (ABI).

## FEATURES

Location/Qualifiers  
 1..587  
 /organism="Xenopus tropicalis"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:8364"  
 /clone="IMAGE:5379775"  
 /tissue\_type="tadpole"  
 /dev\_stage="embryo, stages 40-45"  
 /lab\_host="DH10B (phage-resistant)"  
 /clone\_lib="NICHG XCC\_Emb8"  
 /note="Vector: pcMV-SF0R6.1; Site 1: NotI; Site 2: EcoRV;  
 cloned unidirectionally. Primer: Oligo dT. Average insert  
 size 2.1 kb. Constructed by Invitrogen. Note: This is a  
 Xenopus Gene Collection (XGC) library."

## ORIGIN

Query Match 92.0%; Score 18.4; DB 5; Length 587;  
 Best Local Similarity 95.0%; Pred. No. 3.1e+02;  
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 |||||  
 Db 244 AAAGATGATTAGGCAGAGGT 263

## RESULT 3

CO359322  
 LOCUS DR ATE SU03 G11 adult testis subtracted 1 (TLL) Danio rerio cDNA,  
 DEFINITION mRNA sequence.  
 CO359322  
 ACCESSION CO359322.1 GI:49440639  
 VERSION CO359322.1  
 KEYWORDS EST.  
 SOURCE Danio rerio (zebrafish)

## ORIGINISM

Danio rerio  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Actinopterygii; Neopterygii; Teleostei; Ostariophysi;  
 Cypriniformes; Cyprinidae; Danio.  
 REFERENCE 1 (bases 1 to 612)  
 AUTHORS Li, Y., Chia, J.M., Bartfai, R., Christoffels, A., Yue, G.H., Ke, D.,  
 Ho, M.Y., Hill, J.A., Stupka, E., and Orban, L.  
 TITLE Comparative analysis of the testis and ovary transcripts in  
 zebrafish by combining experimental and computational tools  
 JOURNAL Unpublished (2004)  
 COMMENT Contact: Laszlo ORBAN  
 Reproductive Genomics Group  
 Temasek Life Sciences Laboratory  
 1 Research Link, The NUS, Singapore 117 604  
 Tel: +65 6872 7413  
 Fax: +65 6872 7007  
 Email: laszlo@tll.org.sg

Similar to Q9CUZ3  
High quality sequence stop: 612.  
Location/Qualifiers  
1. .612  
/organism="Danio rerio"  
/mol\_type="mRNA"  
/strain="roh (Singaporean strain)"  
/db\_xref="taxon:7955"  
/sex="male"  
/dev\_stage="adult (fully mature)"  
/clone\_lib="adult testis substracted 1 (TLL)"  
/notes="Organ: pooled testis; Vector: pT-Advantage; cDNA was synthesized from adult testis and ovary total RNA using SMART PCR cDNA synthesis kit (Clontech). PCR-SelectTM cDNA subtraction kit (Clontech) was used to enrich for fragments, which were present in the testis but not in the ovary cDNA. The selectively amplified cDNA fragments (in average 400-800bp in length) were ligated into pT-Advantage (Clontech) and transformed into XL10-Gold competent cells (Stratagene). The insert from randomly selected white colonies was PCR amplified using M13 forward and reverse primers and partially sequenced by using M13 reverse primer."

## ORIGIN

Query Match 92.0%; Score 18.4; DB 7; Length 612;  
Best Local Similarity 95.0%; Pred. No. 3.1e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGCT 20  
|||||  
Db 474 AGAGATGTTAGGCAGGCT 493

## RESULT 4

CN090609 689 bp mRNA linear EST 31-MAR-2004  
LOCUS EC2BBA33CG11.b1 Xenopus tropicalis xtbs plasmid library Xenopus  
DEFINITION tropicalis cDNA clone xtbs33N21 3', mRNA sequence.  
ACCESSION CN090609  
VERSION 1 GI:45883305  
KEYWORDS EST.  
SOURCE Xenopus tropicalis (western clawed frog)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Xenopodinae; Xenopus; Silurana.

## REFERENCE

1 (bases 1 to 689)  
Thuret,R., Fierro,A.C., Coen,L., Perron,M., Demeneix,B., Wegnez,M., Gyapay,G., Weissenbach,J., Wincker,P., Mazabraud,A. and Pollet,N. Exploring the nervous system transcriptome in the model Xenopus tropicalis using EST analysis  
Unpublished (2004)  
Contact: Pollet N  
Transgenese et Genetique des Amphibiens  
CNRS UMR 8080  
IBAC bat 447, Universite Paris Sud, Orsay, F-91405, France  
Tel: +33 169156816  
Fax: +33 169156816  
Email: Nicolas.Pollet@ibaic.u-psud.fr.  
Location/Qualifiers  
1. .689  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/strain="ivory coast"  
/db\_xref="taxon:8364"  
/clone="xtbs33N21"  
/tissue\_type="pool of brains and spinal cords from tadpoles at stages 51-52 and 61-62"  
/dev\_stage="stage 51-52 and 61-62"  
/lab\_host="E.coli DH10B"  
/clone\_lib="Xenopus tropicalis xtbs plasmid library"  
/notes="Vector: pCMVSPORT6 xtbs; Site\_1: Sf11; Site\_2:

## FEATURES

source  
1. .689  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/strain="ivory coast"  
/db\_xref="taxon:8364"  
/clone="xtbs33N21"  
/tissue\_type="pool of brains and spinal cords from tadpoles at stages 51-52 and 61-62"  
/dev\_stage="stage 51-52 and 61-62"  
/lab\_host="E.coli DH10B"  
/clone\_lib="Xenopus tropicalis xtbs plasmid library"  
/notes="Vector: pCMVSPORT6 xtbs; Site\_1: Sf11; Site\_2:

Sf11; Xenopus tropicalis polyA+ RNA was obtained from brain and spinal cord of tadpoles at stages 51-52 and 61-62. cDNAs were synthesized using the SMART system of CLONTECH and directionally cloned into pCMVSPORT6 xtbs, a modified version of pCMVSPORT6 allowing directional cloning using asymmetric Sf11 sites. For antisense RNA synthesis, use T7 promoter and for sense RNA use SP6 promoter. Library constructed by Dr. L. Coen and Prof. B. Demeneix (Museum National d'Histoire Naturelle and CNRS UMR 5166, Paris, France)."

## ORIGIN

Query Match 92.0%; Score 18.4; DB 7; Length 689;  
Best Local Similarity 95.0%; Pred. No. 3.2e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGCT 20  
|||||  
Db 188 AAAGATGATTAGGCAGGCT 207

## RESULT 5

CN099540 731 bp mRNA linear EST 31-MAR-2004  
LOCUS EC2CAA16BD09.b1 Xenopus tropicalis xthr plasmid library Xenopus  
DEFINITION tropicalis cDNA clone xthr16G18 3', mRNA sequence.  
ACCESSION CN099540  
VERSION 1 GI:45892236  
KEYWORDS EST.  
SOURCE Xenopus tropicalis (western clawed frog)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Xenopodinae; Xenopus; Silurana.

## REFERENCE

1 (bases 1 to 731)  
Thuret,R., Fierro,A.C., Coen,L., Perron,M., Demeneix,B., Wegnez,M., Gyapay,G., Weissenbach,J., Wincker,P., Mazabraud,A. and Pollet,N. Exploring the nervous system transcriptome in the model Xenopus tropicalis using EST analysis  
Unpublished (2004)  
Contact: Pollet N  
Transgenese et Genetique des Amphibiens  
CNRS UMR 8080  
IBAC bat 447, Universite Paris Sud, Orsay, F-91405, France  
Tel: +33 169157272  
Fax: +33 169156816  
Email: Nicolas.Pollet@ibaic.u-psud.fr.  
Location/Qualifiers  
1. .731  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/strain="ivory coast"  
/db\_xref="taxon:8364"  
/clone="xthr16G18"  
/tissue\_type="pool of heads and retinas from tailbud stages 25-35"  
/dev\_stage="stage 25-35"  
/lab\_host="E.coli DH10B"  
/clone\_lib="Xenopus tropicalis xthr plasmid library"  
/note="Vector: pCMVSPORT6 xthr; Site\_1: Sf11; Site\_2: Sf11; Xenopus tropicalis polyA+ RNA was obtained from pool of heads and retinas from tailbud stages 25-35 cDNAs were synthesized using the SMART system of CLONTECH and directionally cloned into pCMVSPORT6 xthr, a modified version of pCMVSPORT6 allowing directional cloning using asymmetric Sf11 sites. For antisense RNA synthesis, use T7 promoter and for sense RNA use SP6 promoter. Library constructed by Drs. N. Pollet, M. Perron, M. Wegnez, A. Mazabraud (CNRS UMR 8080, Universite Paris Sud, Orsay, France)."

## FEATURES

source  
1. .731  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/strain="ivory coast"  
/db\_xref="taxon:8364"  
/clone="xthr16G18"  
/tissue\_type="pool of heads and retinas from tailbud stages 25-35"  
/dev\_stage="stage 25-35"  
/lab\_host="E.coli DH10B"  
/clone\_lib="Xenopus tropicalis xthr plasmid library"  
/note="Vector: pCMVSPORT6 xthr; Site\_1: Sf11; Site\_2: Sf11; Xenopus tropicalis polyA+ RNA was obtained from pool of heads and retinas from tailbud stages 25-35 cDNAs were synthesized using the SMART system of CLONTECH and directionally cloned into pCMVSPORT6 xthr, a modified version of pCMVSPORT6 allowing directional cloning using asymmetric Sf11 sites. For antisense RNA synthesis, use T7 promoter and for sense RNA use SP6 promoter. Library constructed by Drs. N. Pollet, M. Perron, M. Wegnez, A. Mazabraud (CNRS UMR 8080, Universite Paris Sud, Orsay, France)."

## ORIGIN

Query Match 92.0%; Score 18.4; DB 7; Length 731;



Sanger Institute  
Hinxton, Cambridgeshire, CB10 1SA, UK  
Email: trop@sanger.ac.uk  
Sanger Xenopus tropicalis EST project 2001  
TROPICALIS\_SEQUENCE\_ID: TTBA018g16.q1k77  
This sequence is from a Xenopus Gene Collection (XGC) library  
constructed by Nigel Garrett.  
Seq primer: T7.

FEATURES  
source  
1..869  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/db\_xref="taxon:8364"  
/clone="TTBA018g16"  
/dev\_stage="tailbud (stage 28-30)"  
/lab\_host="Escherichia coli DH10B."  
/clone\_lib="XGC-tailbud"  
/note="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA  
was oligo dt primed from Sug of poly A+ RNA from tailbud.  
EcoRI-NotI cut cDNA was then ligated into pCS107 with  
EcoRI at the 5' end and NotI at the 3' end."

ORIGIN  
Query Match 92.0%; Score 18.4; DB 7; Length 869;  
Best Local Similarity 95.0%; Pred. No. 3.3e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
||||| ||||| ||||| ||||| |||||  
Db 254 AAAGATGATTAGGCAGAGGT 273

RESULT 9  
LOCUS CO812154  
DEFINITION CO812154 896 bp mRNA linear EST 06-AUG-2004  
5', mRNA sequence.  
ACCESSION CO812154  
VERSION CO812154.1 GI:51030780  
KEYWORDS EST.  
SOURCE Danio rerio (zebrafish)  
ORGANISM Danio rerio

REFERENCE 1 (bases 1 to 896)  
AUTHORS NIH-MGC http://mgi.nci.nih.gov/  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Daniela S. Gerhard, Ph.D.  
Office of Cancer Genomics / NIH  
Bldg. 31 Rm10A07 Bethesda, MD 20892  
Email: c9apbs-r@mail.nih.gov  
Tissue Procurement: John Ngai, Nancy Freeman, NIDCD  
cDNA Library Preparation: Dr. Sumio Sugano  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Agencourt Bioscience Corporation  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LLAM15595 row: a column: 14  
High quality sequence stop: 695.

FEATURES  
source  
1..886  
/organism="Danio rerio"  
/mol\_type="mRNA"  
/db\_xref="taxon:7955"  
/clone="IMAGE:7402168"  
/tissue\_type="olfactory epithelium"  
/lab\_host="DH10B tonA"  
/clone\_lib="NIH\_ZGC\_14"  
/note="Organ: olfactory epithelium; Vector: pME18-FL3;

Site 1: DraIII; Site 2: DraIII; 1st strand cDNA was primed  
with an oligo(dT) primer  
[GGCGTCAGACGCGCTATGGCGCTTTTTTTTTTTTTTTT];  
double-stranded cDNA was ligated to a DraIII adaptor  
(GGCCUACUGG), digested and directionally cloned into  
selected DraIII sites of the pME18-FL3. Library was size  
selected for 1.0 kb, with a average insert size of ~1.2kb.  
Library constructed by Yutaka Suzuki (University of Tokyo  
Institute of Medical Science). Custom primers recommended  
for sequencing: 5' end primer 5'-GGATGTGCTTTACTTCTA-3'  
and 3' end primer 5'-CGACCTGCAGCTCGAGCACA-3'. Note: This  
is a Zebrafish Gene Collection (ZGC) library"

ORIGIN  
Query Match 92.0%; Score 18.4; DB 7; Length 886;  
Best Local Similarity 95.0%; Pred. No. 3.3e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
||||| ||||| ||||| ||||| |||||  
Db 453 AGAGATGTTTAGGCAGAGGT 472

RESULT 10  
LOCUS CR445414/c  
DEFINITION CR445414 XGC-tailbud Xenopus tropicalis cDNA clone TTBA012n19 5',  
mRNA sequence.  
ACCESSION CR445414  
VERSION CR445414.1 GI:48971001  
KEYWORDS EST.  
SOURCE Xenopus tropicalis (western clawed frog)  
ORGANISM Xenopus tropicalis  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;  
Xenopodinae; Xenopus; Silurana.

REFERENCE 1 (bases 1 to 896)  
AUTHORS Croning, M.D.R., Ashurst, J.L., Taylor, R., Garrett, N. and Rogers, J.  
TITLE Sanger Xenopus tropicalis EST project 2001 (2004)  
JOURNAL Unpublished (2004)  
COMMENT Contact: Croning MDR  
Sanger Institute  
Hinxton, Cambridgeshire, CB10 1SA, UK  
Email: trop@sanger.ac.uk  
Sanger Xenopus tropicalis EST project 2001  
TROPICALIS\_SEQUENCE\_ID: TTBA012n19.pkasp6  
This sequence is from a Xenopus Gene Collection (XGC) library  
constructed by Nigel Garrett.  
Seq primer: SP6.

FEATURES  
source  
1..896  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/db\_xref="taxon:8364"  
/clone="TTBA012n19"  
/dev\_stage="tailbud (stage 28-30)"  
/lab\_host="Escherichia coli DH10B."  
/clone\_lib="XGC-tailbud"  
/note="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA  
was oligo dt primed from Sug of poly A+ RNA from tailbud.  
EcoRI-NotI cut cDNA was then ligated into pCS107 with  
EcoRI at the 5' end and NotI at the 3' end."

ORIGIN  
Query Match 92.0%; Score 18.4; DB 7; Length 896;  
Best Local Similarity 95.0%; Pred. No. 3.3e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
||||| ||||| ||||| ||||| |||||  
Db 841 AAAGATGATTAGGCAGAGGT 822

```

RESULT 11
BX699062          910 bp      mRNA      linear      EST 17-NOV-2003
LOCUS             BX699062 XGC-neurula Xenopus tropicalis cDNA clone TNeu073a09 3',
DEFINITION        mRNA sequence.
ACCESSION         BX699062
VERSION           BX699062.1 GI:383361269
KEYWORDS          EST.
SOURCE            Xenopus tropicalis (western clawed frog)
ORGANISM          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                  Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae;
                  Xenopodinae; Xenopus; Silurana.
REFERENCE         1 (bases 1 to 910)
AUTHORS           Croning,M.D.R., Ashurst,J.L., Taylor,R., Zorn,A.M. and Rogers,J.
TITLE            Sanger Xenopus tropicalis EST project 2001 (11_2003)
JOURNAL           Unpublished (2003)
COMMENT          Contact: Croning MDR
                  Sanger Institute
                  Hinxton, Cambridgeshire, CB10 1SA, UK
                  Email: trop@sanger.ac.uk
                  Sanger Xenopus tropicalis EST project 2001
                  TROPICALIS_SEQUENCE ID: TNeu073a09.q1kx7
                  Sequencing primer: T7
                  This sequence is from a Xenopus Gene Collection (XGC) library
                  constructed by Aaron M. Zorn.
                  cDNA was oligo dt primed from Sug of poly A+ RNA from neurula.
                  EcoRI-NotI cut cDNA was then ligated into pCS107 with EcoRI at the
                  5' end and NotI at the 3' end.
                  Vector: pCS107; Site1: EcoRI; Site2: NotI
                  Host: Escherichia coli DH10B.
FEATURES          Location/Qualifiers
                   1..910
                    /organism="Xenopus tropicalis"
                    /mol_type="mRNA"
                    /db_xref="taxon:8364"
                    /clone="TNeu073a09"
                    /dev_stage="neurula"
                    /lab_host="Escherichia coli DH10B"
                    /clone_lib="XGC-neurula"
                    /notes="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA
                    was oligo dt primed from Sug of poly A+ RNA from neurula.
                    EcoRI-NotI cut cDNA was then ligated into pCS107 with
                    EcoRI at the 5' end and NotI at the 3' end."
ORIGIN
Query Match      92.0%; Score 18.4; DB 5; Length 910;
Best Local Similarity 95.0%; Pred. No. 3.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGGCT 20
Db 245 AAAGATGATTAGGCAGGCT 264

RESULT 12
BX683124          913 bp      mRNA      linear      EST 14-NOV-2003
LOCUS             BX683124 XGC-neurula Xenopus tropicalis cDNA clone TNeu069h15, mRNA
DEFINITION        sequence.
ACCESSION         BX683124
VERSION           BX683124.1 GI:38332244
KEYWORDS          EST.
SOURCE            Xenopus tropicalis (western clawed frog)
ORGANISM          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                  Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae;
                  Xenopodinae; Xenopus; Silurana.
REFERENCE         1 (bases 1 to 913)
AUTHORS           Croning,M.D.R., Ashurst,J.L., Taylor,R., Zorn,A.M. and Rogers,J.
TITLE            Sanger Xenopus tropicalis EST project 2001 (11_2003)
JOURNAL           Unpublished (2003)
COMMENT          Contact: Croning MDR

```

```

Sanger Institute
Hinxton, Cambridgeshire, CB10 1SA, UK
Email: trop@sanger.ac.uk
Sanger Xenopus tropicalis EST project 2001
TROPICALIS_SEQUENCE ID: TNeu069h15.q1kx7
Sequencing primer: T7
This sequence is from a Xenopus Gene Collection (XGC) library
constructed by Aaron M. Zorn.
cDNA was oligo dt primed from Sug of poly A+ RNA from neurula.
EcoRI-NotI cut cDNA was then ligated into pCS107 with EcoRI at the
5' end and NotI at the 3' end.
Vector: pCS107; Site 1: EcoRI; Site 2: NotI
Host: Escherichia coli DH10B.
FEATURES          Location/Qualifiers
                   1..913
                    /organism="Xenopus tropicalis"
                    /mol_type="mRNA"
                    /db_xref="taxon:8364"
                    /clone="TNeu069h15"
                    /dev_stage="neurula"
                    /lab_host="Escherichia coli DH10B"
                    /clone_lib="XGC-neurula"
                    /notes="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA
                    was oligo dt primed from Sug of poly A+ RNA from neurula.
                    EcoRI-NotI cut cDNA was then ligated into pCS107 with
                    EcoRI at the 5' end and NotI at the 3' end."
ORIGIN
Query Match      92.0%; Score 18.4; DB 5; Length 913;
Best Local Similarity 95.0%; Pred. No. 3.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGGCT 20
Db 245 AAAGATGATTAGGCAGGCT 264

RESULT 13
BX694706          914 bp      mRNA      linear      EST 17-NOV-2003
LOCUS             BX694706 XGC-neurula Xenopus tropicalis cDNA clone TNeu11c20 3',
DEFINITION        mRNA sequence.
ACCESSION         BX694706
VERSION           BX694706.1 GI:38343826
KEYWORDS          EST.
SOURCE            Xenopus tropicalis (western clawed frog)
ORGANISM          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                  Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae;
                  Xenopodinae; Xenopus; Silurana.
REFERENCE         1 (bases 1 to 914)
AUTHORS           Croning,M.D.R., Ashurst,J.L., Taylor,R., Zorn,A.M. and Rogers,J.
TITLE            Sanger Xenopus tropicalis EST project 2001 (11_2003)
JOURNAL           Unpublished (2003)
COMMENT          Contact: Croning MDR
                  Sanger Institute
                  Hinxton, Cambridgeshire, CB10 1SA, UK
                  Email: trop@sanger.ac.uk
                  Sanger Xenopus tropicalis EST project 2001
                  TROPICALIS_SEQUENCE ID: TNeu11c20.q1kx7
                  Sequencing primer: T7
                  This sequence is from a Xenopus Gene Collection (XGC) library
                  constructed by Aaron M. Zorn.
                  cDNA was oligo dt primed from Sug of poly A+ RNA from neurula.
                  EcoRI-NotI cut cDNA was then ligated into pCS107 with EcoRI at the
                  5' end and NotI at the 3' end.
                  Vector: pCS107; Site1: EcoRI; Site2: NotI
                  Host: Escherichia coli DH10B.
FEATURES          Location/Qualifiers
                   1..914
                    /organism="Xenopus tropicalis"
                    /mol_type="mRNA"
                    /db_xref="taxon:8364"

```



Brazil  
 Tel: +55-11-2704922  
 Fax: +55-11-2707001  
 Email: asimposon@ludwig.org.br  
 This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL  
 (http://www.ludwig.org.br/scripts/gethtml2.pl?tl=CM3&t2=CM3-CT0039-230799-001-a04&t3=1999-07-23&t4=1)  
 Seq primer: puc 18 forward  
 High quality sequence start: 14  
 High quality sequence stop: 139.

#### FEATURES

source  
 1. .494  
 Location/Qualifiers  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /dev\_stage="adult"  
 /clone\_lib="CT0039"  
 /note="Organ: colon; Vector: puc18; Site 1: SmaI; Site 2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."

#### ORIGIN

Query Match 87.0%; Score 17.4; DB 5; Length 494;  
 Best Local Similarity 94.7%; Pred. No. 9.4e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGGAG 19  
 |||  
 Db 408 AGTGATGATTAGGCAGGAG 426

#### RESULT 17

LOCUS BG440037/c  
 DEFINITION GA\_Ea0005K23f Gossypium arboreum 7-10 dpa fiber library Gossypium  
 arboreum cDNA clone GA\_Ea0005K23f, mRNA sequence.

ACCESSION BG440037.1 GI:13349687

VERSION EST.

#### SOURCE

ORGANISM Gossypium arboreum  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
 rosids; eurosids II; Malvales; Malvaceae; Malvoideae; Gossypium.  
 1 (bases 1 to 680)

#### REFERENCE

AUTHORS Wing,R.A., Frisch,D., Yu,Y., Main,D., Rambo,T., Simmons,J.,

Henry,D., Wood,T.C., Leslie,A. and Wilkins,T.A.

TITLE An integrated analysis of the genetics, development, and evolution

of the cotton fiber

JOURNAL Unpublished (2000)

COMMENT Contact: Wing RA

Clemson University Genomics Institute

Clemson University

100 Jordan Hall, Clemson, SC 29634, USA

Tel: 864 656 7288

Fax: 864 656 4293

Email: rwing@clemson.edu

Seq primer: TATACGACTACTATAGG

High quality sequence stop: 600.

#### FEATURES

source  
 1. .680  
 Location/Qualifiers  
 /organism="Gossypium arboreum"  
 /mol\_type="mRNA"  
 /strain="AKA"  
 /cultivar="8400"  
 /db\_xref="taxon:29729"  
 /clone="GA\_Ea0005K23f"  
 /tissue\_type="Fibers isolated from bolls harvested 7-10

dpa"

/lab\_host="E. coli"

/clone\_lib="Gossypium arboreum 7-10 dpa fiber library"

/note="Vector: pBK-CMV; Site\_1: EcoRI; Site\_2: XhoI"

#### ORIGIN

Query Match 87.0%; Score 17.4; DB 4; Length 680;  
 Best Local Similarity 94.7%; Pred. No. 9.9e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 GAGATGATTAGGCAGGAGT 20

|||||

Db 203 GAGATGATTAGGCAGGAGT 185

#### RESULT 18

LOCUS BH039638

DEFINITION BH039638 741 bp DNA linear GSS 17-JUL-2001

RPCI-24-273E14, TJ RPCI-24 Mus musculus genomic clone

RPCI-24-273E14, genomic survey sequence.

ACCESSION BH039638

VERSION BH039638.1 GI:14817784

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

#### ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 1 (bases 1 to 741)

#### REFERENCE

AUTHORS Zhao,S., Nierman,W., Malek,J., Shatsman,S., Akinret,B., Levins,M.,

Tsegaye,G., Geer,K., Krol,M., Shvartsbeyn,A., Gebregeorgis,E.,

Russell,D., de Jong,P. and Fraser,C.M.

Mouse BAC End Sequences from Library RPCI-24

Unpublished (1999)

Other GSSs: RPCI-24-273E14.TV

Contact: Shaying Zhao

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850, USA

Tel: 301 838 0200

Fax: 301 838 0208

Email: szhao@tigr.org

Clones are derived from the mouse BAC library RPCI-24. For BAC

library availability, please contact Pieter de Jong

(pdejong@mail.cho.org). Clones may be purchased from BACPAC

Resources (http://www.choi.org/bacpac/orderingframe.htm). BAC end

plate: http://www.tigr.org/tdb/bac\_ends/mouse/bac\_end\_intro.html

Seq primer: SP6

Class: BAC ends.

#### FEATURES

source  
 1. .741  
 Location/Qualifiers  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /strain="C57BL/6J"  
 /db\_xref="taxon:10090"  
 /clone="RPCI-24-273E14"  
 /sex="Male"  
 /cell\_type="Spleen/Brain"  
 /clone\_lib="RPCI-24"  
 /note="Vector: pTARBAC1; Site\_1: BamHI; Site\_2: BamHI;  
 RPCI-24 Mouse BAC Library produced by Pieter de Jong. The  
 library was cloned in the pTARBAC1 cloning vector at the  
 BamHI sites using MboI partially digested male C57BL/6J  
 DNA."

#### ORIGIN

Query Match 87.0%; Score 17.4; DB 8; Length 741;  
 Best Local Similarity 94.7%; Pred. No. 1e+03;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 GAGATGATTAGGCAGGAGT 20

|||||

Db 299 GAGATGATTAGGCAGGAGT 317



```

RESULT 19
CNS029UK
LOCUS
DEFINITION
    CNS029UK 1032 bp DNA linear GSS 01-SEP-2000
    Tetraodon nigroviridis genome survey sequence T7 end of clone
    249B13 of library G from Tetraodon nigroviridis, genomic survey
    sequence.
ACCESSION
    AL187733
VERSION
    AL187733.1 GI:7825837
KEYWORDS
    GSS; genome survey sequence.
SOURCE
    Tetraodon nigroviridis
    ORGANISM
        Tetraodon nigroviridis
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
        Acanthomorpha; Acanthopterygii; Percormorpha; Tetraodontiformes;
        Tetraodontidae; Tetraodontidae; Tetraodon.
REFERENCE
    1 Roest Crolius,H., Jaillon,O., Dasilva,C., Bouneau,L., Fisher,C.,
      Bernot,A., Fizames,C., Wincker,P., Brottier,P., Quetier,F.,
      Saurin,W. and Weissenbach,J.
      Estimate of human gene number provided by genome-wide analysis
      using Tetraodon nigroviridis DNA sequence
      Nat. Genet. 25 (2), 235-238 (2000)
      20296633
      10835645
REFERENCE
    2 Roest Crolius,H., Jaillon,O., Dasilva,C., Ozouf-Costaz,C.,
      Fizames,C., Fischer,C., Bouneau,L., Billault,A., Quetier,F.,
      Saurin,W., Bernot,A. and Weissenbach,J.
      Characterization and repeat analysis of the compact genome of the
      freshwater pufferfish Tetraodon nigroviridis
      Genome Res. 10 (7), 939-949 (2000)
      20359837
      10899143
REFERENCE
    3 (bases 1 to 1032)
      Genoscope.
      Direct Submission
      Submitted (12-APR-2000) Genoscope - Centre National de Sequencage :
      BP 191 91006 EVRY cedex - FRANCE [E-mail : seqref@genoscope.cns.fr
      - Web : www.genoscope.cns.fr]
      This sequence is a single read and was generated as part of a large
      scale clone-end sequencing project of the Tetraodon nigroviridis
      genome. For more information, please take a look at
      http://www.genoscope.cns.fr/Tetraodon.
FEATURES
    source
        1..1032
        /organism="Tetraodon nigroviridis"
        /mol_type="genomic DNA"
        /db_xref="taxon:99883"
        /clone="249B13"
        /clone_lib="G"
        /note="Genoscope sequence ID : COAG249CA07LP1-end : T7"
ORIGIN
    Query Match 87.0%; Score 17.4; DB 9; Length 1032;
    Best Local Similarity 94.7%; Pred. No. 1.1e+03;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

    QY 1 AGAGATGATTAGCAGAGG 19
       |||||
    Db 387 AGAGATGATGAGCAGAGG 405
       |||||

RESULT 20
CNS027K3/c
LOCUS
DEFINITION
    CNS027K3 1044 bp DNA linear GSS 01-SEP-2000
    Tetraodon nigroviridis genome survey sequence T7 end of clone
    243E11 of library G from Tetraodon nigroviridis, genomic survey
    sequence.
ACCESSION
    AL184764
VERSION
    AL184764.1 GI:7822868
KEYWORDS
    GSS; genome survey sequence.
REFERENCE
    1 Roest Crolius,H., Jaillon,O., Dasilva,C., Bouneau,L., Fisher,C.,
      Bernot,A., Fizames,C., Wincker,P., Brottier,P., Quetier,F.,
      Saurin,W. and Weissenbach,J.
      Estimate of human gene number provided by genome-wide analysis
      using Tetraodon nigroviridis DNA sequence
      Nat. Genet. 25 (2), 235-238 (2000)
      20296633
      10835645
REFERENCE
    2 Roest Crolius,H., Jaillon,O., Dasilva,C., Ozouf-Costaz,C.,
      Fizames,C., Fischer,C., Bouneau,L., Billault,A., Quetier,F.,
      Saurin,W., Bernot,A. and Weissenbach,J.
      Characterization and repeat analysis of the compact genome of the
      freshwater pufferfish Tetraodon nigroviridis
      Genome Res. 10 (7), 939-949 (2000)
      20359837
      10899143
REFERENCE
    3 (bases 1 to 1032)
      Genoscope.
      Direct Submission
      Submitted (12-APR-2000) Genoscope - Centre National de Sequencage :
      BP 191 91006 EVRY cedex - FRANCE [E-mail : seqref@genoscope.cns.fr
      - Web : www.genoscope.cns.fr]
      This sequence is a single read and was generated as part of a large
      scale clone-end sequencing project of the Tetraodon nigroviridis
      genome. For more information, please take a look at
      http://www.genoscope.cns.fr/Tetraodon.
FEATURES
    source
        1..1032
        /organism="Tetraodon nigroviridis"
        /mol_type="genomic DNA"
        /db_xref="taxon:99883"
        /clone="249B13"
        /clone_lib="G"
        /note="Genoscope sequence ID : COAG249CA07LP1-end : T7"
ORIGIN
    Query Match 87.0%; Score 17.4; DB 9; Length 1032;
    Best Local Similarity 94.7%; Pred. No. 1.1e+03;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

    QY 1 AGAGATGATTAGCAGAGG 19
       |||||
    Db 387 AGAGATGATGAGCAGAGG 405
       |||||

RESULT 21
BB361792/c
LOCUS
DEFINITION
    BB361792 RIKEN full-length enriched, 16 days embryo head Mus
    musculus cDNA clone C13006N13 3' similar to X76772 M.musculus mRNA
    for ribosomal protein S3, mRNA sequence.
ACCESSION
    BB361792
VERSION
    BB361792.1 GI:9073620
KEYWORDS
    EST.
SOURCE
    Mus musculus (house mouse)
    ORGANISM
        Mus musculus
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
    1 (bases 1 to 248)
      Konno,H., Aizawa,K., Akahira,S., Akiyama,J., Arakawa,T.,
      Carninci,P., Endo,T., Fukuda,S., Fukunishi,Y., Hara,A., Hayatsu,N.,
      Hirozane,T., Hori,F., Iahii,Y., Iahikawa,J., Iahikawa,T., Itoh,M.,
      Izawa,M., Kadota,K., Kagawa,I., Kai,C., Kawai,J., Kikuchi,N.,
      Kiyosawa,H., Kojima,Y., Kondo,S., Koya,S., Kurihara,C.,
      Kusakabe,M., Matsuyama,T., Miki,R., Mizuno,Y., Nakamura,M., Oda,H.,

```

```

SOURCE
    ORGANISM
        Tetraodon nigroviridis
        Tetraodon nigroviridis
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
        Acanthomorpha; Acanthopterygii; Percormorpha; Tetraodontiformes;
        Tetraodontidae; Tetraodontidae; Tetraodon.
REFERENCE
    1 Roest Crolius,H., Jaillon,O., Dasilva,C., Bouneau,L., Fisher,C.,
      Bernot,A., Fizames,C., Wincker,P., Brottier,P., Quetier,F.,
      Saurin,W. and Weissenbach,J.
      Estimate of human gene number provided by genome-wide analysis
      using Tetraodon nigroviridis DNA sequence
      Nat. Genet. 25 (2), 235-238 (2000)
      20296633
      10835645
REFERENCE
    2 Roest Crolius,H., Jaillon,O., Dasilva,C., Ozouf-Costaz,C.,
      Fizames,C., Fischer,C., Bouneau,L., Billault,A., Quetier,F.,
      Saurin,W., Bernot,A. and Weissenbach,J.
      Characterization and repeat analysis of the compact genome of the
      freshwater pufferfish Tetraodon nigroviridis
      Genome Res. 10 (7), 939-949 (2000)
      20359837
      10899143
REFERENCE
    3 (bases 1 to 1044)
      Genoscope.
      Direct Submission
      Submitted (12-APR-2000) Genoscope - Centre National de Sequencage :
      BP 191 91006 EVRY cedex - FRANCE [E-mail : seqref@genoscope.cns.fr
      - Web : www.genoscope.cns.fr]
      This sequence is a single read and was generated as part of a large
      scale clone-end sequencing project of the Tetraodon nigroviridis
      genome. For more information, please take a look at
      http://www.genoscope.cns.fr/Tetraodon.
FEATURES
    source
        1..1044
        /organism="Tetraodon nigroviridis"
        /mol_type="genomic DNA"
        /db_xref="taxon:99883"
        /clone="243E11"
        /clone_lib="G"
        /note="Genoscope sequence ID : COAG243AC06LP1-end : T7"
ORIGIN
    Query Match 87.0%; Score 17.4; DB 9; Length 1044;
    Best Local Similarity 94.7%; Pred. No. 1.1e+03;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

    QY 1 AGAGATGATTAGCAGAGG 19
       |||||
    Db 396 AGAGATGATGAGCAGAGG 378
       |||||

RESULT 21
BB361792/c
LOCUS
DEFINITION
    BB361792 RIKEN full-length enriched, 16 days embryo head Mus
    musculus cDNA clone C13006N13 3' similar to X76772 M.musculus mRNA
    for ribosomal protein S3, mRNA sequence.
ACCESSION
    BB361792
VERSION
    BB361792.1 GI:9073620
KEYWORDS
    EST.
SOURCE
    Mus musculus (house mouse)
    ORGANISM
        Mus musculus
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
    1 (bases 1 to 248)
      Konno,H., Aizawa,K., Akahira,S., Akiyama,J., Arakawa,T.,
      Carninci,P., Endo,T., Fukuda,S., Fukunishi,Y., Hara,A., Hayatsu,N.,
      Hirozane,T., Hori,F., Iahii,Y., Iahikawa,J., Iahikawa,T., Itoh,M.,
      Izawa,M., Kadota,K., Kagawa,I., Kai,C., Kawai,J., Kikuchi,N.,
      Kiyosawa,H., Kojima,Y., Kondo,S., Koya,S., Kurihara,C.,
      Kusakabe,M., Matsuyama,T., Miki,R., Mizuno,Y., Nakamura,M., Oda,H.,

```



20202663  
MEDLINE  
PUBMED  
COMMENT

Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?ti=MR2&t2=MR2-BN0364-220800-012-b02&t3=2000-08-22&t4=1)  
Seq primer: puc 18 forward  
High quality sequence stop: 145.  
Location/Qualifiers  
1. .145  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/dev\_stage="Adult"  
/clone\_lib="BN0364"  
/note="Organ: breast normal; Vector: puc18; Site\_1: SmaI;  
Site\_2: SmaI; A mini-library was made by cloning products  
derived from ORESTES PCR (U.S. Letters Patent application  
No. 196.716 - Ludwig Institute for Cancer Research)  
profiles into the pUC 18 vector. Reverse transcription of  
tissue mRNA and cDNA amplification were performed under  
low stringency conditions."

FEATURES  
source

Query Match 84.0%; Score 16.8; DB 2; Length 145;  
Best Local Similarity 90.0%; Pred. No. 1.6e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGT 20  
||||| ||||| ||||| |||||  
Db 46 AGAGATGTTTGTAGTCAGAGT 65

RESULT 24  
BF330451  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BF330451 146 bp mRNA EST 22-NOV-2000  
MR2-BN0364-280800-010-b02 BN0364 Homo sapiens cDNA, mRNA sequence.  
BF330451  
EST.  
BF330451.1 GI:11301199

Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 145)  
Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,  
Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F.,  
Goldman, G.H., Carvalho, A.F., Matsukuma, A., Baia, G.S., Simpson, D.H.,  
Brunstein, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V.,  
O'Hare, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and  
Simpson, A.J.

Shotgun sequencing of the human transcriptome with ORF expressed  
sequence tags  
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)

20202663  
MEDLINE  
PUBMED  
COMMENT

Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?ti=MR2&t2=MR2-BN0364-280800-012-b02&t3=2000-08-22&t4=1)  
Seq primer: puc 18 forward  
High quality sequence stop: 146.  
Location/Qualifiers  
1. .146  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/dev\_stage="Adult"  
/clone\_lib="BN0364"  
/note="Organ: breast normal; Vector: puc18; Site\_1: SmaI;  
Site\_2: SmaI; A mini-library was made by cloning products  
derived from ORESTES PCR (U.S. Letters Patent application  
No. 196.716 - Ludwig Institute for Cancer Research)  
profiles into the pUC 18 vector. Reverse transcription of  
tissue mRNA and cDNA amplification were performed under  
low stringency conditions."

FEATURES  
source

Query Match 84.0%; Score 16.8; DB 2; Length 146;  
Best Local Similarity 90.0%; Pred. No. 1.6e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGT 20  
||||| ||||| ||||| |||||  
Db 47 AGAGATGTTTGTAGTCAGAGT 66

RESULT 25  
BZ350602  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BZ350602 387 bp DNA linear GSS 12-NOV-2002  
ht58d07 g1 WGS-SpicolorF (JM107 adapted methyl filtered) Sorghum  
bicolor genomic clone ht58d07 5', genomic survey sequence.  
BZ350602  
GSS.  
BZ350602.1 GI:24913429

Sorghum bicolor (sorghum)  
Sorghum bicolor  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD  
clade; Panicoideae; Andropogoneae; Sorghum.  
1 (bases 1 to 387)  
Rabinowicz, P.D., O'Shaughnessy, A.L., Ballja, V., Dedhia, N.,  
Katzenburger, F., King, L., Miller, B., Muller, S., Nascimento, L.,  
Zutavern, T., Palmer, L., McCombie, W.R. and Martienssen, R.A.  
Genomic shotgun sequences from Sorghum bicolor (methyl-filtered)  
Unpublished (2002)  
Contact: W. Richard McCombie  
Lita Annenberg Hazen Genome Sequencing Center  
Cold Spring Harbor Laboratory  
PO Box 100, Cold Spring Harbor, NY 11724, USA  
Tel: 516 367 8884  
Fax: 516 367 8874  
Email: mcombie@cshl.org  
Plate: ht58 row: d column: 07  
Seq primer: -21M13UnivRev  
Class: shotgun  
High quality sequence stop: 387.  
Location/Qualifiers  
1. .387  
/organism="Sorghum bicolor"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:4558"  
/clone="ht58d07"  
/lab\_host="JM107 or DHSa"  
/clone\_lib="WGS-SbicolorF (JM107 adapted methyl filtered)"  
/note="Site 1: Xba I; Site 2: Xba I; The vector was  
digested with XbaI and one nucleotide was added by fill in  
in the recessive 3' end. The genomic DNA was nebulized,  
end repaired, adaptor ligated and size fractionated using  
sephadex. The resulting fragments were between 0.8 and 3

kb and were cloned into the vector (.x/y reads in M13mp19, .b/g reads in pUC19). The same ligation was transformed in either JM107 or DH5a."

## ORIGIN

Query Match 84.0%; Score 16.8; DB 8; Length 387;  
Best Local Similarity 90.0%; Pred. No. 1.8e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGAGGT 20  
|||||  
Db 208 AGAGATGATTATTCAGAGGT 227  
|||||

## RESULT 26

AJ713073 388 bp mRNA linear EST 30-JUN-2004  
DEFINITION AJ713073 LKPD01 Homo sapiens cDNA clone LKPD01049, mRNA sequence.  
ACCESSION AJ713073  
VERSION AJ713073.1 GI:49498685  
KEYWORDS EST.  
SOURCE Homo sapiens (human)

## ORGANISM

Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 388)  
Defitta, C., Tombolan, L., Kronnie, G., Romualdi, C., Vitulo, N.,  
Basso, G. and Lanfranchi, G.

## REFERENCE

A leukemia-enriched cDNA microarray platform identified new  
transcripts with relevance to the biology of leukemias

## JOURNAL

Unpublished (2004)

## COMMENT

Contact: Depitta C

Biology and CRIBI

University of Padova

Via U. Bassi, 58/B, 35131, ITALY.

## FEATURES

Location/Qualifiers  
1..388  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="LKPD01049"  
/tissue\_type="bone marrow"  
/clone\_lib="LKPD01"  
/note="caucasian"

## ORIGIN

Query Match 84.0%; Score 16.8; DB 1; Length 388;  
Best Local Similarity 90.0%; Pred. No. 1.8e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGAGGT 20  
|||||

Db 86 AGAATGATGAGGCAGAGGT 105  
|||||

## RESULT 27

AA503497/c 407 bp mRNA linear EST 20-AUG-1997  
LOCUS AA503497  
DEFINITION AA503497.1 NCI\_CGAP Pr8 Homo sapiens cDNA clone IMAGE:956706  
similar to TR:G434304 G434304 367BP EXPRESSED SEQUENCE TAG mRNA ;,  
mRNA sequence.

## ACCESSION

AA503497

## VERSION

AA503497.1 GI:2238464

## KEYWORDS

## SOURCE

EST.  
Homo sapiens (human)

## ORGANISM

Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

1 (bases 1 to 407)  
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.

## AUTHORS

National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
Tumor Gene Index

## JOURNAL

Unpublished (1997)

## COMMENT

Contact: Robert Strausberg, Ph.D.  
Email: cgabs-r@mail.nih.gov  
Tissue Procurement: David G. Bostwick, M.D., Rodrigo F. Chuaqui,  
M.D., Michael R. Emmert-Buck, M.D., Ph.D.  
cDNA Library Preparation: David B. Krizman, Ph.D.  
DNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
[www-bio.llnl.gov/bbrp/image/image.html](http://www-bio.llnl.gov/bbrp/image/image.html)  
Insert Length: 538 Std Error: 0.00  
Seq primer: -40ml3 fwd. ET from Amersham  
High quality sequence stop: 330.

## FEATURES

## source

Location/Qualifiers  
1..407  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:956706"  
/sex="male"  
/tissue\_type="prostate"  
/lab\_host="DH10B"  
/clone\_lib="NCI CGAP Pr8"  
/note="Vector: PAMP10; mRNA made from invasive prostate  
tumor, cDNA made by oligo-dT priming. Non-directionally  
cloned. Size-selected on agarose gel, average insert  
size 600 bp."

## ORIGIN

Query Match 84.0%; Score 16.8; DB 1; Length 407;  
Best Local Similarity 90.0%; Pred. No. 1.8e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ACAGATGATTAGGCAGAGGT 20  
|||||

Db 351 AGAAGATGAGGCAGAGGT 332  
|||||

## RESULT 28

AJ572696 423 bp mRNA linear EST 28-JUL-2003  
LOCUS AJ572696  
DEFINITION AJ572696 HM3/RH2 Homo sapiens cDNA clone HSPD45782, mRNA sequence.  
ACCESSION AJ572696  
VERSION AJ572696.1 GI:33296557  
KEYWORDS EST.  
SOURCE Homo sapiens (human)

## ORGANISM

Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

1 (bases 1 to 423)  
Laveder, P., De Pitta, C., Vitulo, N., Valle, G. and Lanfranchi, G.  
Oligo-directed RNase H cleavage of abundant mRNAs in skeletal  
muscle

## AUTHORS

Unpublished (2003)

## JOURNAL

Contact: Laveder P

## COMMENT

CRIBI Biotechnology Centre  
University of Padua  
Via U. Bassi 58/B, 35121 Padua, Italy  
ABI Chromatograms and other information are available on WWW at  
<http://muscle.cribi.unipd.it>  
BIOLIMS code: shr-000004-0-H07

## Seq primer:

PC2R.

## Location/Qualifiers

1..423  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="HSPD45782"  
/sex="female"  
/tissue\_type="pectoral muscle (after mastectomy)"  
/clone\_lib="HM3/RH2"

## FEATURES

## source

## ORIGIN

Query Match 84.0%; Score 16.8; DB 1; Length 423;  
 Best Local Similarity 90.0%; Pred. No. 1.8e+03;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 75 AGAATGATGAGGCAGAGGT 94

RESULT 29  
 LOCUS BX975154 484 bp DNA linear GSS 05-JUL-2004  
 DEFINITION Reverse strand read from insert in 3'HPRT insertion targeting and chromosome engineering clone MHP76122, genomic survey sequence.  
 ACCESSION BX975154  
 VERSION BX975154.1 GI:49706577  
 KEYWORDS GSS; genome survey sequence; MICR.  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 484)  
 AUTHORS Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weyden,L., Rogers,J., Smith,J., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y., Jonkers,J., and Bradley,A.  
 TITLE Direct Submission  
 JOURNAL Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK. http://www.sanger.ac.uk/MICR

FEATURES  
 source  
 1..484  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10090"  
 /clone="MHP76122"  
 /clone\_lib="MHPp"

ORIGIN

Query Match 84.0%; Score 16.8; DB 9; Length 484;  
 Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 194 AGAGATGATTAGGAGAGT 213

RESULT 30  
 BE558110/c  
 LOCUS BE558110 506 bp mRNA linear EST 30-AUG-2000  
 DEFINITION fl19f03.y1 Zebrafish Research Genetics C32 fin Danio rerio cDNA 5' similar to TR:O15249 O15249 PDZ DOMAIN PROTEIN. [2] TR:O60833 ;contains element TAR1 repetitive element ;, mRNA sequence.  
 ACCESSION BE558110  
 VERSION BE558110.1 GI:9822600  
 KEYWORDS EST.  
 SOURCE Danio rerio (zebrafish)  
 ORGANISM Danio rerio  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.  
 REFERENCE 1 (bases 1 to 506)  
 AUTHORS Clark,M., Johnson,S.L., Lehrach,H., Lee,R., Li,F., Marra,M., Eddy,S., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T., Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers,Y., Person,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurn,R., Ritter,E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R., Waterson,R. and Wilson,R.  
 TITLE Washu Zebrafish EST Project 1998  
 JOURNAL Unpublished (1998)  
 COMMENT Contact: Stephen L. Johnson  
 Washington University School of Medicine  
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA  
 Tel: 314 286 1800

Fax: 314 286 1810  
 Email: zbrafish@watson.wustl.edu  
 cDNA Library Preparation: Ning Wu. cDNA Library Arrayed by: Research Genetics. DNA Sequencing by: Washington University Genome Sequencing Center Clone Distribution: Research Genetics web address: http://www.researchgenetics.com/  
 Seq primer: T3 ET from Amersham  
 High quality sequence stop: 470.

FEATURES  
 source  
 1..506  
 /organism="Danio rerio"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:7955"  
 /tissue\_type="Fin"  
 /lab\_host="GensHogs (HS996, a phage-resistant isolate of DH10B)"  
 /clone\_lib="Zebrafish Research Genetics C32 fin"  
 /note="Vector: pT73D-Pac with a modified polylinker; Site 1: EcoRI; Site 2: NotI; 1st strand cDNA was prepared from zebrafish(C32) fin, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library is non-normalized. Library was constructed by Ning Wu. NOTE: This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info.llnl.gov) for further information"

ORIGIN

Query Match 84.0%; Score 16.8; DB 2; Length 506;  
 Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
 DB 385 AGAGTGATCAGGCAGAGGT 366

RESULT 31  
 LOCUS AZ336360 509 bp DNA linear GSS 29-SEP-2000  
 DEFINITION IM0066A09R Mouse 10kb plasmid UUGCIM library Mus musculus genomic clone UUGCIM0066A09 R, genomic survey sequence.  
 ACCESSION AZ336360  
 VERSION AZ336360.1 GI:10405580  
 KEYWORDS GSS  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 509)  
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmood,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.  
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
 JOURNAL Unpublished (2000)  
 COMMENT Contact: Robert B. Weiss  
 University of Utah  
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA  
 Tel: 801 585 5606  
 Fax: 801 585 7177  
 Email: ddunn@genetics.utah.edu  
 Insert Length: 10000 Std Error: 0.00  
 Plate: 0066 row: A column: 09  
 Seq primer: CACACAGGAACAGCTATGACC  
 Class: plasmid ends  
 High quality sequence stop: 509.  
 Location/Qualifiers  
 1..509

FEATURES  
 source

/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUGC1M0066A09"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/clone\_lib="Mouse 10kb plasmid UUGC1M library"  
/note="Vector: PWD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (G14732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

## ORIGIN

Query Match 84.0%; Score 16.8; DB 8; Length 509;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
|||||  
Db 68 AGAGATGATTAGGCAGAGGT 87

## RESULT 32

AQ317545 525 bp DNA linear GSS 04-MAY-1999  
LOCUS RPC111-79113.TJC RPC1-11 Homo sapiens genomic clone RPC1-11-79113,  
DEFINITION genomic survey sequence.

ACCESSION AQ317545  
VERSION AQ317545.1 GI:4048796  
KEYWORDS GSS.  
SOURCE Homo sapiens (human)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 525)  
Adams,M.D., Rounsley,S.D., Zhao,S., Bass,S., Linher,K., Golden,K.,  
Berry,K., Granger,D., Suh,E., Wible,C., de Jong,P. and Venter,J.C.  
Use of human BAC End Sequences for Sequence-Ready Map Building  
Unpublished (1998)

## COMMENT

Other GSSs: RPC111-79113.TV  
Contact: Shaying Zhao, William Nierman, Mark Adams  
Department of Eukaryotic Genomics  
The Institute for Genomic Research  
9712 Medical Center Dr., Rockville, MD 20850  
Tel: 301 838 0200  
Fax: 301 838 0208  
Email: hbeetigr.org

Clones are derived from the human BAC library RPC1-11. For BAC library availability, please contact Pieter de Jong ([pieter@dejong.med.buffalo.edu](mailto:pieter@dejong.med.buffalo.edu)). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering>) or from Research Genetics ([info@resgen.com](http://info@resgen.com)). BAC end search page: [http://www.tigr.org/tdb/humgen/bac\\_end\\_search/bac\\_end\\_search.html](http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html)  
Seq primer: S86  
Class: BAC ends.

FEATURES  
source Location/Qualifiers  
1..525

/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="GDB:7530156"  
/db\_xref="taxon:9606"  
/clone="RPC1-11-79113"  
/sex="Male"  
/cell\_type="Lymphocytes"  
/clone\_lib="RPC1-11"  
/note="Vector: pBACE3.6; Site 1: EcoRI; Site 2: EcoRI;  
RPC111 Human Male BAC Library"

## ORIGIN

Query Match 84.0%; Score 16.8; DB 8; Length 525;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
|||||  
Db 21 AGAGAGATTAGCAGAGGT 40

## RESULT 33

CB719936 526 bp mRNA linear EST 10-APR-2003  
LOCUS AMGNNUC:NRDGL-00073-C10-A nrdgl (10855) Rattus norvegicus cDNA  
DEFINITION clone nrdgl-00073-c10 5', mRNA sequence.

ACCESSION CB719936  
VERSION CB719936.1 GI:29777078  
KEYWORDS EST.  
SOURCE Rattus norvegicus (Norway rat)  
ORGANISM Rattus norvegicus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.

REFERENCE 1 (bases 1 to 526)  
AUTHORS Amgen EST Program.  
TITLE Amgen Rat EST Program  
JOURNAL Unpublished (2003)  
COMMENT Contact: Dan Fitzpatrick  
Amgen, Inc  
One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA  
Tel: 805 447-4881  
Plate: 00073 row: c column: 10.

FEATURES  
source Location/Qualifiers  
1..526

/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10116"  
/clones="nrdgl-00073-c10"  
/tissue\_type="Dorsal Root Ganglia"  
/clone\_lib="nrdgl (10855)"  
/note="Vector: pSPORT1; Site 1: SalI; Site 2: NotI; rat dorsal root ganglia"

## ORIGIN

Query Match 84.0%; Score 16.8; DB 6; Length 526;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20  
|||||  
Db 434 AGAGAGATTAGGCAGAGGT 453

## RESULT 34

BE605742 531 bp mRNA linear EST 30-AUG-2000  
LOCUS fl19f03.x1 Zebrafish Research Genetics C32 fin Danio rerio cDNA 3'  
DEFINITION similar to TR:O15249 O15249 PDZ DOMAIN PROTEIN. [2] TR:O60833  
;contains element TAR1 repetitive element ;, mRNA sequence.

ACCESSION BE605742  
VERSION BE605742.1 GI:9863011  
KEYWORDS EST.

**SOURCE**  
ORGANISM Danio rerio (zebrafish)

**REFERENCE**  
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.  
1 (bases 1 to 531)  
Clark, M., Johnson, S.L., Lehrach, H., Lee, R., Li, F., Marra, M., Eddy, S., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wyllie, T., Underwood, K., Steptoe, M., Theising, B., Allen, M., Bowers, Y., Person, B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter, E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R., Waterston, R., and Wilson, R.

**TITLE**  
JOURNAL WASHU Zebrafish EST Project 1998  
COMMENT Other ESTs: fl19f03.y1  
Contact: Stephen L. Johnson  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: zbrafish@watson.wustl.edu  
cDNA Library Preparation: Ning Wu. cDNA Library Arrayed by: Research Genetics. DNA Sequencing by: Washington University Genome Sequencing Center. Clone distribution: Research Genetics web address: <http://www.researchgenetics.com/>  
Seq primer: 17 ET from Amersham  
High quality sequence stop: 426.

**FEATURES**  
source  
1..531  
/organism="Danio rerio"  
/mol\_type="mRNA"  
/db\_xref="taxon:7955"  
/tissue\_type="fin"  
/lab\_host="GeneHogs (HS996, a phage-resistant isolate of DH10B)"  
/clone\_lib="Zebrafish Research Genetics C32 fin"  
/note="Vector: pT73D-Pac with a modified polylinker; Site 1: EcoRI; Site 2: NotI; 1st strand cDNA was prepared from zebrafish(C32) fin, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library is non-normalized. Library was constructed by Ning Wu. NOTE: This clone is available royalty-free through LNL; contact the IMAGE Consortium ([info.lnl.gov](http://info.lnl.gov/)) for further information"

**ORIGIN**  
Query Match 84.0%; Score 16.8; DB 2; Length 531;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 AGAGATGATTAGGCAGAGGT 20  
Db 357 AGAGGTGATCAGGCAGAGGT 376

**RESULT 35**  
BQ122423  
LOCUS BQ122423  
DEFINITION BQ122423 GLSD Medicago truncatula cDNA clone pGLSD-28N20, mRNA sequence.  
ACCESSION BQ122423.1 GI:20174385  
VERSION BQ122423  
KEYWORDS EST.  
SOURCE Medicago truncatula (barrel medic)  
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Trifolieae; Medicago.  
1 (bases 1 to 533)  
REFERENCE 1 Grusak, M.A., Samac, D., Town, C.D., Van Aken, S., Utterback, T.,

**SOURCE**  
JOURNAL Cheung, F. and Fraser, C.M.  
COMMENT Unpublished (2002)  
Contact: Grusak, M.A.  
USDA/ARS Children's Nutrition Research Center  
Baylor College of Medicine  
1100 Bates Street, Houston, TX 77030-2600, USA  
Tel: 713 798 7044  
Fax: 713 798 7078  
Email: mgrusak@bcm.tmc.edu  
TIGR sequence name: MTRAD82TK More information is available at: [www.medicago.org](http://www.medicago.org)  
Seq primer: SKmod (CTA GAA CTA gtg gat CC).  
Location/Qualifiers  
1..533  
/organism="Medicago truncatula"  
/mol\_type="mRNA"  
/cultivar="Al7"  
/db\_xref="taxon:3880"  
/clone="pGLSD-28N20"  
/tissue\_type="Immature seeds"  
/dev\_stage="25 to 35 days after pollination"  
/lab\_host="XL0LR"  
/clone\_lib="GLSD"  
/note="Vector: pBluescript SK-; Site 1: EcoRI; Site 2: XhoI; Immature seeds, collected from pods ranging in age from 25 to 35 days after pollination, were harvested from greenhouse-grown plants. Seed were removed and separated from pod walls and immediately frozen in liquid nitrogen. Seeds throughout the age range were pooled for mRNA extraction. cDNA was prepared from polyA+ enriched RNA. The cDNA was directionally ligated into the Unizap XR vector from Stratagene and packaged using Gigapack III Gold packaging extracts. Plasmids containing cDNA inserts were excised from the recombinant lambda-Zap phage using Ex-assist helper phage and propagated in XL0LR cells."

**ORIGIN**  
Query Match 84.0%; Score 16.8; DB 5; Length 533;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 AGAGATGATTAGGCAGAGGT 20  
Db 384 AGAGATGATGAGGCAGAGTT 403

**RESULT 36**  
CK766395  
LOCUS CK766395  
DEFINITION eca01-43ms3-f11 Eca01 Eschscholzia californica cDNA clone eca01-43ms3-f11 5', mRNA sequence.  
ACCESSION CK766395.1 GI:42720294  
VERSION CK766395  
KEYWORDS EST.  
SOURCE Eschscholzia californica (California poppy)  
ORGANISM Eschscholzia californica  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; Ranunculales; Papaveraceae; Eschscholziaceae; Eschscholzia.  
1 (bases 1 to 537)  
REFERENCE 1 (bases 1 to 537)  
AUTHORS DePamphilis, C., Carlson, J., Ma, H., Tanksley, S., Field, D., Leebens-Mack, J., Zahn, L.M., Kong, H., Ilut, D., Druckenmiller, M., Landherr, L., Hu, Y., Plock, S., Wall, K., Chioresan, S., Albert, V., Doyle, J., Frohlich, W., Miller, W., Oppenheimer, D., Soltis, D., Soltis, P. and Theissen, G.  
Generation of ESTs from early flower buds of Eschscholzia californica  
Unpublished (2002)  
Contact: Claude DePamphilis or James Leebens-Mack  
Mueller Laboratory  
Penn State University  
208 Mueller Laboratory, Department of Biology, ATTN Rm212, Penn

State University, University Park, PA 16802, USA  
Tel: 814 863 6413  
Fax: 814 865 9131  
Email: cwd3@psu.edu or jhl10@psu.edu

The sequence provided is trimmed of vector and low quality regions.  
Full sequence and original trace file are available from the Plant  
Genome Network website (<http://pgn.cornell.edu>)  
Plate: eca01-43ms3 row: f column: 11  
Seq primer: M13F.

#### FEATURES source

Location/Qualifiers  
1. 537  
/organism="Eschscholzia californica"  
/mol\_type="mRNA"  
/cultivar="Aurantia Orange"  
/db\_xref="taxon:3467"  
/clone="eca01-43ms3-fl1"  
/tissue\_type="flower buds <= 2.5mm"  
/dev\_stage="millimeter buds"  
/lab\_host="SOLR"  
/clone\_lib="Eca01"

/notes="Vector: pBluescript SK (+/-); Site 1: EcoRI;  
Site 2: XhoI; Plants were grown in greenhouse at Penn  
State from commercially available seeds. Only floral buds  
with diameter of 2.5 mm or less were collected. This is a  
directionally cloned, non-normalized library. Avg. insert  
length: 1702; Primers: M13F and M13R; Antibiotic: 50 ug/ml  
Ampicillin; Primary Titer: 7B6 pfu total; Amplified Titer:  
1.68E11 pfu/ml; Mass Excised Titer: 5.6E8 total; This  
library has been generated by the Floral Genome Project  
(FGP). We would like to thank Huck Life Sciences  
Consortium for their assistance. The Floral Genome Project  
is funded by NSF's Plant Genome Research Program  
(DBI-0115684). More information about the project can be  
obtained at <http://fgp.bio.psu.edu>"

#### ORIGIN

Query Match 84.0%; Score 16.8; DB 7; Length 537;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGCAGAGGT 20  
|||||  
DB 337 AGAGATGATCAGCAGAGGT 356

#### RESULT 37 AQ491131

LOCUS  
DEFINITION  
RPCI-11-246M17.TJ RPCI-11 Homo sapiens genomic clone  
RPCI-11-246M17, genomic survey sequence.

ACCESSION  
AQ491131  
VERSION  
AQ491131.1 GI:4677005

KEYWORDS  
GSS.

SOURCE  
Homo sapiens (human)

#### ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 558)

Zhao, S., Adams, M.D., Nierman, W., Malek, J., de Jong, P. and  
Venter, J.C.

#### AUTHORS

Use of BAC End Sequences from Library RPCI-11 for Sequence-Ready

Map Building

Unpublished (1997)

Contact: Shaying Zhao, William Nierman, Mark Adams

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850

Tel: 301 838 0200

Fax: 301 838 0208

Email: hbe@tigr.org

Clones are derived from the human BAC library RPCI-11. For BAC  
library availability, please contact Pieter de Jong  
([pieter@dejong.med.buffalo.edu](mailto:pieter@dejong.med.buffalo.edu)). Clones may be purchased from

#### FEATURES source

Location/Qualifiers  
1. 558  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="GDB:7594384"  
/db\_xref="taxon:9606"  
/clone="RPCI-11-246M17"  
/sex="Male"  
/cell\_type="Lymphocytes"  
/clone\_lib="RPCI-11"  
/note="Vector: pBACE3.6; Site 1: EcoRI; Site 2: EcoRI;  
RPCI11 Human Male BAC Library"

#### ORIGIN

Query Match 84.0%; Score 16.8; DB 8; Length 558;  
Best Local Similarity 90.0%; Pred. No. 1.9e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGCAGAGGT 20  
|||||

DB 86 AGAGATGATGAGCAGGGGT 105  
|||||

#### RESULT 38

AQ554673

LOCUS

DEFINITION

RPCI-11-381N22.TV RPCI-11 Homo sapiens genomic clone

RPCI-11-381N22, genomic survey sequence.

ACCESSION

AQ554673

VERSION

AQ554673.1 GI:4913850

KEYWORDS

GSS.

SOURCE

Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 568)

Zhao, S., Adams, M.D., Nierman, W., Malek, J., de Jong, P. and

Venter, J.C.

Use of BAC End Sequences from Library RPCI-11 for Sequence-Ready

Map Building

Unpublished (1997)

Other GSSs: RPCI-11-381N22.TJ

Contact: Shaying Zhao, William Nierman, Mark Adams

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850

Tel: 301 838 0200

Fax: 301 838 0208

Email: hbe@tigr.org

Clones are derived from the human BAC library RPCI-11. For BAC

library availability, please contact Pieter de Jong

([pieter@dejong.med.buffalo.edu](mailto:pieter@dejong.med.buffalo.edu)). Clones may be purchased from

#### FEATURES source

Location/Qualifiers  
1. 568  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="GDB:7646253"  
/db\_xref="taxon:9606"  
/clone="RPCI-11-381N22"  
/sex="Male"  
/cell\_type="Lymphocytes"  
/clone\_lib="RPCI-11"  
/note="Vector: pBACE3.6; Site 1: EcoRI; Site 2: EcoRI;

BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering>) or from  
Research Genet cs ([info@resgen.com](mailto:info@resgen.com)). BAC end search page:  
[http://www.tigr.org/tldb/hungen/bac\\_end\\_search/bac\\_end\\_search.html](http://www.tigr.org/tldb/hungen/bac_end_search/bac_end_search.html).  
Seq primer: SP6  
Class: BAC ends.



## RPC111 Human Male BAC Library"

```

ORIGIN
  Query Match      84.0%; Score 16.8; DB 8; Length 568;
  Best Local Similarity 90.0%; Pred. No. 1.9e+03;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    ||||| ||||| ||||| |||||
Db 15 AGAGAGGATTAGTCAGAGGT 34

RESULT 39
BJ690447
LOCUS
DEFINITION BJ690447 HREST library Haplochromis sp. 'red tail sheller' cDNA
ACCESSION BJ690447.1 GI:46533568
VERSION BJ690447
KEYWORDS EST.
SOURCE Haplochromis sp. 'red tail sheller'
ORGANISM Haplochromis sp. 'red tail sheller'
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Perciformes; Labroidae; Cichlidae; Haplochromis.
REFERENCE 1 (bases 1 to 599)
AUTHORS Watanabe,M., Kobayashi,N., Shin-i,T., Kohara,Y. and Okada,N.
TITLE Orf sequences of cichlid in Lake Victoria are essentially same
JOURNAL Unpublished (2004)
COMMENT Contact: Tadaasu Shin-i
Center For Genetic Resource Information
National Institute of Genetics
1111 Yata, Mishima, Shizuoka 411-8540, Japan
Tel: 81-559-81-6856
Fax: 81-559-81-6855
Email: tshini@genes.nig.ac.jp.

FEATURES
    source
    1..599
        /organism="Haplochromis sp. 'red tail sheller'"
        /mol_type="mRNA"
        /db_xref="taxon:257976"
        /clone="no589h05"
        /tissue_type="jaw"
        /dev_stage="varied"
        /clone_lib="HREST library"

ORIGIN
  Query Match      84.0%; Score 16.8; DB 4; Length 599;
  Best Local Similarity 90.0%; Pred. No. 1.9e+03;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    ||||| ||||| ||||| |||||
Db 45 AGAGATGTTTAAGCAGAGGT 64

RESULT 40
CL186343/c
LOCUS
DEFINITION CL186343 614 bp DNA linear GSS 06-JAN-2004
  104 401.10900146.116 32411.077 Sorghum methylation-filtered library
  (LibID: 104) Sorghum bicolor genomic clone 10900146, genomic survey
  sequence.
ACCESSION CL186343
VERSION CL186343.1 GI:40698866
KEYWORDS GSS.
SOURCE Sorghum bicolor (sorghum)
ORGANISM Sorghum bicolor
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Sorghum.
REFERENCE 1 (bases 1 to 614)
AUTHORS Budiman,M.A., Flick,E., Jones,J., Nunberg,A., Citek,R.W.,

```

```

TITLE
JOURNAL
COMMENT

FEATURES
    source
    1..614
        /organism="Sorghum bicolor"
        /mol_type="genomic DNA"
        /cultivar="ATx623"
        /db_xref="taxon:4558"
        /clone="10900146"
        /clone_lib="Sorghum methylation-filtered library (LibID:
  104)"
        /note="Organ: leaf; Vector: pBCSK(-); Site_1: HincII; DNA
  prepared from purified nuclei was randomly sheared,
  end-repaired, size fractionated to enrich for the 0.5 to 5
  kb fraction, ligated into HincII-digested pBCSK(-) vector
  and electroporated into E. coli cells. This is a
  methylation-filtered library."

ORIGIN
  Query Match      84.0%; Score 16.8; DB 9; Length 614;
  Best Local Similarity 90.0%; Pred. No. 1.9e+03;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGAGATGATTAGGCAGAGGT 20
    ||||| ||||| ||||| |||||
Db 106 AGAGAGGATTAGGCAGAGGT 87

RESULT 41
B00642/c
LOCUS
DEFINITION B00642 627 bp DNA linear GSS 13-JUL-1996
  csRL-117e7-u csRL flow sorted Chromosome 11 specific cosmid Homo
  sapiens genomic clone csRL-117e7, genomic survey sequence.
ACCESSION B00642
VERSION B00642.1 GI:1409920
KEYWORDS GSS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 627)
AUTHORS Jones,D., Ward,T., Gillilan,E., Schagemann,J., Probst,S.,
  Harris,J., DeFord,J., McFarland,J., Burzinski,K., Khan,M.,
  Kupfer,K. and Garner,H.R.
TITLE Genomic Sequence Sampled Map of Chromosome 11
JOURNAL Unpublished (1996)
COMMENT Contact: Evans GA, Shane Probst
McDermott Center for Human Growth and Development
University of Texas Southwestern Medical Center At Dallas
5323 Harry Hines Blvd, Dallas TX 75235-8591
Tel: 214-648-1600
Fax: 214-648-1666
Email: gevas@utsw.swmed.edu, shane@mcdermott.swmed.edu
PCR Primers
FORWARD: CTCCTCATCTCTAACCCTCC
BACKWARD: GCATTGAGTTGGTTAGTC
Seq primer: T7
Class: cosmid ends
High quality sequence stop: 627.

```

```

Robbins,D., Rohlfing,T., Bradford,K., Fries,J., McMenamy,J.,
Trani,L., Isak,A., Zimmerman,C., Lakey,N. and Bedell,J.A.
GeneThresher methylation filtered genomic sequences from Sorghum
bicolor
Unpublished (2004)
Contact: Bedell JA
Orion Genomics, LLC
4041 Forest Park Ave, St. Louis, MO 63108, USA
Tel: 314 615 6979
Fax: 314 615 5975
Email: jbedell@oriongenomics.com
Plate: 401 row: c column: 18
Seq primer: T3 Reverse
Class: shotgun
High quality sequence stop: 614.
Location/Qualifiers
    1..614
        /organism="Sorghum bicolor"
        /mol_type="genomic DNA"
        /cultivar="ATx623"
        /db_xref="taxon:4558"
        /clone="10900146"
        /clone_lib="Sorghum methylation-filtered library (LibID:
  104)"
        /note="Organ: leaf; Vector: pBCSK(-); Site_1: HincII; DNA
  prepared from purified nuclei was randomly sheared,
  end-repaired, size fractionated to enrich for the 0.5 to 5
  kb fraction, ligated into HincII-digested pBCSK(-) vector
  and electroporated into E. coli cells. This is a
  methylation-filtered library."

```

```

FEATURES
  source
    Location/Qualifiers
      1. .627
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /clones="CSRL-117e7"
        /sex="female"
        /cell_type="chimeric hamster somatic cell hybrid"
        /clone_lib="CSRL flow sorted Chromosome 11 specific cosmid"
        /notes="vector: sCos-1; Human Chromosome 11 specific cosmid library prepared from flow sorted human Chromosome 11 derived from Chinese Hamster Ovary (CHO) monochromosomal somatic cell hybrid, J1"

ORIGIN
  Query Match      84.0%; Score 16.8; DB 8; Length 627;
  Best Local Similarity 90.0%; Pred. No. 1.9e+03;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      75 AGAGATGAGGAGCAGAGGT 56

RESULT 42
CD304890      663 bp mRNA linear EST 16-SEP-2003
LOCUS
DEFINITION
  Strongylocentrotus purpuratus cDNA clone
  MPMGP691C0520;MPI_SURUDI_20C5 5', mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Strongylocentrotus purpuratus
  Strongylocentrotus purpuratus
  Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa;
  Echinoidea; Euechinoidea; Echinacea; Echinoidea;
  Strongylocentrotidae; Strongylocentrotus.

REFERENCE
  1 (bases 1 to 663)
  Poustka,A.J., Groth,D., Hennig,S., Thamm,S., Cameron,A., Beck,A.,
  Reinhardt,R., Herwig,R., Panopoulou,G. and Lehrach,H.
  Generation, annotation, evolutionary analysis, and database
  integration of 20,000 unique sea urchin EST clusters
  Genome Res. 13 (12), 2736-2746 (2003)
  Contact: Poustka AJ
  Laboratory 145, dept.Lehrach
  Max-Planck-Institut fuer Molekulare Genetik
  Ihnestr. 63-73 D-14195 Berlin, Germany
  Tel: +49 30 8413 1235
  Fax: +49 30 8413 1128
  Email: poustka@molgen.mpg.de
  The library was characterised by oligonucleotide fingerprinting
  (ONF) to reduce sequencing redundancy. According to the ONF
  procedure, clones that display the same hybridisation matrix with a
  battery of 200 8mer oligonucleotides are grouped into clusters. One
  clone per ONF cluster is selected for sequencing. The size of each
  cluster is an indicator of the frequency of a transcript in the
  analysed library. The cluster size as well as the coordinates of
  the other clones assigned to the same ONF cluster as the clone from
  which the above EST is generated is available at the sea urchin
  project web site at: http://www.molgen.mpg.de/ag_seaurchin/. cDNA
  clones and filters are distributed via the Resource Center/Primary
  Database of the German Human Genome Project (http://www.rzpd.de)
  PCR Primers
  FORWARD: 5' CCCAGGCTTACACTTTATGTCCTCCGCTCG 3' (M13RSP) 5'-seq
  BACKWARD: 5' GCTATTAGCGAGTCGCGAAGGGAGGTGTG 3' (M13FSP) 3'-seq
  Seq primer: 5'-CGGTCCGAATTCCTCCGGT-3' pSport3/86
  High quality sequence stop: 663.
  Location/Qualifiers
    1. .663
      /organism="Strongylocentrotus purpuratus"
      /mol_type="mRNA"

```

```

/db_xref="taxon:7668"
/clone="MPMGp691C0520;MPI_SURUDI_20C5"
/tissue_type="whole larva"
/dev_stage="larva 2-3 weeks"
/lab_host="E.coli, XL1 blue"
/clone_lib="Sea urchin larva cDNA library MPMGP691"
/notes="Vector: pSport1; Site_1: NotI; Site_2: SalI; Random
primed and directionally cloned in pSport1 vector using a
NotI (5'-pGACTAGTTCATGATCGGCGCGGCC (T)15-3' and a
SalI 5'-TCGACCCACGCTCCG-3'adapters (Gibco BRL)"

ORIGIN
  Query Match      84.0%; Score 16.8; DB 6; Length 663;
  Best Local Similarity 90.0%; Pred. No. 2e+03;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      133 AGAGAAGATTAGGAGAGGT 152

RESULT 43
BH975438      699 bp DNA linear GSS 02-OCT-2002
LOCUS
DEFINITION
  odh59a02.g1 B.oleracea002 Brassica oleracea genomic, genomic survey
  sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Brassica oleracea
  Brassica oleracea
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
  rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
  1 (bases 1 to 699)
  Delehaunty,K., Fewell,G., Fulton,L., McCombie,W.R., Miner,T.,
  Nash,W., Rabinowicz,P.D. and Wilson,R.K.
  Whole genome shotgun reads from Brassica oleracea
  Unpublished (2002)
  Contact: Richard K. Wilson
  Genome Sequencing Center
  Washington University School of Medicine
  Email: submissions@watson.wustl.edu
  Plate: odh59 row: a column: 02
  Seq primer: -28RPpOT reverse
  Class: shotgun
  High quality sequence start: 49
  High quality sequence stop: 535.
  Location/Qualifiers
    1. .699
      /organism="Brassica oleracea"
      /mol_type="genomic DNA"
      /db_xref="taxon:3712"
      /clone_lib="B.oleracea002"
      /notes="vector: pOTw13; Whole genome shotgun library from
      flowering buds. DNA was purified from a crude nuclear
      prep using Brassica oleracea T01000H3 buds provided by
      Thomas Osborn at the University of Wisconsin. Genomic
      DNA was provided by Pablo Rabinowicz (CSHL) and the
      shotgun library prepared at Washington University Genome
      Sequencing Center."

ORIGIN
  Query Match      84.0%; Score 16.8; DB 8; Length 699;
  Best Local Similarity 90.0%; Pred. No. 2e+03;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      103 AGAGGTGATTAAGCAGAGGT 122

RESULT 44

```

```

BH973998/c
LOCUS       BH973998             707 bp    DNA    linear    GSS 02-OCT-2002
DEFINITION  odh10C03.b1 B.oleracea002 Brassica oleracea genomic, genomic survey
            sequence.
ACCESSION   BH973998
VERSION     BH973998.1  GI:23457001
KEYWORDS    GSS.
SOURCE      Brassica oleracea
            Brassica oleracea
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 707)
AUTHORS     Delaunay,K., Fewell,G., Fulton,L., McCombie,W.R., Miner,T.,
            Nash,W., Rabinowicz,P.D. and Wilson,R.K.
TITLE       Whole genome shotgun reads from Brassica oleracea
COMMENT     Unpublished (2002)
            Contact: Richard K. Wilson
            Genome Sequencing Center
            Washington University School of Medicine
            Email: submissions@watson.wustl.edu
            Plate: odh10 row: c column: 03
            Seq primer: -2LUPpOT forward
            Class: shotgun
            High quality sequence start: 16
            High quality sequence stop: 551.
FEATURES             source
     1..707
     /organism="Brassica oleracea"
     /mol_type="genomic DNA"
     /db_xref="taxon:3712"
     /clone_lib="B.oleracea002"
     /note="Vector: pOTW13; Whole genome shotgun library from
     flowering buds. DNA was purified from a crude nuclear
     prep using Brassica oleracea TO1000DH3 buds provided by
     Thomas Osborn at the University of Wisconsin. Genomic
     DNA was provided by Pablo Rabinowicz (CSHL) and the
     shotgun library prepared at Washington University Genome
     Sequencing Center."
ORIGIN
Query Match      84.0%; Score 16.8; DB 8; Length 707;
Best Local Similarity 90.0%; Pred. NO. 2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1  ACAGATGATTAGGCAGAGCT 20
    ||| ||||| ||||| ||||| |||||
DB   575 AGGATGATTAGGCAGAGCT 556

RESULT 45
CN791475/c
LOCUS       CN791475             716 bp    mRNA    linear    EST 26-MAY-2004
DEFINITION  4126207 BARC 8BOV Bos taurus cDNA clone 8BOV_42M11 5', mRNA
            sequence.
ACCESSION   CN791475
VERSION     CN791475.1  GI:47687455
KEYWORDS    EST.
SOURCE      Bos taurus (cow)
            Bos taurus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
            Bovinae; Bos.
            1  (bases 1 to 716)
            Baumann,R.G., Baldwin,R.L., Sonstegard,T.S., Van Tassel,C.P. and
            Matukumalli,L.K.
            Construction and Analysis of a cDNA Library Generated From
            Intestinal Muscle and Epithelial Tissues of Holstein Cattle
            Unpublished (2004)
            Contact: Richard G. Baumann
            Bovine Functional Genomics Lab
            ANRI
            BLDG 162: BARC-EAST, Beltsville, MD 20705, USA

```

```

Tel: 3015048604
Fax: 3015048744
Email: rbaumann@anri.barc.usda.gov
Single pass sequencing. Bases called and trimmed with phred
0.000925 using options -trim_alt '-trim_fasta. Vector identified
by cross_match using options -minmatch 12 -minscore 18
Plate: 42 row: M column: 11
Seq primer: CCTATTAGTGACATATAGAAC
High quality sequence stop: 716.
FEATURES             source
     1..716
     /organism="Bos taurus"
     /mol_type="mRNA"
     /strains="Holstein"
     /db_xref="taxon:9913"
     /clone_lib="8BOV 42M11"
     /sex="Female"
     /tissue_type="Epithelial, Muscle"
     /dev_stage="Lactating, Neonatal"
     /lab_host="DH10B Tona"
     /clone_lib="BARC 8BOV"
     /note="Organ: Intestine; Vector: pCMVSPORT6.1; Site 1:
     NotI; Site 2: EcoRI; Normalized cow cDNA intestinal mRNA
     library in pCMVSPORT6.1, constructed from equimolar mRNA
     pools derived from 5 sources, 4 lactating intestinal, 1
     neonatal intestinal 4/5 Lactating, Proximal Duodenum,
     Jejunum, Distal Ileum, Colon, 1/5 Neonatal, Proximal
     Duodenum, Jejunum, Distal Ileum"
ORIGIN
Query Match      84.0%; Score 16.8; DB 7; Length 716;
Best Local Similarity 90.0%; Pred. NO. 2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1  ACAGATGATTAGGCAGAGCT 20
    ||| ||||| ||||| ||||| |||||
DB   258 AGACATGCTTAGGCAGAGCT 239

RESULT 46
AZ519049
LOCUS       AZ519049             718 bp    DNA    linear    GSS 15-OCT-2000
DEFINITION  RPCI-11-79113.TJD RPCI-11 Homo sapiens genomic clone RPCI-11-79113,
            genomic survey sequence.
ACCESSION   AZ519049
VERSION     AZ519049.1  GI:10830166
KEYWORDS    GSS.
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1  (bases 1 to 718)
            Zhao,S., Adams,M.D., Nierman,W., Malek,J., de Jong,P. and
            Venter,J.C.
            BAC end sequences of library RPCI-11
            Unpublished (1997)
            Other GSSs: RPCI11-79113.TJC RPCI11-79113.TV
            Contact: Shaying Zhao
            Department of Eukaryotic Genomics
            The Institute for Genomic Research
            9712 Medical Center Dr., Rockville, MD 20850, USA
            Tel: 301 838 0200
            Fax: 301 838 0208
            Email: szhao@tigr.org
            Clones are derived from the human BAC library RPCI-11. For BAC
            library availability, please contact Pieter de Jong
            (pieter@dejong.med.buffalo.edu). Clones may be purchased from
            BACPAC Resources (http://bacpac.med.buffalo.edu/ordering) or from
            Research Genet cs (info@resgen.com). BAC end search page:
            http://www.tigr.org/tdb/hungen/bac_end_search/bac_end_search.html.
            This BAC end was generated during the R&D process and may have
            higher chance of clone tracking errors.
            Seq primer: SP6

```

Class: BAC ends.  
Location/Qualifiers  
1. .718  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="GDB:7530156"  
/db\_xref="taxon:9606"  
/clones="RPCI-11-79113"  
/sex="Male"  
/cell\_type="Lymphocytes"  
/clone\_lib="RPCI-11"  
/note="Vector: pBAC3.6; Site 1: EcoRI; Site 2: EcoRI;  
RPCI11 Human Male BAC Library"

ORIGIN  
Query Match 84.0%; Score 16.8; DB 8; Length 718;  
Best Local Similarity 90.0%; Pred. No. 2e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGAGGT 20  
|||||  
Db 32 AGAGAGGATTAGACAGAGGT 51  
|||||

RESULT 47  
BQ782214/c  
LOCUS  
DEFINITION BQ782214 729 bp mRNA linear EST 26-JUL-2002  
UI-R-PF0-cpj-o-14-0-UI.s1 NCI CGAP\_PFO Rattus norvegicus cDNA clone  
UI-R-PF0-cpj-o-14-0-UI 3', mRNA sequence.  
ACCESSION BQ782214  
VERSION BQ782214.1 GI:21990686  
KEYWORDS EST.  
SOURCE Rattus norvegicus (Norway rat)  
ORGANISM Rattus norvegicus  
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.  
REFERENCE 1 (bases 1 to 729)  
AUTHORS Bonaldo,M.F., Lennon,G. and Soares,M.B.  
TITLE Normalization and subtraction: two approaches to facilitate gene  
discovery  
JOURNAL Genome Res. 6 (9), 791-806 (1996)  
MEDLINE 97044477  
PubMed 8889548  
COMMENT Contact: Soares, MB  
Coordinated Laboratory for Computational Genomics  
University of Iowa  
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA  
Tel: 319 335 8250  
Fax: 319 335 9565  
Email: bento-soares@uiowa.edu  
Tissue Procurement: Jeff Stevens  
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa  
cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa  
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa  
Clone Distribution: DISTRIBUTION: Researchers may obtain clones  
from Research Genetics (www.resgen.com).  
Seq primer: M13 FORWARD  
POLYA=Yes.

Location/Qualifiers  
1. .729  
/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10116"  
/clone="UI-R-PF0-cpj-o-14-0-UI"  
/tissue\_type="Mixed tissues"  
/dev\_stage="Adult"  
/lab\_host="DH10B (Life Technologies) (T1 phage resistant)"  
/clone\_lib="NCI CGAP\_PFO"  
/note="Vector: pRT3-Pac (Pharmacia) with a modified  
polylinker; Site 1: EcoRI; Site 2: Not I; UI-R-PF0 is a  
subtracted cDNA library containing the following  
tissue(s): Normal cartilage and SR-JWS Tumor Line . The

subtraction was made according to Bonaldo, Lennon and Soares, Genome Research, 6:791-806, 1996. The oligonucleotide used to prime the synthesis of first-strand cDNA contains a library tag sequence that is located between the Not I site and the (dt)18 tail. The sequence tags for these libraries are: CTAATGGACG, CATTCTTGTA.  
TAG\_TISSUE=rat SRC-JWST tumor line  
TAG\_LIB=UI-R-PFO  
TAG\_SEQ=CAATCTTGTA"

ORIGIN  
Query Match 84.0%; Score 16.8; DB 5; Length 729;  
Best Local Similarity 90.0%; Pred. No. 2e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 AGAGATGATTAGGCAGAGGT 20  
|||||  
Db 585 AGAGAAGATTAGGCAAGGT 566  
|||||

RESULT 48  
CL189821/c  
LOCUS  
DEFINITION CL189821 734 bp DNA linear GSS 06-JAN-2004  
104 407 10905649 114 32475 007 Sorghum methylation-filtered library  
(LibID: 104) Sorghum bicolor genomic clone 10905649, genomic survey  
sequence.  
ACCESSION CL189821  
VERSION CL189821.1 GI:40702344  
KEYWORDS GSS.  
SOURCE Sorghum bicolor (sorghum)  
ORGANISM Sorghum bicolor  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD  
clade; Panicoideae; Andropogoneae; Sorghum.  
REFERENCE 1 (bases 1 to 734)  
AUTHORS Budiman,M.A., Flick,E., Jones,J., Nunberg,A., Citek,R.W.,  
Robbins,D., Rohlfing,T., Bradford,K., Fries,J., McMenamy,J.,  
Trani,L., Isak,A., Zimmerman,C., Lakey,N. and Bedell,J.A.,  
GeneThresher methylation filtered genomic sequences from Sorghum  
bicolor  
JOURNAL Unpublished (2004)  
COMMENT Contact: Bedell JA  
Orion Genomics, LLC  
4041 Forest Park Ave, St. Louis, MO 63108, USA  
Tel: 314 615 6979  
Fax: 314 615 5975  
Email: jbedell@oriongenomics.com  
Plate: 407 row: i column: 01  
Seq primer: M13/pUC Forward  
Class: shotgun  
High quality sequence stop: 734.  
Location/Qualifiers  
1. .734  
/organism="Sorghum bicolor"  
/mol\_type="genomic DNA"  
/cultivar="ATx623"  
/db\_xref="taxon:4558"  
/clone="10905649"  
/clone\_lib="Sorghum methylation-filtered library (LibID:  
104)"  
/note="Organ: leaf; Vector: pBCSK(-); Site 1: HincII; DNA  
prepared from purified nuclei was randomly sheared,  
end-repaired, size fractionated to enrich for the 0.5 to 5  
kb fraction, ligated into HincII-digested pBCSK(-) vector  
and electroporated into E. coli cells. This is a  
methylation-filtered library."

ORIGIN  
Query Match 84.0%; Score 16.8; DB 9; Length 734;  
Best Local Similarity 90.0%; Pred. No. 2e+03;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      159 AGAGATGATTAGCAGATGT 140

RESULT 49
BZ345634
LOCUS   BZ345634
DEFINITION BZ345634 746 bp DNA linear GSS 12-NOV-2002
          hs87c01.b1 WGS-SbicolorF (JM107 adapted methyl filtered) Sorghum
          bicolor genomic clone hs87c01 5', genomic survey sequence.
ACCESSION BZ345634
VERSION   BZ345634.1 GI:24903898
KEYWORDS  GSS.
SOURCE    Sorghum bicolor (sorghum)
ORGANISM  Sorghum bicolor
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
          clade; Panicoideae; Andropogoneae; Sorghum.
          1 (bases 1 to 746)
          Rabinowicz,P.D., O'Shaughnessy,A.L., Balija,V., Dedhia,N.,
          Katzenburger,F., King,L., Miller,B., Muller,S., Nascimento,L.,
          Zutavern,T., Palmer,L., McCombie,W.R. and Martienssen,R.A.,
          Genomic shotgun sequences from Sorghum bicolor (methyl-filtered)
          Unpublished (2002)
          Contact: W. Richard McCombie
          Lita Annenberg Hazen Genome Sequencing Center
          Cold Spring Harbor Laboratory
          PO Box 100, Cold Spring Harbor, NY 11724, USA
          Tel: 516 367 8884
          Fax: 516 367 8874
          Email: mcombie@cshl.org
          Plate: hs87 row: c column: 01
          Seq primer: -21M13UnivPwD
          Class: shotgun
          High quality sequence stop: 746.
FEATURES             source
   1..746
    /organism="Sorghum bicolor"
    /mol_type="genomic DNA"
    /db_xref="taxon:4558"
    /clone="hs87c01"
    /lab_host="JM107 or DH5a"
    /clone_lib="WGS-SbicolorF (JM107 adapted methyl filtered)"
    /note="Site 1: Xba I; Site 2: Xba I; The vector was
    digested with XbaI and one nucleotide was added by fill in
    in the recessive 3' end. The genomic DNA was nebulized,
    end repaired, adaptor ligated and size fractionated using
    sephadex. The resulting fragments were between 0.8 and 3
    kb and were cloned into the vector (.X/Y reads in M13mp19,
    .b/g reads in pUC19). The same ligation was transformed in
    either JM107 or DH5a."

ORIGIN
Query Match      84.0%; Score 16.8; DB 8; Length 746;
Best Local Similarity 90.0%; Pred. No. 2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      75 AGAGATGATTGGGAGAGGT 56

Search completed: December 15, 2004, 16:49:26
Job time : 1350.5 secs

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 753)
Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weyden,L.,
Jonkers,J., Smith,J., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y.,
Rogers,J. and Bradley,A.
Direct Submission
Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. http://www.sanger.ac.uk/MICER
Location/Qualifiers
   1..753
    /organism="Mus musculus"
    /mol_type="genomic DNA"
    /db_xref="taxon:10090"
    /clone="MHP113b19"
    /clone_lib="MHPp"

ORIGIN
Query Match      84.0%; Score 16.8; DB 9; Length 753;
Best Local Similarity 90.0%; Pred. No. 2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      75 AGAGATGATTGGGAGAGGT 56

Search completed: December 15, 2004, 16:49:26
Job time : 1350.5 secs

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 753)
Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weyden,L.,
Jonkers,J., Smith,J., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y.,
Rogers,J. and Bradley,A.
Direct Submission
Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. http://www.sanger.ac.uk/MICER
Location/Qualifiers
   1..753
    /organism="Mus musculus"
    /mol_type="genomic DNA"
    /db_xref="taxon:10090"
    /clone="MHP113b19"
    /clone_lib="MHPp"

ORIGIN
Query Match      84.0%; Score 16.8; DB 8; Length 746;
Best Local Similarity 90.0%; Pred. No. 2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGAGATGATTAGGCAGAGGT 20
      |||||
Db      409 AGAGATGATTATTCAGAGGT 428

RESULT 50
CR100681/c
LOCUS   CR100681/c
DEFINITION CR100681 753 bp DNA linear GSS 05-JUL-2004
          Forward strand read from insert in 3'HPRT insertion targeting and
          chromosome engineering clone MHP113b19, genomic survey sequence.
ACCESSION CR100681
VERSION   CR100681.1 GI:49848081
KEYWORDS  GSS; genome survey sequence; MICER.
SOURCE    Mus musculus (house mouse)
ORGANISM  Mus musculus
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

**THIS PAGE LEFT BLANK**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 15, 2004, 09:10:16 ; Search time 764 Seconds  
(without alignments)  
1237.950 Million cell updates/sec

Title: US-08-901-612A-58  
Perfect score: 20  
Sequence: 1 agagaugaumaggcagaggt 20  
Scoring table: IDENTITY NUC  
Gapop 10.0, Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 100 summaries

Database : GenEmbl.\*  
1: gb\_ba.\*  
2: gb\_htg.\*  
3: gb\_in.\*  
4: gb\_om.\*  
5: gb\_ov.\*  
6: gb\_pat.\*  
7: gb\_ph.\*  
8: gb\_pl.\*  
9: gb\_pr.\*  
10: gb\_ro.\*  
11: gb\_sts.\*  
12: gb\_sy.\*  
13: gb\_un.\*  
14: gb\_vi.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	6	AR027809 Sequence
C 2	20	100.0	27	6	AX147024 Sequence
3	20	100.0	30	6	AR027810 Sequence
4	20	100.0	30	6	AR027840 Sequence
C 5	20	100.0	87	6	AX151115 Sequence
C 6	20	100.0	93	14	HBPRECAA
C 7	20	100.0	99	14	HBPRECA
C 8	20	100.0	99	14	HBPRECB
C 9	20	100.0	99	14	HBPRECC
C 10	20	100.0	99	14	HBPRECD
C 11	20	100.0	99	14	HBPRECE
C 12	20	100.0	99	14	HBPRECF
C 13	20	100.0	99	14	HBPRECG
C 14	20	100.0	99	14	HBPRECH
C 15	20	100.0	99	14	HBPRECI
C 16	20	100.0	99	14	HBPRECK
C 17	20	100.0	99	14	HBPRECL
C 18	20	100.0	99	14	HBPRECM
C 19	20	100.0	129	6	AX151114 Sequence

AF528205	Hepatitis	150	14	AF528205
AF528206	Hepatitis	150	14	AF528206
AF528207	Hepatitis	150	14	AF528207
AF528208	Hepatitis	150	14	AF528208
AF528209	Hepatitis	150	14	AF528209
AF528210	Hepatitis	150	14	AF528210
AF528211	Hepatitis	150	14	AF528211
AF528212	Hepatitis	150	14	AF528212
AF528213	Hepatitis	150	14	AF528213
AF528214	Hepatitis	150	14	AF528214
AF528215	Hepatitis	150	14	AF528215
AF528216	Hepatitis	150	14	AF528216
AF528217	Hepatitis	150	14	AF528217
AF528218	Hepatitis	150	14	AF528218
AF528219	Hepatitis	150	14	AF528219
AF528220	Hepatitis	150	14	AF528220
AF528221	Hepatitis	150	14	AF528221
AF528222	Hepatitis	150	14	AF528222
AF528224	Hepatitis	150	14	AF528224
AF528225	Hepatitis	150	14	AF528225
AF528226	Hepatitis	150	14	AF528226
AF528227	Hepatitis	150	14	AF528227
AF528228	Hepatitis	150	14	AF528228
AF528229	Hepatitis	150	14	AF528229
AF528231	Hepatitis	150	14	AF528231
AF528232	Hepatitis	150	14	AF528232
AF528233	Hepatitis	150	14	AF528233
AF528234	Hepatitis	150	14	AF528234
AF528235	Hepatitis	150	14	AF528235
AF528236	Hepatitis	150	14	AF528236
AF528237	Hepatitis	150	14	AF528237
AF528238	Hepatitis	150	14	AF528238
AF528239	Hepatitis	150	14	AF528239
AF528240	Hepatitis	150	14	AF528240
AF528241	Hepatitis	150	14	AF528241
AF528242	Hepatitis	150	14	AF528242
AF528243	Hepatitis	150	14	AF528243
AF528244	Hepatitis	150	14	AF528244
AF528245	Hepatitis	150	14	AF528245
AF528246	Hepatitis	150	14	AF528246
AF528247	Hepatitis	150	14	AF528247
AF528248	Hepatitis	150	14	AF528248
AF528249	Hepatitis	150	14	AF528249
AF528250	Hepatitis	150	14	AF528250
AF528251	Hepatitis	150	14	AF528251
AF528252	Hepatitis	150	14	AF528252
AF528253	Hepatitis	150	14	AF528253
AF528254	Hepatitis	150	14	AF528254
AF528255	Hepatitis	150	14	AF528255
AF528256	Hepatitis	150	14	AF528256
AF528257	Hepatitis	150	14	AF528257
AF528258	Hepatitis	150	14	AF528258
AF528259	Hepatitis	150	14	AF528259
AF528261	Hepatitis	150	14	AF528261
AF528263	Hepatitis	150	14	AF528263
AF528264	Hepatitis	150	14	AF528264
AF528265	Hepatitis	150	14	AF528265
AF528266	Hepatitis	150	14	AF528266
AF528267	Hepatitis	150	14	AF528267
AF528268	Hepatitis	150	14	AF528268
AF528269	Hepatitis	150	14	AF528269
AF528270	Hepatitis	150	14	AF528270
AF528271	Hepatitis	150	14	AF528271
AF528272	Hepatitis	150	14	AF528272
AF528273	Hepatitis	150	14	AF528273
AF528274	Hepatitis	150	14	AF528274
AF528275	Hepatitis	150	14	AF528275
AF528276	Hepatitis	150	14	AF528276
AF528277	Hepatitis	150	14	AF528277
AF528278	Hepatitis	150	14	AF528278
AF528279	Hepatitis	150	14	AF528279
AF528280	Hepatitis	150	14	AF528280
AF528281	Hepatitis	150	14	AF528281

C 93 20 100.0 150 14 AF528282 Hepatitis  
 C 94 20 100.0 150 14 AF528283 Hepatitis  
 C 95 20 100.0 150 14 AF528284 Hepatitis  
 C 96 20 100.0 150 14 AF528286 Hepatitis  
 C 97 20 100.0 150 14 AF528287 Hepatitis  
 C 98 20 100.0 150 14 AF528288 Hepatitis  
 C 99 20 100.0 150 14 AF528289 Hepatitis  
 C 100 20 100.0 150 14 AF528290 Hepatitis

## ALIGNMENTS

RESULT 1  
 AR027809  
 LOCUS AR027809 20 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 7 from patent US 5856459.  
 ACCESSION AR027809  
 VERSION AR027809.1 GI:5938629  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Frank,B.L., Roberts,P.C., Goodchild,J., Craig,J.Charles. and Mills,J.S.  
 TITLE Oligonucleotides specific for hepatitis B virus  
 JOURNAL Patent: US 5856459-A 7 05-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

## ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 1 AGAGATGATTAGGCAGAGGT 20

RESULT 2  
 AX147024/c  
 LOCUS AX147024 27 bp DNA linear PAT 08-JUN-2001  
 DEFINITION Sequence 18 from Patent WO0137291.  
 ACCESSION AX147024  
 VERSION AX147024.1 GI:14346295  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 REFERENCE 1  
 AUTHORS Weindel,K., Riedling,M. and Geiger,A.  
 TITLE Magnetic glass particles, method for their preparation and uses thereof  
 JOURNAL Patent: WO 0137291-A 18 25-MAY-2001;  
 FEATURES Roche Diagnostics GmbH (DE)  
 source Location/Qualifiers  
 1..27  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Synthetic oligonucleotide primer (HBV reverse)"

modified\_base 27  
 /note="derivatization with a p-(t-butyl)benzyl-residue"  
 /mod\_base=OTHER

## ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 27;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 21 AGAGATGATTAGGCAGAGGT 2

RESULT 3  
 AR027810  
 LOCUS AR027810 30 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 8 from patent US 5856459.  
 ACCESSION AR027810  
 VERSION AR027810.1 GI:5938630  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)  
 AUTHORS Frank,B.L., Roberts,P.C., Goodchild,J., Craig,J.Charles. and Mills,J.S.  
 TITLE Oligonucleotides specific for hepatitis B virus  
 JOURNAL Patent: US 5856459-A 8 05-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..30  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

## ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 11 AGAGATGATTAGGCAGAGGT 30

RESULT 4  
 AR027840  
 LOCUS AR027840 30 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 38 from patent US 5856459.  
 ACCESSION AR027840  
 VERSION AR027840.1 GI:5938660  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)  
 AUTHORS Frank,B.L., Roberts,P.C., Goodchild,J., Craig,J.Charles. and Mills,J.S.  
 TITLE Oligonucleotides specific for hepatitis B virus  
 JOURNAL Patent: US 5856459-A 38 05-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..30  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

## ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 11 AGAGATGATTAGGCAGAGGT 30

RESULT 5  
 AX151115/c  
 LOCUS AX151115 87 bp DNA linear PAT 22-JUN-2001  
 DEFINITION Sequence 4 from Patent WO0138498.  
 ACCESSION AX151115  
 VERSION AX151115.1 GI:14533317  
 KEYWORDS

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 1 AGAGATGATTAGGCAGAGGT 20

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 1 AGAGATGATTAGGCAGAGGT 20

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 1 AGAGATGATTAGGCAGAGGT 20

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 1 AGAGATGATTAGGCAGAGGT 20

Query Match 100.0%; Score 20; DB 6; Length 30;  
 Best Local Similarity 85.0%; Pred. No. 17;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 DB 1 AGAGATGATTAGGCAGAGGT 20



```

SOURCE      synthetic construct
ORGANISM    artificial construct
REFERENCE   1
AUTHORS     Stuyver, L., Schinazi, R., de Gendt, S., van Geyt, C., Zoulim, F.,
            Fried, M. and Roseau, R.
TITLE       A new genotype of hepatitis b virus
JOURNAL     Patent: WO 0138498-A 4 31-MAY-2001;
            Pharmasset, Inc. (US) ; INNOGENETICS N.V. (BE)
FEATURES    Location/Qualifiers
            source
              1..87
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
ORIGIN
Query Match      100.0%; Score 20; DB 6; Length 87;
Best Local Similarity 85.0%; Pred. NO. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|:|:|:|:|:|:|:|:|
Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 6
HPBPBREC/CA
LOCUS      HPBPBREC/CA 93 bp DNA linear VRL 24-JAN-2003
DEFINITION Hepatitis B virus variant B3 genomic RNA, entire pre-C region.
ACCESSION  D30625 D01192
VERSION     D30625.1 GI:484048
KEYWORDS   .
SOURCE     Hepatitis B virus
ORGANISM   Hepatitis B virus
REFERENCE  1 (bases 1 to 93)
AUTHORS    Galibert, F., Mandart, E., Fitoussi, F., Tiollais, P. and Charnay, P.
TITLE      Nucleotide sequence of the hepatitis B virus genome (subtype ayw)
            cloned in E. coli
JOURNAL    Nature 281 (5733), 646-650 (1979)
MEDLINE    81012091
PUBMED     399327
REFERENCE  2 (bases 1 to 93)
AUTHORS    Li, J., Tong, S., Vitvitski, L., Zoulim, F. and Trepo, C.
TITLE      Rapid detection and further characterization of infection with
            hepatitis B virus variants containing a stop codon in the distal
            pre-C region
JOURNAL    J. Gen. Virol. 71 (Pt 9), 1993-1998 (1990)
MEDLINE    91011344
PUBMED     2212990
FEATURES    Location/Qualifiers
            source
              1..93
                /organism="Hepatitis B virus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10407"
                /notes="HBeAg-negative HBV variant B3-pre-C region"
            gene
              1..93
                /genes="pre-C/C"
            CDS
              1..93
                /genes="pre-C/C"
                /codon_start=1
                /product="pre-C/C protein"
                /protein_id="BAA06312.1"
                /db_xref="GI:507810"
                /translation="MQLFHLCLIIISCTPTFQASKLCIGWLWGMD"
            variation
              25
                /genes="pre-C/C"
                /note="Base substitution has occurred at this position in
                E2"
            variation
              37
                /genes="pre-C/C"
                /note="Base substitution has occurred at this position in
                E2"

SOURCE      synthetic construct
ORGANISM    artificial construct
REFERENCE   1
AUTHORS     Stuyver, L., Schinazi, R., de Gendt, S., van Geyt, C., Zoulim, F.,
            Fried, M. and Roseau, R.
TITLE       A new genotype of hepatitis b virus
JOURNAL     Patent: WO 0138498-A 4 31-MAY-2001;
            Pharmasset, Inc. (US) ; INNOGENETICS N.V. (BE)
FEATURES    Location/Qualifiers
            source
              1..87
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
ORIGIN
Query Match      100.0%; Score 20; DB 6; Length 87;
Best Local Similarity 85.0%; Pred. NO. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|:|:|:|:|:|:|:|:|
Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 7
HPBPBREC/CA
LOCUS      HPBPBREC/CA 99 bp DNA linear VRL 11-MAY-1994
DEFINITION Hepatitis B virus type1 precore protein (pre-C region, C) gene, 5'
            end.
ACCESSION  M76687.1 GI:485341
VERSION     M76687.1
KEYWORDS    e antigen; precore protein; tolerogen.
SOURCE     Hepatitis B virus
ORGANISM   Hepatitis B virus
REFERENCE  1 (bases 1 to 99)
AUTHORS    Santantonio, T., Jung, M.C., Miska, S., Pastore, G., Pape, G.R. and
            Will, H.
TITLE      Prevalence and type of pre-C HBV mutants in anti-HBe positive
            carriers with chronic liver disease in a highly endemic area
JOURNAL    Virology 183 (2), 840-844 (1991)
MEDLINE    91306476
PUBMED     1853582
FEATURES    Original source text: Hepatitis B virus DNA.
            Location/Qualifiers
            source
              1..99
                /organism="Hepatitis B virus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10407"
            gene
              10..93
                /genes="C"
            CDS
              10..93
                /genes="C"
                /standard_name="pre-C region"
                /codon_start=1
                /product="precore protein"
                /protein_id="AAA45507.1"
                /db_xref="GI:485342"
                /translation="MQLFHLCLIIISCTPTFQASKLCIGWL"

SOURCE      synthetic construct
ORGANISM    artificial construct
REFERENCE   1
AUTHORS     Stuyver, L., Schinazi, R., de Gendt, S., van Geyt, C., Zoulim, F.,
            Fried, M. and Roseau, R.
TITLE       A new genotype of hepatitis b virus
JOURNAL     Patent: WO 0138498-A 4 31-MAY-2001;
            Pharmasset, Inc. (US) ; INNOGENETICS N.V. (BE)
FEATURES    Location/Qualifiers
            source
              1..87
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
ORIGIN
Query Match      100.0%; Score 20; DB 6; Length 87;
Best Local Similarity 85.0%; Pred. NO. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|:~|:~|:~|:~|:~|:~|:~
Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 8
HPBPBREC/CA
LOCUS      HPBPBREC/CA 99 bp DNA linear VRL 11-MAY-1994
DEFINITION Hepatitis B virus type1 precore protein (pre-C region, C) gene, 5'
            end.
ACCESSION  M76687.1 GI:485341
VERSION     M76687.1
KEYWORDS    e antigen; precore protein; tolerogen.
SOURCE     Hepatitis B virus
ORGANISM   Hepatitis B virus
REFERENCE  1 (bases 1 to 99)
AUTHORS    Santantonio, T., Jung, M.C., Miska, S., Pastore, G., Pape, G.R. and
            Will, H.
TITLE      Prevalence and type of pre-C HBV mutants in anti-HBe positive
            carriers with chronic liver disease in a highly endemic area
JOURNAL    Virology 183 (2), 840-844 (1991)
MEDLINE    91306476
PUBMED     1853582
FEATURES    Original source text: Hepatitis B virus DNA.
            Location/Qualifiers
            source
              1..99
                /organism="Hepatitis B virus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10407"
            gene
              10..93
                /genes="C"
            CDS
              10..93
                /genes="C"
                /standard_name="pre-C region"
                /codon_start=1
                /product="precore protein"
                /protein_id="AAA45507.1"
                /db_xref="GI:485342"
                /translation="MQLFHLCLIIISCTPTFQASKLCIGWL"

```

```

variation          92
                   /gene="C"
                   /note="g in wt; a in virus type 1 (creates internal stop
                   codon)"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 8
HPBPBREC/c
LOCUS
DEFINITION
Hepatitis B virus type 2precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76688
VERSION M76688.1 GI:485343
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and
Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive
carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
Location/Qualifiers
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
variation
6 /note="c in wt; t in virus type 3"
10..93
/gene="C"
CDS 10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA45508.1"
/db_xref="GI:485344"
/translation="MQLFHLCLIIISCSCTVQASKLCIGWL"
variation
58 /gene="C"
/gene="C"
/note="g in wt; t in virus type 3 (val to phe)"
92
variation
92 /gene="C"
/note="g in wt; a in virus type 3 (creates internal stop
codon)"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 10
HPBPBREC/c
LOCUS
DEFINITION
Hepatitis B virus type 4 precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76690
VERSION M76690.1 GI:485347
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and
Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive
carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
Location/Qualifiers
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
variation
2 /note="c in wt; t in virus type 2"
10..93
/gene="C"
CDS 10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA45508.1"
/db_xref="GI:485344"
/translation="MQLFHLCLIIISCSCTVQASKLCIGWL"
variation
92 /gene="C"
/gene="C"
/note="g in wt; a in virus type 2 (creates internal stop
codon)"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 9
HPBPBREC/c
LOCUS
DEFINITION
Hepatitis B virus type 3precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76689

```

```

VERSION M76689.1 GI:485345
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and
Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive
carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
Location/Qualifiers
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
variation
6 /note="c in wt; t in virus type 3"
10..93
/gene="C"
CDS 10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA45509.1"
/db_xref="GI:485346"
/translation="MQLFHLCLIIISCSCTVQASKLCIGWL"
variation
58 /gene="C"
/gene="C"
/note="g in wt; t in virus type 3 (val to phe)"
92
variation
92 /gene="C"
/note="g in wt; a in virus type 3 (creates internal stop
codon)"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:|||||
Db 42 AGAGATGATTAGGCAGAGGT 23

RESULT 10
HPBPBREC/c
LOCUS
DEFINITION
Hepatitis B virus type 4 precure protein (pre-C region, C) gene, 5'
end.
ACCESSION M76690
VERSION M76690.1 GI:485347
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and
Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive
carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
Location/Qualifiers
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"

```

```
/db_xref="taxon:10407"
10..93
/gene="C"
CDS
10..93
/gene="C"
/standard_name="pre-C region"
/codon_start=1
/product="precure protein"
/protein_id="AAA4510.1"
/db_xref="GI:485348"
/translation="MQLFHLCLIISCSCTVQASKLCLGWL"
92
/gene="C"
/notes="g in wt; a in virus type 4 (creates internal stop codon)"
95
/notes="g in wt; a in virus type 4 (gly to asp)"
95
variation
variation
ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGGT 20
|||||:|:|:|:|:|
Db 42 AGAGATGATTAGGCAGGT 23

RESULT 12
HBPBREC/c 99 bp DNA linear VRL 11-MAY-1994
LOCUS Hepatitis B virus type 6 precure protein (pre-C region, C) gene, 5'
DEFINITION end.
ACCESSION M76692
VERSION M76692.1 GI:485351
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
COMMENT Original source text: Hepatitis B virus DNA.
FEATURES
source
1..99
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"
10..99
/gene="C"
/misc_feature
10..99
/gene="C"
/product="precure protein"
/notes="putative cds"
11
variation
11
/gene="C"
/notes="t in wt; c in virus type 6 (loss of start codon)"
ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 99;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGGT 20
|||||:|:|:|:|:|
Db 42 AGAGATGATTAGGCAGGT 23

RESULT 13
HBPBREC/c 99 bp DNA linear VRL 11-MAY-1994
LOCUS Hepatitis B virus type 7 precure protein (pre-C region, C) gene, 5'
DEFINITION end.
ACCESSION M76693
VERSION M76693.1 GI:485352
KEYWORDS e antigen; precure protein; tolerogen.
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1 (bases 1 to 99)
AUTHORS Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL Virology 183 (2), 840-844 (1991)
MEDLINE 91306476
PUBMED 1853582
```

```

COMMENT      Original source text: Hepatitis B virus DNA.
FEATURES
  source
    1..99
    /organism="Hepatitis B virus"
    /mol_type="genomic DNA"
    /db_xref="taxon:10407"
    10..93
    /gene="C"
    misc_feature
      10..93
      /gene="C"
      /product="precure protein"
      /standard_name="pre-C region note: putative CDS"
    variation
      10
    /gene="C"
    /note="a in wt; t in virus type 7 (loss of start codon)"
    variation
      14
    /gene="C"
    /note="a in wt; g in virus type 7 (gln to arg)"
    variation
      92
    /gene="C"
    /note="g in wt; a in virus type 7 (creates internal stop codon)"
  ORIGIN
    Query Match      100.0%; Score 20; DB 14; Length 99;
    Best Local Similarity 85.0%; Pred. No. 16;
    Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

    QY 1 AGAGAUGAUUAGGCAGAGGT 20
        |||||:|||||
    Db 42 AGAGATGATTAGGCAGAGGT 23

  RESULT 15
  HPBPREDI/c
  LOCUS
  DEFINITION
    Hepatitis B virus type 9 precure protein (pre-C region, C) gene, 5'
    end.
  ACCESSION
    M76695
  VERSION
    M76695.1 GI:485354
  KEYWORDS
    e antigen; precure protein; tolerogen.
  SOURCE
    Hepatitis B virus
  ORGANISM
    Hepatitis B virus
  REFERENCE
    1 (bases 1 to 99)
    Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and
    Will,H.
    Prevalence and type of pre-C HBV mutants in anti-HBe positive
    carriers with chronic liver disease in a highly endemic area
    Virology 183 (2), 840-844 (1991)
  JOURNAL
    MEDLINE
    PUBMED
    1853582
  COMMENT
    Original source text: Hepatitis B virus DNA.
  FEATURES
    source
      1..99
      /organism="Hepatitis B virus"
      /mol_type="genomic DNA"
      /db_xref="taxon:10407"
      10..93
      /gene="C"
      misc_feature
        10..93
        /gene="C"
        /product="precure protein"
        /standard_name="pre-C region note: putative CDS"
      variation
        13
        /gene="C"
        /note="c in wt; t in virus type 9 (creates internal stop codon)"
      variation
        92
        /gene="C"
        /note="g in wt; a in virus type 9 (creates internal stop codon)"
      variation
        95
        /note="g in wt; a in virus type 9 (gly to asp)"
  ORIGIN
    Query Match      100.0%; Score 20; DB 14; Length 99;
    Best Local Similarity 85.0%; Pred. No. 16;
    Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

    QY 1 AGAGAUGAUUAGGCAGAGGT 20
        |||||:|||||
    Db 42 AGAGATGATTAGGCAGAGGT 23

  RESULT 16
  HPBPREDI/c
  LOCUS
  DEFINITION
    Hepatitis B virus type 11 precure protein (pre-C region, C) gene,
    5' end.
  ACCESSION
    M76697
  VERSION
    M76697.1 GI:485357
  KEYWORDS
    e antigen; precure protein; tolerogen.
  SOURCE
    Hepatitis B virus
  ORGANISM
    Hepatitis B virus

```

REFERENCE	Viruses; Retrovird viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS	1 (bases 1 to 99) Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE	Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL	Virology 183 (2), 840-844 (1991)
MEDLINE	91306476
PUBMED	1853582
COMMENT	Original
FEATURES	source text: Hepatitis B virus DNA. Location/Qualifiers 1..99 /organism="Hepatitis B virus" /mol_type="genomic DNA" /db_xref="taxon:10407" 10..99 /gene="C" 10..>99 /gene="C" /standard_name="pre-C region" /codon_start=1 /product="precore protein" /protein_id="AA045513.1" /db_xref="GI:485358" /translation="MQLFHLCLIIISVHLLFKPPSCALGGFGTW" 42..43 /gene="C" /note="frameshift mutation, deletion of single base in virus type 11" 94 /gene="C"
variation	
variation	
ORIGIN	
Query Match	100.0%; Score 20; DB 14; Length 99;
Best Local Similarity	85.0%; Pred No.16;
Matches	17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy	1 AGAGAUGAUAGGCAGAGGT 20      : : : : : :
Db	42 AGAGATGATTAGGCAGAGGT 23    : : : : :
RESULT 17	
HPBPREFL/C	
LOCUS	Hepatitis B virus type 12 precore protein (pre-C region, C) gene, 99 bp DNA linear VRL 11-MAY-1994
DEFINITION	Hepatitis B virus type 12 precore protein (pre-C region, C) gene, 99 bp DNA linear VRL 11-MAY-1994
ACCESSION	M76698
VERSION	M76698.1 GI:485359
KEYWORDS	e antigen; precore protein; tolerogen.
SOURCE	Hepatitis B virus
ORGANISM	Hepatitis B virus
REFERENCE	Viruses; Retrovird viruses; Hepadnaviridae; Orthohepadnavirus.
AUTHORS	1 (bases 1 to 99) Santantonio,T., Jung,M.C., Miska,S., Pastore,G., Pape,G.R. and Will,H.
TITLE	Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
JOURNAL	Virology 183 (2), 840-844 (1991)
MEDLINE	91306476
PUBMED	1853582
COMMENT	Original
FEATURES	source text: Hepatitis B virus DNA. Location/Qualifiers 1..99 /organism="Hepatitis B virus" /mol_type="genomic DNA" /db_xref="taxon:10407" 10..99 /gene="C" 10..>99 /gene="C" /standard_name="pre-C region" /codon_start=1
source	
gene	
CDS	

```

Db      42 AGAGATGATTAGGCAGAGGT 23

RESULT 19
AX151114/c
LOCUS   AX151114               129 bp      DNA      linear      PAT 22-JUN-2001
DEFINITION Sequence 3 from Patent WO0138498.
ACCESSION AX151114
VERSION   AX151114.1 GI:14533316
KEYWORDS  synthetic construct
SOURCE    synthetic construct
ORGANISM  artificial sequences.

REFERENCE
1 Stuyver, L., Schinazi, R., de Gendt, S., van Geyt, C., Zoulim, F.,
  Fried, M. and Roessau, R.
  A new genotype of hepatitis B virus
  Patent: WO 0138498-A 3 31-MAY-2001;
  Pharmasset, Inc. (US); INNOGENETICS N.V. (BE)
  Location/Qualifiers
    1..129
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"

ORIGIN
Query Match      100.0%; Score 20; DB 6; Length 129;
Best Local Similarity 85.0%; Pred. No. 16;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
|||||:|||||
Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 20
AF528205/c
LOCUS   AF528205               150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC1123 core antigen precursor, gene, partial
          cds.
ACCESSION AF528205
VERSION   AF528205.1 GI:32810971
KEYWORDS  Hepatitis B virus
SOURCE    Hepatitis B virus
ORGANISM  Hepatitis B virus
REFERENCE  1 (bases 1 to 150)
          Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
          Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
          Comparative evaluation of HBV precore and basal core promoter
          mutants in Indian patients with diverse clinical manifestations
          Unpublished
          2 (bases 1 to 150)
          Reference
          Authors
          Title
          Journal
          Submitted (11-JUL-2002) Hepatitis Division, National Institute of
          Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
          Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1123"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87557.1"
            /db_xref="GI:32810971"
            /translation="MQLFHLCLIISCSCTVQASKLGLWLXG"

FEATURES
source
misc_feature
CDS

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
|||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 21
AF528206/c
LOCUS   AF528206               150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC1112 core antigen precursor, gene, partial
          cds.
ACCESSION AF528206
VERSION   AF528206.1 GI:32810973
KEYWORDS  Hepatitis B virus
SOURCE    Hepatitis B virus
ORGANISM  Hepatitis B virus
REFERENCE  1 (bases 1 to 150)
          Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
          Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
          Comparative evaluation of HBV precore and basal core promoter
          mutants in Indian patients with diverse clinical manifestations
          Unpublished
          2 (bases 1 to 150)
          Reference
          Authors
          Title
          Journal
          Submitted (11-JUL-2002) Hepatitis Division, National Institute of
          Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
          Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1112"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87557.1"
            /db_xref="GI:32810971"
            /translation="MQLFHLCLIISCSCTVQASKLGLWLXG"

FEATURES
source
misc_feature
CDS

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
|||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 22
AF528207/c
LOCUS   AF528207               150 bp      DNA      linear      VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC20 core antigen precursor, gene, partial cds.
ACCESSION AF528207
VERSION   AF528207.1 GI:32810975
KEYWORDS  Hepatitis B virus
SOURCE    Hepatitis B virus
ORGANISM  Hepatitis B virus
REFERENCE  1 (bases 1 to 150)
          Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
          Gandhe, S.S., Chadha, M.S., Walimbe, A.M. and Arankalle, V.A.
          Comparative evaluation of HBV precore and basal core promoter
          mutants in Indian patients with diverse clinical manifestations
          Unpublished
          2 (bases 1 to 150)
          Reference
          Authors
          Title
          Journal
          Submitted (11-JUL-2002) Hepatitis Division, National Institute of
          Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
          Location/Qualifiers
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1123"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87556.1"

FEATURES
source
misc_feature
CDS

```

```

Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
1 (bases 1 to 150)
Gandhe.S.S., Chaddha.M.S., Walimbe.A.M. and Arankalle,V.A.
Comparative evaluation of HBV precore and basal core promoter
mutants in Indian patients with diverse clinical manifestations
Unpublished
JOURNAL
REFERENCE
AUTHORS
TITLE
JOURNAL
SUBMITTED (11-JUL-2002) Hepatitis Division, National Institute of
Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES
source
1..150
/organism="Hepatitis B virus"
/proviral
/mol_type="genomic DNA"
/isolate="ASC20"
/isolation_source="asymptomatic HBsAg carrier"
/db_xref="taxon:10407"
/country="India"
<1..>150
/misc_feature
/notes="contains partial basal core promoter"
64..>150
/notes="contains complete precore region"
/codon_start=1
/product="core antigen precursor"
/protein_id="AAP87558.1"
/db_xref="GI:32810976"
/translation="MQLFHLCLIIISCSPTVQASKLCGLWLWG"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 23
AF528208/c
LOCUS
DEFINITION
Hepatitis B virus ASC340 nonfunctional core antigen precursor,
ACCESSION AF528208
VERSION AF528208.1 GI:32810977
KEYWORDS
Hepatitis B virus
ORGANISM
Hepatitis B virus
Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE
AUTHORS
TITLE
Gandhe.S.S., Chaddha.M.S., Walimbe.A.M. and Arankalle,V.A.
Comparative evaluation of HBV precore and basal core promoter
mutants in Indian patients with diverse clinical manifestations
Unpublished
JOURNAL
REFERENCE
AUTHORS
TITLE
Gandhe.S.S., Chaddha.M.S., Walimbe.A.M. and Arankalle,V.A.
Submitted (11-JUL-2002) Hepatitis Division, National Institute of
Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES
source
1..150
/organism="Hepatitis B virus"
/proviral
/mol_type="genomic DNA"
/isolate="ASC340"
/isolation_source="asymptomatic HBsAg carrier"
/db_xref="taxon:10407"
/country="India"
<1..>150
/misc_feature
/notes="contains partial basal core promoter"
64..>150
/notes="contains complete precore region"
/codon_start=1
/product="core antigen precursor"
/protein_id="AAP87559.1"
/db_xref="GI:32810979"
/translation="MQLFHLCLIIISCSPTVQASKLCGLWLWG"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 24
AF528209/c
LOCUS
DEFINITION
Hepatitis B virus ASC58 core antigen precursor, gene, partial cds.
ACCESSION AF528209
VERSION AF528209.1 GI:32810978
KEYWORDS
Hepatitis B virus
ORGANISM
Hepatitis B virus
Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE
AUTHORS
TITLE
Gandhe.S.S., Chaddha.M.S., Walimbe.A.M. and Arankalle,V.A.
Comparative evaluation of HBV precore and basal core promoter
mutants in Indian patients with diverse clinical manifestations
Unpublished
JOURNAL
REFERENCE
AUTHORS
TITLE
Gandhe.S.S., Chaddha.M.S., Walimbe.A.M. and Arankalle,V.A.
Submitted (11-JUL-2002) Hepatitis Division, National Institute of
Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES
source
1..150
/organism="Hepatitis B virus"
/proviral
/mol_type="genomic DNA"
/isolate="ASC58"
/isolation_source="asymptomatic HBsAg carrier"
/db_xref="taxon:10407"
/country="India"
<1..>150
/misc_feature
/notes="contains partial basal core promoter"
64..>150
/notes="contains complete precore region"
/codon_start=1
/product="core antigen precursor"
/protein_id="AAP87559.1"
/db_xref="GI:32810979"
/translation="MQLFHLCLIIISCSPTVQASKLCGLWLWG"

ORIGIN
Query Match 100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 25
AF528210/c
LOCUS
DEFINITION
Hepatitis B virus ASC470 nonfunctional core antigen precursor,
ACCESSION AF528210
VERSION AF528210.1 GI:32810980
KEYWORDS
Hepatitis B virus

```

```

SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
AUTHORS     Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            source
            1..150
            /organism="Hepatitis B virus"
            /mol_type="genomic DNA"
            /isolate="ASC470"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"
            misc_feature
            100.0%; Score 20; DB 14; Length 150;
            Best Local Similarity 85.0%; Pred. No. 15;
            Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
            ORIGIN
Query Match
Best Local Similarity 85.0%; Score 20; DB 14; Length 150;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY      1 AGAGAUAUAGGCAGAGGT 20
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 26
AF528211/c
LOCUS      Hepatitis B virus ASC335 core antigen precursor, gene, partial cds.
DEFINITION
ACCESSION AF528211
VERSION   AF528211.1 GI:32810981
KEYWORDS
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
AUTHORS     Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC335"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region"
            misc_feature
            100.0%; Score 20; DB 14; Length 150;
            Best Local Similarity 85.0%; Pred. No. 15;
            Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
            CDS
            1 AGAGAUAUAGGCAGAGGT 20
            Db      96 AGAGATGATTAGGCAGAGGT 77

```

```

/codon_start=1
/product="core antigen precursor"
/protein_id="AAP87560.1"
/db_xref="GI:32810982"
/translation="MQLFHLCLIISCSCTTVQASKLCGLWLWG"

ORIGIN
Query Match
Best Local Similarity 85.0%; Score 20; DB 14; Length 150;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY      1 AGAGAUAUAGGCAGAGGT 20
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 27
AF528212/c
LOCUS      Hepatitis B virus ASC343 core antigen precursor, gene, partial cds.
DEFINITION
ACCESSION AF528212
VERSION   AF528212.1 GI:32810983
KEYWORDS
SOURCE      Hepatitis B virus
ORGANISM    Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
AUTHORS     Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
            source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC343"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region"
            misc_feature
            100.0%; Score 20; DB 14; Length 150;
            Best Local Similarity 85.0%; Pred. No. 15;
            Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
            CDS
            1 AGAGAUAUAGGCAGAGGT 20
            Db      96 AGAGATGATTAGGCAGAGGT 77

ORIGIN
Query Match
Best Local Similarity 85.0%; Score 20; DB 14; Length 150;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY      1 AGAGAUAUAGGCAGAGGT 20
Db      96 AGAGATGATTAGGCAGAGGT 77

RESULT 28
AF528213/c
LOCUS      Hepatitis B virus ASC404 core antigen precursor, gene, partial cds.
DEFINITION
ACCESSION AF528213
VERSION   AF528213.1 GI:32810985
KEYWORDS

```



Source	Organism	Reference	Authors	Title	Journal	Reference	Authors	Title	Journal	Features
Hepatitis B virus	Hepatitis B virus	Viruses; Retroviridae; Hepadnaviridae; Orthohepadnavirus.	Gandhe, S.S., Chaddha, M.S., Walimbe, A.M. and Arankalle, V.A.	Comparative evaluation of HBV precore and basal core promoter mutants in Indian patients with diverse clinical manifestations	Unpublished	2 (bases 1 to 150)	Gandhe, S.S., Chaddha, M.S., Walimbe, A.M. and Arankalle, V.A.	Comparative evaluation of HBV precore and basal core promoter mutants in Indian patients with diverse clinical manifestations	Unpublished	2 (bases 1 to 150)
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						
Best Local Similarity	85.0%;	Pred. No. 15;								
Matches	17;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;	
misc_feature	<1..>150	/note="contains partial basal core promoter"								
CDS	64..>150	/note="contains complete precore region"								
ORIGIN										
Query Match	100.0%;	Score 20;	DB 14;	Length 150;						

[illegible]

```

DEFINITION  Hepatitis B virus ASC1035 core antigen precursor, gene, partial
              cds.
ACCESSION   AF528216
VERSION     AF528216.1  GI:32810991
SOURCE      Hepatitis B virus
            Hepatitis B virus
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1035"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /notes="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87565.1"
            /db_xref="GI:32810992"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

misc_feature
            <1..>150
            /note="contains partial basal core promoter"

CDS
            64..>150
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87565.1"
            /db_xref="GI:32810992"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 32
AF528217/c
LOCUS       Hepatitis B virus ASC1061 nonfunctional core antigen precursor,
DEFINITION  gene, partial sequence.
ACCESSION   AF528217
VERSION     AF528217.1  GI:32810993
SOURCE      Hepatitis B virus
            Hepatitis B virus
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1061"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /notes="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87566.1"
            /db_xref="GI:32810995"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

misc_feature
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /notes="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87566.1"
            /db_xref="GI:32810995"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

CDS
            64..>150
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87566.1"
            /db_xref="GI:32810995"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 34
AF528218/c
LOCUS       Hepatitis B virus ASC339 core antigen precursor, gene, partial cds.
DEFINITION  Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
ACCESSION   AF528218
VERSION     AF528218.1  GI:32810994
SOURCE      Hepatitis B virus
            Hepatitis B virus
            Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC339"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /notes="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87566.1"
            /db_xref="GI:32810995"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

misc_feature
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /notes="contains complete precore region"
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87566.1"
            /db_xref="GI:32810995"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

CDS
            64..>150
            /codon_start=1
            /product="core antigen precursor"
            /protein_id="AAP87566.1"
            /db_xref="GI:32810995"
            /translation="MQLFHLIIISCSPTVQASKLCGLWLMG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 34

```

```
AF528219/c
LOCUS       AF528219        150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION  Hepatitis B virus ASC295 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION   AF528219
VERSION     AF528219.1  GI:32810996
KEYWORDS    .
SOURCE      .
  ORGANISM  .
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC295"
                     /isolation_source="asymptomatic HBsAg carrier"
                     /specific_host="Homo sapiens"
                     /db_xref="taxon:10407"
     misc_feature    <1..>150
                     /note="contains partial basal core promoter"
     misc_feature    64..>150
                     /note="contains complete precore region; nonfunctional
                     core antigen precursor due to mutation"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:::|||||||
Db 96 AGAGATGATTAGCGCAGGT 77

RESULT 35
AF528220/c
LOCUS       AF528220        150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION  Hepatitis B virus ASC1027 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION   AF528220
VERSION     AF528220.1  GI:32810997
KEYWORDS    .
SOURCE      .
  ORGANISM  .
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1027"
     misc_feature    <1..>150
                     /note="contains partial basal core promoter"
     misc_feature    64..>150
                     /note="contains complete precore region; nonfunctional
                     core antigen precursor due to mutation"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:::|||||||
Db 96 AGAGATGATTAGCGCAGGT 77

RESULT 36
AF528221/c
LOCUS       AF528221        150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION  Hepatitis B virus ASC1029 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION   AF528221
VERSION     AF528221.1  GI:32810998
KEYWORDS    .
SOURCE      .
  ORGANISM  .
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1029"
                     /isolation_source="asymptomatic HBsAg carrier"
                     /specific_host="Homo sapiens"
                     /db_xref="taxon:10407"
     misc_feature    <1..>150
                     /note="contains partial basal core promoter"
     misc_feature    64..>150
                     /note="contains complete precore region; nonfunctional
                     core antigen precursor due to mutation"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:::|||||||
Db 96 AGAGATGATTAGCGCAGGT 77

RESULT 37
AF528222/c
LOCUS       AF528222        150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION  Hepatitis B virus ASC298 core antigen precursor, gene, partial cds.
ACCESSION   AF528222
VERSION     AF528222.1  GI:32810999
KEYWORDS    .
SOURCE      .
  ORGANISM  .
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1027"
```

```
/isolation_source="asymptomatic HBsAg carrier"
/specific_host="Homo sapiens"
/db_xref="taxon:10407"
/country="India"
<1..>150
/note="contains partial basal core promoter"
64..>150
/note="contains complete precore region; nonfunctional
core antigen precursor due to mutation"
misc_feature
misc_feature
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:::|||||||
Db 96 AGAGATGATTAGCGCAGGT 77

RESULT 36
AF528221/c
LOCUS       AF528221        150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION  Hepatitis B virus ASC1029 nonfunctional core antigen precursor,
gene, partial sequence.
ACCESSION   AF528221
VERSION     AF528221.1  GI:32810998
KEYWORDS    .
SOURCE      .
  ORGANISM  .
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1029"
                     /isolation_source="asymptomatic HBsAg carrier"
                     /specific_host="Homo sapiens"
                     /db_xref="taxon:10407"
     misc_feature    <1..>150
                     /note="contains partial basal core promoter"
     misc_feature    64..>150
                     /note="contains complete precore region; nonfunctional
                     core antigen precursor due to mutation"
ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
    |||||:::|||||||
Db 96 AGAGATGATTAGCGCAGGT 77

RESULT 37
AF528222/c
LOCUS       AF528222        150 bp    DNA    linear    VRL 31-JUL-2003
DEFINITION  Hepatitis B virus ASC298 core antigen precursor, gene, partial cds.
ACCESSION   AF528222
VERSION     AF528222.1  GI:32810999
KEYWORDS    .
SOURCE      .
  ORGANISM  .
    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Comparative evaluation of HBV precore and basal core promoter
            mutants in Indian patients with diverse clinical manifestations
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS     Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE       Direct Submission
JOURNAL     Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES             Location/Qualifiers
     source          1..150
                     /organism="Hepatitis B virus"
                     /proviral
                     /mol_type="genomic DNA"
                     /isolate="ASC1027"
```

```

KEYWORDS      Hepatitis B virus
SOURCE        Hepatitis B virus
ORGANISM      Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE     1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Comparative evaluation of HBV precore and basal core promoter
             mutants in Indian patients with diverse clinical manifestations
JOURNAL      Unpublished
REFERENCE     2 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE        Direct Submission
JOURNAL      Submitted (11-JUL-2002) Hepatitis Division, National Institute of
             Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES     Location/Qualifiers
             1..150
             /organism="Hepatitis B virus"
             /proviral
             /mol_type="genomic DNA"
             /isolate="ASC298"
             /isolation_source="asymptomatic HBsAg carrier"
             /specific_host="Homo sapiens"
             /db_xref="taxon:10407"
             /country="India"
             /note="contains partial basal core promoter"
misc_feature  <1..>150
CDS          64..>150
             /note="contains complete precore region"
             /codon_start=1
             /product="core antigen precursor"
             /protein_id="AAP87567.1"
             /db_xref="GI:32811000"
             /translation="MQLPHLCIIISCSCTVQASKLCGLWLG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 38
AF528224/c
LOCUS      Hepatitis B virus 150 bp DNA linear VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC263 nonfunctional core antigen precursor,
             gene, partial sequence.
ACCESSION  AF528224
VERSION     AF528224.1 GI:32811002
KEYWORDS   Hepatitis B virus
SOURCE     Hepatitis B virus
ORGANISM   Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE  1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
             mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
             Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
             1..150
             /organism="Hepatitis B virus"
             /proviral
             /mol_type="genomic DNA"
             /isolate="ASC263"
             /isolation_source="asymptomatic HBsAg carrier"
             /specific_host="Homo sapiens"

```

```

             /db_xref="taxon:10407"
             /country="India"
             /note="contains partial basal core promoter"
             /note="contains complete precore region; nonfunctional
             core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 39
AF528225/c
LOCUS      Hepatitis B virus 150 bp DNA linear VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC1036 nonfunctional core antigen precursor,
             gene, partial sequence.
ACCESSION  AF528225
VERSION     AF528225.1 GI:32811003
KEYWORDS   Hepatitis B virus
SOURCE     Hepatitis B virus
ORGANISM   Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE  1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
             mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
             Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES     Location/Qualifiers
             1..150
             /organism="Hepatitis B virus"
             /proviral
             /mol_type="genomic DNA"
             /isolate="ASC1036"
             /isolation_source="asymptomatic HBsAg carrier"
             /specific_host="Homo sapiens"
             /db_xref="taxon:10407"
             /country="India"
             /note="contains partial basal core promoter"
             /note="contains complete precore region; nonfunctional
             core antigen precursor due to mutation"

misc_feature  <1..>150
misc_feature  64..>150

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 40
AF528226/c
LOCUS      Hepatitis B virus 150 bp DNA linear VRL 31-JUL-2003
DEFINITION Hepatitis B virus ASC1062 nonfunctional core antigen precursor,
             gene, partial sequence.
ACCESSION  AF528226
VERSION     AF528226.1 GI:32811004
KEYWORDS

```

```

SOURCE      Hepatitis B virus
ORGANISM    Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE   1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
           mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
             source
               1..150
               /organism="Hepatitis B virus"
               /proviral
               /mol_type="genomic DNA"
               /isolate="ASC1062"
               /isolation_source="asymptomatic HBsAg carrier"
               /specific_host="Homo sapiens"
               /db_xref="taxon:10407"
               /country="India"
               <1..>150
               /note="contains partial basal core promoter"
               64..>150
               /note="contains complete precore region; nonfunctional
               core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 41
LOCUS      AF528227/c
DEFINITION Hepatitis B virus ASC1065 nonfunctional core antigen precursor,
           gene, partial sequence.
ACCESSION  AF528227
VERSION     AF528227.1 GI:32811005
KEYWORDS   Hepatitis B virus
           Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
ORGANISM   Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
           mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
             source
               1..150
               /organism="Hepatitis B virus"
               /proviral
               /mol_type="genomic DNA"
               /isolate="ASC1065"
               /isolation_source="asymptomatic HBsAg carrier"
               /specific_host="Homo sapiens"
               /db_xref="taxon:10407"
               /country="India"
               <1..>150
               /note="contains partial basal core promoter"
               64..>150
               /note="contains complete precore region; nonfunctional
               core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 42
LOCUS      AF528228/c
DEFINITION Hepatitis B virus ASC1072 nonfunctional core antigen precursor,
           gene, partial sequence.
ACCESSION  AF528228
VERSION     AF528228.1 GI:32811006
KEYWORDS   Hepatitis B virus
           Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
ORGANISM   Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
           mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
             source
               1..150
               /organism="Hepatitis B virus"
               /proviral
               /mol_type="genomic DNA"
               /isolate="ASC1072"
               /isolation_source="asymptomatic HBsAg carrier"
               /specific_host="Homo sapiens"
               /db_xref="taxon:10407"
               /country="India"
               <1..>150
               /note="contains partial basal core promoter"
               64..>150
               /note="contains complete precore region; nonfunctional
               core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 43
LOCUS      AF528229/c
DEFINITION Hepatitis B virus ASC1074 nonfunctional core antigen precursor,
           gene, partial sequence.
ACCESSION  AF528229
VERSION     AF528229.1 GI:32811007
KEYWORDS   Hepatitis B virus
           Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
ORGANISM   Hepatitis B virus
REFERENCE   1 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Comparative evaluation of HBV precore and basal core promoter
           mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
             source
               1..150
               /organism="Hepatitis B virus"
               /proviral
               /mol_type="genomic DNA"
               /isolate="ASC1065"
               /isolation_source="asymptomatic HBsAg carrier"
               /specific_host="Homo sapiens"
               /db_xref="taxon:10407"
               /country="India"
               <1..>150
               /note="contains partial basal core promoter"
               64..>150
               /note="contains complete precore region; nonfunctional
               core antigen precursor due to mutation"

misc_feature
misc_feature

```

```

TITLE      Comparative evaluation of HBV precore and basal core promoter
JOURNAL    Unpublished
REFERENCE 2 (bases 1 to 150)
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1074"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 44
AF528231/c
LOCUS
DEFINITION    Hepatitis B virus ASC1091 nonfunctional core antigen precursor,
Gene, partial sequence.
ACCESSION    AF528231
VERSION      AF528231.1 GI:32811009
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1091"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 45
AF528232/c
LOCUS
DEFINITION    Hepatitis B virus ASC265 nonfunctional core antigen precursor,
Gene, partial sequence.
ACCESSION    AF528232
VERSION      AF528232.1 GI:32811010
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC265"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 46
AF528233/c
LOCUS
DEFINITION    Hepatitis B virus ASC262 nonfunctional core antigen precursor,
Gene, partial sequence.
ACCESSION    AF528233
VERSION      AF528233.1 GI:32811011
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC1091"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;

```

```

Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 45
AF528232
LOCUS
DEFINITION    Hepatitis B virus ASC265 nonfunctional core antigen precursor,
Gene, partial sequence.
ACCESSION    AF528232
VERSION      AF528232.1 GI:32811010
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC265"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 46
AF528233/c
LOCUS
DEFINITION    Hepatitis B virus ASC262 nonfunctional core antigen precursor,
Gene, partial sequence.
ACCESSION    AF528233
VERSION      AF528233.1 GI:32811011
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC265"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 46
AF528233/c
LOCUS
DEFINITION    Hepatitis B virus ASC262 nonfunctional core antigen precursor,
Gene, partial sequence.
ACCESSION    AF528233
VERSION      AF528233.1 GI:32811011
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 150)
AUTHORS      Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
            Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   source
            1..150
            /organism="Hepatitis B virus"
            /proviral
            /mol_type="genomic DNA"
            /isolate="ASC265"
            /isolation_source="asymptomatic HBsAg carrier"
            /specific_host="Homo sapiens"
            /db_xref="taxon:10407"
            /country="India"
            <1..>150
            /note="contains partial basal core promoter"
            64..>150
            /note="contains complete precore region; nonfunctional
            core antigen precursor due to mutation"

misc_feature
misc_feature

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;

```

```

TITLE      Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
           source
             1..150
             /organism="Hepatitis B virus"
             /mol_type="genomic DNA"
             /isolate="ASC262"
             /isolation_source="asymptomatic HBsAg carrier"
             /specific_host="Homo sapiens"
             /db_xref="taxon:10407"
             /country="India"
             <1..>150
             /note="contains partial basal core promoter"
             <64..>150
             /note="contains complete precursor region; nonfunctional
             core antigen precursor due to mutation"

misc_feature
           64..>150
           /note="contains complete precursor region; nonfunctional
           core antigen precursor due to mutation"

misc_feature
           64..>150
           /note="contains complete precursor region; nonfunctional
           core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 47
AF528234/c
LOCUS      Hepatitis B virus ASC1109 nonfunctional core antigen precursor,
DEFINITION gene, partial sequence.
ACCESSION  AF528234
VERSION    AF528234.1 GI:32811012
KEYWORDS   "Hepatitis B virus"
ORGANISM   Hepatitis B virus
REFERENCE  1 (bases 1 to 150)
AUTHORS   Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE     Comparative evaluation of HBV precore and basal core promoter
           mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE     Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
           source
             1..150
             /organism="Hepatitis B virus"
             /mol_type="genomic DNA"
             /isolate="ASC1275"
             /isolation_source="asymptomatic HBsAg carrier"
             /specific_host="Homo sapiens"
             /db_xref="taxon:10407"
             /country="India"
             <1..>150
             /note="contains partial basal core promoter"
             <64..>150
             /note="contains complete precursor region"
             /codon_start=1
             /product="core antigen precursor"
             /protein_id="AAP87568.1"
             /db_xref="GI:32811014"
             /translation="MQLPHLCIIISCSPTQASKLCGLGLWG"

misc_feature
           <1..>150
           /note="contains partial basal core promoter"
           <64..>150
           /note="contains complete precursor region"

CDS
           1
           /codon_start=1
           /product="core antigen precursor"
           /protein_id="AAP87568.1"
           /db_xref="GI:32811014"
           /translation="MQLPHLCIIISCSPTQASKLCGLGLWG"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 77

RESULT 49
AF528236/c
LOCUS      Hepatitis B virus ASC1274 nonfunctional core antigen precursor,
DEFINITION gene, partial sequence.
ACCESSION  AF528236
VERSION    AF528236.1 GI:32811015
KEYWORDS   "Hepatitis B virus"
ORGANISM   Hepatitis B virus
REFERENCE  1 (bases 1 to 150)
AUTHORS   Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE     Comparative evaluation of HBV precore and basal core promoter
           mutants in Indian patients with diverse clinical manifestations
JOURNAL    Unpublished
AUTHORS    Gandhe,S.S., Chadha,M.S., Walimbe,A.M. and Arankalle,V.A.
TITLE     Direct Submission
JOURNAL    Submitted (11-JUL-2002) Hepatitis Division, National Institute of
           Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra 411001, India
FEATURES   Location/Qualifiers
           source
             1..150
             /organism="Hepatitis B virus"
             /mol_type="genomic DNA"
             /isolate="ASC1109"
             /isolation_source="asymptomatic HBsAg carrier"
             /specific_host="Homo sapiens"
             /db_xref="taxon:10407"
             /country="India"
             <1..>150
             /note="contains partial basal core promoter"
             <64..>150
             /note="contains complete precursor region; nonfunctional
             core antigen precursor due to mutation"

misc_feature
           <1..>150
           /note="contains partial basal core promoter"
           <64..>150
           /note="contains complete precursor region; nonfunctional
           core antigen precursor due to mutation"

misc_feature
           <1..>150
           /note="contains partial basal core promoter"
           <64..>150
           /note="contains complete precursor region; nonfunctional
           core antigen precursor due to mutation"

ORIGIN
Query Match      100.0%; Score 20; DB 14; Length 150;
Best Local Similarity 85.0%; Pred. No. 15;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20
    |||||:|||||
Db 96 AGAGATGATTAGGCAGAGGT 20
```

Search completed: December 15, 2004, 16:04:29  
Job time : 765 secs

Query Match 100.0%; Score 20; DB 14; Length 150;  
Best Local Similarity / 85.0%; Pred. No. 15;  
Matches 17; Conservative 3; Mismatches 0; Indels 0  
/translation="RQLFHLCLLLSCSPTVQASKLCCTGLWLG"  
ORIGIN

Query Match	100.0%;	Score 20;	DB 14;	Length 150;
Best Local Similarity	/ 85.0%;	Pred. No. 15;		
Matches 17;	Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;





C 95 19 95.0 22 2 AAT73885 Aat73885 Human hep  
 C 96 19 95.0 87 2 AAT05545 Aat05545 Human hep  
 C 97 19 95.0 94 2 AAT73892 Aat73892 Human hep  
 C 98 19 95.0 94 2 AAT73890 Aat73890 Human hep  
 C 99 19 95.0 94 2 AAT73887 Aat73887 Human hep  
 C 100 19 95.0 94 2 AAT73889 Aat73889 Human hep

## ALIGNMENTS

RESULT 1  
 AAT72560  
 ID AAT72560 standard; DNA; 20 BP.  
 XX AC AAT72560;  
 XX DT 03-SEP-1997 (first entry)  
 XX DE Hepatitis B virus RNA antisense oligonucleotide HBV43a.  
 XX KW HBV; HBV infection; inhibition; replication; ss.  
 XX OS Synthetic.  
 XX FH Key Location/Qualifiers  
 FT misc\_feature 1..20  
 FT /tag= a  
 FT /note= "Internucleotide linkages are phosphorothioate"  
 XX PN WO9639502-A1.  
 XX PD 12-DEC-1996.  
 XX PF 04-JUN-1996; 96WO-EP002432.  
 XX PR 06-JUN-1995; 95US-00467397.  
 XX PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 XX PA (HYBR-) HYBRIDON INC.  
 XX PI Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;  
 XX PI Roberts NA, Roberts PC, Slade A;  
 XX DR WPI; 1997-043124/04.  
 XX Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -  
 used in the detection and treatment of HBV infection.  
 PS Claim 1; Page 12; 81pp; English.  
 XX The present sequence represents a synthetic oligonucleotide HBV43a which  
 is complementary to a portion of the hepatitis B virus (HBV) RNA. The  
 antisense oligonucleotide may be used to detect the presence of HBV in a  
 sample. The antisense oligonucleotide, and oligonucleotides containing a  
 sequence which is complementary to at least two non-contiguous regions  
 of an HBV nucleic acid, may be used for inhibiting HBV replication in a  
 cell or for the treatment of HBV infection  
 XX Sequence 20 BP; 7 A; 1 C; 8 G; 4 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 5.8;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ACAGAGUAGUAGGCGAGGCT 20  
 |||||:|||||  
 Db 1 ACAGATGATTAGGCGAGGCT 20  
 RESULT 2  
 AAT72561  
 ID AAT72561 standard; DNA; 20 BP.

XX AAT72561;  
 AC 03-SEP-1997 (first entry)  
 DT Hepatitis B virus RNA antisense oligonucleotide HBV43Ma.  
 DE HBV; HBV infection; inhibition; replication; ss.  
 KW Synthetic.  
 XX FH Key Location/Qualifiers  
 FT misc\_feature 1..20  
 FT /tag= a  
 FT /note= "Internucleotide linkages are phosphorothioate"  
 XX PN WO9639502-A1.  
 XX PD 12-DEC-1996.  
 XX PF 04-JUN-1996; 96WO-EP002432.  
 XX PR 06-JUN-1995; 95US-00467397.  
 XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 XX PA (HYBR-) HYBRIDON INC.  
 XX PI Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;  
 XX PI Roberts NA, Roberts PC, Slade A;  
 XX DR WPI; 1997-043124/04.  
 XX Oligonucleotide(s) complementary to hepatitis B virus (HBV) sequences -  
 used in the detection and treatment of HBV infection.  
 PS Claim 1; Page 12; 81pp; English.

XX The present sequence represents a synthetic oligonucleotide HBV43Ma which  
 CC is complementary to a portion of the hepatitis B virus (HBV) RNA. The  
 CC antisense oligonucleotide may be used to detect the presence of HBV in a  
 CC sample. The antisense oligonucleotide, and oligonucleotides containing a  
 CC sequence which is complementary to at least two non-contiguous regions  
 CC of an HBV nucleic acid, may be used for inhibiting HBV replication in a  
 CC cell or for the treatment of HBV infection  
 XX  
 SQ Sequence 20 BP; 7 A; 1 C; 8 G; 1 T; 3 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 5.8;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 Db 1 AGAGAUGAUUAGGCAGAGGT 20  
 RESULT 3  
 AAA88131  
 ID AAA88131 standard; RNA; 25 BP.  
 XX  
 AC AAA88131;  
 XX  
 DT 15-SEP-2003 (revised)  
 DT 13-DEC-2000 (first entry)  
 XX  
 DE SP6 RNA polymerase promoter sequence SEQ ID NO:3.  
 KW Hepatitis B virus; HBV; detection; probe; promoter; ss.  
 XX  
 OS Enterobacteria phage SP6.  
 XX  
 PN US6100024-A.  
 XX  
 PD 08-AUG-2000.  
 XX  
 PF 08-FEB-1991; 91US-00652888.  
 XX  
 PR 08-FEB-1991; 91US-00652888.  
 XX  
 PA (PROM-) PROMEGA CORP.  
 XX  
 PI Hudson GR, Dimond RL, Schumm JW;  
 XX  
 DR WPI; 2000-542420/49.  
 XX  
 PT Single-stranded DNA probe comprising an anti-target nucleic acid, a (-)-  
 PT promoter segment linked to the anti-target segment and a reporter  
 PT segment, useful for detecting a target nucleic acid, e.g. hepatitis B  
 PT virus, in a sample.  
 XX  
 PS Example 3; Col 19-20; 18pp; English.  
 XX  
 CC The present invention describes a single-stranded DNA probe (I)  
 CC comprising in 3'-5' order, an anti-target nucleic acid segment, a (-)-  
 CC promoter segment functionally linked to the anti-target segment, and a  
 CC nucleic acid reporter segment. The probe is useful for testing a sample  
 CC of a nucleic acid for the presence of a target nucleic acid segment or  
 CC for detecting a target nucleic acid segment in a sample. The probe may  
 CC also be used for the detection of hepatitis B virus (HBV). The present  
 CC sequence represents a bacteriophage SP6 RNA polymerase promoter sequence  
 CC which is used in an example from the present invention. (Updated on 15-  
 CC SEP-2003 to standardise OS field)  
 XX  
 SQ Sequence 25 BP; 10 A; 1 C; 10 G; 0 T; 4 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 3; Length 25;  
 Best Local Similarity 95.0%; Pred. No. 5.9;  
 Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 Db 1 AGAGAUGAUUAGGCAGAGGT 20  
 RESULT 4  
 AAH25416/c  
 ID AAH25416 standard; DNA; 27 BP.  
 XX  
 AC AAH25416;  
 XX  
 DT 22-AUG-2001 (first entry)  
 DE Reverse PCR primer used to amplify a HBV DNA fragment.  
 XX  
 KW Magnetic glass particle; nucleic acid purification; PCR primer; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 27  
 FT /\*tag= a  
 FT /note= "derivatisation with a p-(t-butyl)benzyl-residue"  
 XX  
 PN WO200137291-A1.  
 XX  
 PD 25-MAY-2001.  
 XX  
 PF 17-NOV-2000; 2000WO-EP011459.  
 XX  
 PR 17-NOV-1999; 99EP-00122853.  
 PR 12-MAY-2000; 2000EP-00110165.  
 XX  
 PA (HOFF) ROCHE DIAGNOSTICS GMBH.  
 XX  
 PI Weindel K, Riedling M, Geiger A;  
 XX  
 DR WPI; 2001-381247/40.  
 XX  
 PT Novel composition of magnetic glass particles for purification of DNA or  
 PT RNA in automated processes.  
 XX  
 PS Example 7; Page 99; 105pp; English.  
 XX  
 CC The specification describes a composition of magnetic glass particles,  
 CC which contain at least one magnetic object with a mean diameter between 5  
 CC -500 nm. The composition is useful for the purification of nucleic acids.  
 CC The composition can be used to process large quantities of nucleic acid  
 CC samples, because it does not involve the particles being centrifuged or  
 CC the fluids being drawn through glass fiber filters. PCR primers AAH25415-  
 CC 16 were used to amplify HBV DNA fragments. The amplified fragment can be  
 CC purified using the method of the invention  
 XX  
 SQ Sequence 27 BP; 5 A; 10 C; 2 G; 10 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 4; Length 27;  
 Best Local Similarity 85.0%; Pred. No. 6;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 Db 21 AGAGATGATTAGGCAGAGGT 2  
 RESULT 5  
 AAT72562  
 ID AAT72562 standard; DNA; 30 BP.  
 XX  
 AC AAT72562;  
 XX  
 DT 03-SEP-1997 (first entry)  
 XX  
 DE Hepatitis B virus RNA antisense oligonucleotide HBV88b.



```
FT modified_base 6 /mod_base= um
FT /tag= h
FT /mod_base= gm
FT modified_base 7 /tag= i
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 8 /tag= j
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 9 /tag= k
FT /mod_base= cm
FT modified_base 10 /tag= l
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 11 /tag= m
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 12 /tag= n
FT /mod_base= gm
FT modified_base 13 /tag= o
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 14 /tag= p
FT /mod_base= gm
FT modified_base 15 /tag= q
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 16 /tag= r
FT /mod_base= um
FT modified_base 17 /tag= s
FT /mod_base= gm
FT modified_base 18 /tag= s
FT /mod_base= OTHER
FT /note= "2'-O-methyladenosine"
FT modified_base 19 /tag= u
FT /mod_base= um
FT modified_base 20 /tag= v
FT /mod_base= um
FT XX W09639502-A1.
FT PN
FT XX
FT PD
FT XX
FT PF 04-JUN-1996; 96WO-EP002432.
FT XX
FT PR 06-JUN-1995; 95US-00467397.
FT XX
FT PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.
FT PA (HYBR-) HYBRIDON INC.
FT XX
FT PI Craig CJ, Frank BL, Goodchild J, Jupp R, Kilukie RE, Mills JS;
FT PI Roberts NA, Roberts PC, Slade A;
FT XX
FT DR WPI; 1997-043124/04.
FT XX
FT XX Oligo:nucleotide(s) complementary to hepatitis B virus (HBV) sequences -
FT PT used in the detection and treatment of HBV infection.
FT XX

PS Claim 1; Page 12; 81pp; English.
XX
CC The present sequence represents a synthetic oligonucleotide HBV88Mb which
CC is complementary to a portion of the hepatitis B virus (HBV) RNA. The
CC antisense oligonucleotide may be used to detect the presence of HBV in a
CC sample. The antisense oligonucleotide, and oligonucleotides containing a
CC sequence which is complementary to at least two non-contiguous regions
CC of an HBV nucleic acid, may be used for inhibiting HBV replication in a
CC cell or for the treatment of HBV infection
XX
SQ Sequence 30 BP; 12 A; 3 C; 10 G; 1 T; 4 U; 0 Other;
Query Match 100.0%; Score 20; DB 2; Length 30;
Best Local Similarity 100.0%; Pred. No. 6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGAGAUGAUAUAGGCAGAGGT 20
Db 11 AGAGAUGAUAUAGGCAGAGGT 30
RESULT 8
AAT72615
ID AAT72615 standard; DNA; 30 BP.
XX
AC AAT72615;
XX
DT 04-SEP-1997 (first entry)
XX
DE Hepatitis B virus RNA antisense oligonucleotide HBV-87Mb.
XX
KW HBV; HBV infection; inhibition; replication; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..30 /tag= a
FT /note= "Internucleotide linkages are phosphorothioate"
FT misc_RNA 1..10 /tag= b
FT /note= "2'-OME RNA"
FT modified_base 1 /tag= c
FT /mod_base= OTHER
FT modified_base 2 /note= "2'-O-methyladenosine"
FT /tag= d
FT /mod_base= gm
FT modified_base 3 /tag= e
FT /mod_base= OTHER
FT modified_base 4 /note= "2'-O-methyladenosine"
FT /tag= f
FT /mod_base= gm
FT modified_base 5 /tag= g
FT /mod_base= OTHER
FT modified_base 6 /note= "2'-O-methyladenosine"
FT /tag= h
FT /mod_base= um
FT modified_base 7 /tag= i
FT /mod_base= gm
FT modified_base 8 /tag= j
FT /mod_base= OTHER
FT modified_base 9 /note= "2'-O-methyladenosine"
FT /tag= k
FT /mod_base= um
FT
```

modified\_base 10  
 /\*tag= 1  
 /mod\_base= um  
 WO9639502-A1.  
 12-DEC-1996.  
 04-JUN-1996; 96WO-EP002432.  
 06-JUN-1995; 95US-00467397.  
 (HOFF) HOFFMANN LA ROCHE & CO AG F.  
 (HYBR-) HYBRIDON INC.  
 Craig CJ, Frank BL, Goodchild J, Jupp R, Kilkuskie RE, Mills JS;  
 Roberts NA, Roberts PC, Slade A;  
 WPI; 1997-043124/04.  
 Oligonucleotide(s) complementary to hepatitis B virus (HBV) sequences -  
 used in the detection and treatment of HBV infection.  
 Claim 5; Page 15; 81pp; English.  
 The present sequence represents a synthetic oligonucleotide HBV-87Mb  
 which contains a sequence which is complementary to at least two non-  
 contiguous regions of a hepatitis B virus (HBV) nucleic acid. The  
 antisense oligonucleotide may be used to detect the presence of HBV in a  
 sample. The antisense oligonucleotide, and oligonucleotides complementary  
 to a portion of the HBV RNA, may be used for inhibiting HBV replication  
 in a cell or for the treatment of HBV infection  
 Sequence 30 BP; 10 A; 2 C; 12 G; 3 T; 3 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 6;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 DB 1 AGAGAUGAUUAGGCAGAGGT 20  
 RESULT 9  
 ADC64742/c  
 ID ADC64742 standard; RNA; 39 BP.  
 AC ADC64742;  
 DT 18-DEC-2003 (first entry)  
 DE Hepatitis B virus DNA polymerase related RNA oligonucleotide.  
 KW screening; antiviral; hepatitis B virus; HBV; DNA polymerase; ss.  
 XX Synthetic.  
 OS Hepatitis B virus.  
 XX KR2002007891-A.  
 XX 29-JAN-2002.  
 XX 19-JUL-2000; 2000KR-00041420.  
 XX 19-JUL-2000; 2000KR-00041420.  
 XX (MOGA-) MOGAM BIOTECHNOLOGY INST.  
 PA (VIRO-) VIROGEN CO LTD.  
 XX Ji HJ, Jung SI, Kim YC, Min MG, Ryu WS, Yoon GS;  
 WPI; 2003-309015/30.

XX Screening of antiviral agents by protein-priming activity of hepatitis B  
 PT virus DNA polymerase.  
 XX Disclosure; Page 12; 13pp; Korean.  
 XX The present invention describes a method of screening for an antiviral  
 CC agent by the protein-priming activity of hepatitis B virus (HBV) DNA  
 CC polymerase. Also described is developing an antiviral agent with a high  
 CC selectivity to HBV which can be used for high-throughput screening. The  
 CC present sequence represents an RNA oligonucleotide which is used in the  
 CC exemplification of the present invention.  
 XX Sequence 39 BP; 5 A; 13 C; 3 G; 0 T; 18 U; 0 Other;  
 SQ Query Match 100.0%; Score 20; DB 10; Length 39;  
 Best Local Similarity 85.0%; Pred. No. 6.2;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 DB 27 AGAGAUGAUUAGGCAGAGGT 8  
 RESULT 10  
 AAA88130/c  
 ID AAA88130 standard; DNA; 64 BP.  
 XX AC AAA88130;  
 XX 15-SEP-2003 (revised)  
 DT 13-DEC-2000 (first entry)  
 DE SP6 RNA polymerase promoter sequence SEQ ID NO:2.  
 XX Hepatitis B virus; HBV; detection; probe; promoter; ds.  
 KW Enterobacteria phage SP6.  
 OS US6100024-A.  
 PN 08-AUG-2000.  
 PD 08-FEB-1991; 91US-00652888.  
 PF 08-FEB-1991; 91US-00652888.  
 PR (PROM-) PROMEGA CORP.  
 XX Hudson GR, Dimond RL, Schumm JW;  
 PI WPI; 2000-542420/49.  
 DR Single-stranded DNA probe comprising an anti-target nucleic acid, a (-)-  
 PT promoter segment linked to the anti-target segment and a reporter  
 PT segment, useful for detecting a target nucleic acid, e.g. hepatitis B  
 PT virus, in a sample.  
 XX Example 3; Col 19-20; 18pp; English.  
 PS The present invention describes a single-stranded DNA probe (I)  
 CC comprising in 3'-5' order, an anti-target nucleic acid segment, a (-)-  
 CC promoter segment functionally linked to the anti-target segment, and a  
 CC nucleic acid reporter segment. The probe is useful for testing a sample  
 CC of a nucleic acid for the presence of a target nucleic acid segment or  
 CC for detecting a target nucleic acid segment in a sample. The probe may  
 CC also be used for the detection of hepatitis B virus (HBV). The present  
 CC sequence represents a bacteriophage SP6 RNA polymerase promoter sequence  
 CC which is used in an example from the present invention. (Updated on 15-  
 CC SEP-2003 to standardise OS field)  
 XX Sequence 64 BP; 14 A; 22 C; 4 G; 24 T; 0 U; 0 Other;



ABK29867;  
23-APR-2002 (first entry)  
Wild type hepatitis B virus core promoter.  
Cyclin D1 promoter; CD40L promoter; hepatitis B virus promoter;  
HBV promoter; vancomycin-resistant enterococci promoter; VRE promoter;  
vanH promoter; androgen receptor promoter; AR promoter;  
human epidermal growth factor receptor 2 promoter; Her2 promoter;  
beta lactamase promoter; B1a promoter; transgene; cancer; breast cancer;  
colon cancer; immunological disorder; prostate cancer; cytostatic;  
autoimmune disease; HBV pre-S promoter; HBV-X promoter;  
Enterococcus infection; immunosuppressive; antibacterial; antiviral;  
gene expression modulator; multiple sclerosis; MS;  
chronic hepatic insufficiency; cirrhosis; hepatocellular carcinoma;  
systematic lupus erythematosus; SLE; graft-vs-host disease; GVHD;  
familial adenomatous polyposis; rheumatoid arthritis; PCR; primer;  
transgenic; ds.  
Hepatitis B virus.  
Key Location/Qualifiers  
misc\_binding 61..72  
/\*tag= a  
/bound moiety= "HNF4"  
/note= "Hepatocyte nuclear factor 4"  
misc\_binding 80..90  
/\*tag= b  
/bound moiety= "HNF3-1"  
/note= "Hepatocyte nuclear factor 3-1"  
misc\_binding 115..126  
/\*tag= c  
/bound moiety= "HNF3-2"  
/note= "Hepatocyte nuclear factor 3-2"  
WO200194600-A2.  
13-DEC-2001.  
06-JUN-2001; 2001WO-US018343.  
06-JUN-2000; 2000US-0209549P.  
(GENE-) GENELABS TECHNOLOGIES INC.  
Kim JP, Starr DB, Tam AW, Lurance ME, Michelotti EF;  
Velligan MD, Latour DR, Thomas RL, Kongpachith A, Sheppard LT;  
Lim MY, Bruice TW;  
WPI; 2002-130595/17.  
New nucleic acid regulatory sequences, which are able to regulate  
expression of a gene operably linked to a promoter, useful for regulating  
the expression of transgenes and for treating e.g., cancer and  
immunological diseases.  
Disclosure; Fig 1A, 95pp; English.  
The invention describes an isolated nucleic acid regulatory sequence for  
a cyclin D1 promoter, a CD40L promoter, vancomycin-resistant enterococci  
(VRE) promoter, an HBV promoter, androgen receptor (AR) promoter, Human  
epidermal growth factor receptor 2 (HER2) promoter, or a beta lactamase  
(Bla) promoter. Transcription regulatory sequences may be used to  
regulate expression of the endogenous, autologous or heterologous genes  
operably linked to the promoter, and may be incorporated into  
heterologous nucleic acid constructs for use in regulated expression of  
transgenes. Regulated expression of cyclin D1 can be used in cancer  
therapies, such as breast, colon or pancreatic cancers and familial  
adenomatous polyposis. Regulation of the activity of CD40L gene promoter  
may be used in the treatment of immunological disorders, such as  
autoimmune diseases e.g. multiple sclerosis (MS), systematic lupus  
erythematosus (SLE), graft-vs-host disease (GVHD) and rheumatoid

CC arthritis. Regulated expression of genes under the control of the HBV  
CC (hepatitis B)-specific core, pre-S and X promoters can be used in the  
CC therapy of HBV disease, chronic hepatic insufficiency, cirrhosis,  
CC hepatocellular carcinoma, and in the regulated expression of liver cell-  
CC specific genes. Regulated expression of the vanH gene promoter can be  
CC used in treatment of Enterococcus infection, while regulated expression  
CC of the androgen receptor gene can be used in the treatment of prostate  
CC cancer. This sequence represents the hepatitis B virus core promoter the  
CC regulatory regions of which are described in the method of the invention  
XX  
SQ Sequence 250 BP; 66 A; 59 C; 62 G; 63 T; 0 U; 0 Other;  
Query Match 100.0%; Score 20; DB 6; Length 250;  
Best Local Similarity 85.0%; Pred. No. 7.6;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGAGAUGAUUAGGCAGAGGT 20  
Db 248 AGAGATGATTAGGCAGAGGT 229  
RESULT 14  
AAD27422/c  
ID AAD27422 standard; DNA; 639 BP.  
XX  
AC AAD27422;  
XX  
DT 18-APR-2002 (first entry)  
XX  
DE Hepatitis B virus (HBV) core antigen (HBcAg) encoding DNA #1.  
XX  
KW Hepatitis B virus; HBV; core antigen; HBcAg; immune system; typhoid;  
KW prophylactic; gene therapy; vaccine; hepatitis A virus; HAV; herpes;  
KW hepatitis C virus; HCV; influenza; foot-and-mouth disease; diarrhoea;  
KW tuberculosis; polio; rabies; acquired immunodeficiency syndrome; AIDS;  
KW dengue fever; yellow fever; malaria; whooping cough; salmonellosis;  
KW food poisoning; meningitis; gonorrhea; antiviral; antibacterial;  
KW antiprotozoal; ds.  
XX  
OS Hepatitis B virus.  
XX  
FH Key Location/Qualifiers  
FT CDS 1..639  
FT /\*tag= a  
FT /product= "HBcAg"  
XX  
XX WO200198333-A2.  
XX  
XX 27-DEC-2001.  
XX  
XX 22-JUN-2001; 2001WO-GB002817.  
XX  
XX 22-JUN-2000; 2000GB-00015308.  
XX 06-OCT-2000; 2000GB-00024544.  
XX  
XX (CELL-) CELLTech PHARM LTD.  
XX  
XX Page M, Li J, Pumpens P;  
XX  
XX WPI; 2002-098223/13.  
XX P-PSDB; AAE17018.  
XX  
XX New proteins comprising a modified hepatitis B core antigen, useful as a  
XX vaccine in prophylactic or therapeutic vaccination of the human or animal  
XX body, particularly against hepatitis B virus infection.  
XX  
XX Disclosure; Page 38-39; 40pp; English.  
XX  
XX The invention relates to modified proteins comprising hepatitis B virus  
XX (HBV) core antigen (HBcAg) wherein one or more of the four arginine  
XX repeats has been deleted and the protein comprising the C-terminal  
XX cysteine of HBcAg. The deleted region may be replaced by an epitope from  
XX a protein other than HBcAg, in which case the HBcAg acts as a carrier to



CC present the epitope to the immune system. This chimeric protein or its  
 CC nucleic acid is useful as a vaccine or in a method of prophylactic or  
 CC therapeutic vaccination of the human or animal body, particularly against  
 CC HBV. The nucleic acid encoding the protein may be used in gene therapy or  
 CC DNA vaccination protocols. The chimeric protein or its nucleic acid may  
 CC also be used as the basis of a prophylactic vaccine against a range of  
 CC diseases, e.g. HBV, hepatitis A virus (HAV), hepatitis C virus (HCV),  
 CC influenza, foot-and-mouth disease, polio, herpes, rabies, acquired  
 CC immunodeficiency syndrome (AIDS), dengue fever, yellow fever, malaria,  
 CC tuberculosis, whooping cough, salmonellosis, typhoid, food poisoning,  
 CC diarrhoea, meningitis or gonorrhoea. The present sequence is a DNA  
 CC encoding Hepatitis B virus core antigen (HBcAg)

XX  
 SQ Sequence 639 BP; 147 A; 161 C; 141 G; 190 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 6; Length 639;  
 Best Local Similarity 85.0%; Pred. No. 8.4;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUGAUUAGGCAGAGGT 20  
 Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 15  
 AAD31509/c  
 ID AAD31509 standard; DNA; 639 BP.  
 AC AAD31509;  
 XX  
 DT 18-JUN-2002 (first entry)  
 DE Hepatitis B virus core antigen (HBcAg) encoding DNA.  
 KW Hepatitis B virus core antigen; HBcAg; prophylactic; viral hepatitis;  
 KW therapeutic; vaccine; acquired immune deficiency syndrome; influenza;  
 KW polio; herpes; rabies; AIDS; foot-and-mouth disease; ds.  
 XX  
 OS Hepatitis B virus.  
 FH Key Location/Qualifiers  
 FT CDS 1..639  
 FT /tag= a  
 FT /product= "Hbc protein"  
 FT sig\_peptide 1..87  
 FT /tag= b  
 FT mat\_peptide 88..636  
 FT /tag= c  
 FT /product= "Mature Hbc protein"

XX WO200177158-A1.  
 PN  
 XX 18-OCT-2001.  
 PD  
 XX  
 PF 09-APR-2001; 2001WO-GB001607.  
 XX  
 XX 07-APR-2000; 2000EP-00107118.  
 XX  
 PA (MEDE-) MEDEVA EURO LTD.  
 XX  
 PI Gehin A, Gilbert R, Stuart D, Rowlands D;  
 XX  
 DR WPI; 2002-239995/29.  
 DR P-PSDB; AAE19793.  
 XX  
 PT Hepatitis B (HB) core antigen fusion proteins, useful as vaccines for the  
 PT prophylactic or therapeutic treatment of humans or animals against e.g.  
 PT HB virus, viral hepatitis, hepatitis C virus, influenza, or foot-and-  
 PT mouth disease.  
 XX  
 XX Disclosure; Page 23-24; 27pp; English.  
 PS  
 XX The present invention relates to hepatitis B virus (HBV) core antigen

CC (HBcAg) fusion proteins and polynucleotides encoding such proteins.  
 CC Sequences of the invention are useful in methods of prophylactic or  
 CC therapeutic vaccination or to manufacture medicaments for prophylactic or  
 CC against viral hepatitis. They are also useful as a prophylactic vaccine  
 CC against e.g. hepatitis C virus, influenza, polio, herpes, rabies,  
 CC acquired immune deficiency syndrome (AIDS) or foot-and-mouth disease. The  
 CC present sequence is a DNA encoding hepatitis B virus core antigen (HBcAg)

XX  
 SQ Sequence 639 BP; 147 A; 161 C; 141 G; 190 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 6; Length 639;  
 Best Local Similarity 85.0%; Pred. No. 8.4;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUGAUUAGGCAGAGGT 20  
 Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 16  
 ADL56756/c  
 ID ADL56756 standard; DNA; 646 BP.  
 AC ADL56756;  
 XX  
 DT 17-JUN-2004 (first entry)  
 DE HBV precore/core DNA.  
 KW ds; precore/core; cancer; genetic disease; arthritis; AIDS.  
 XX  
 OS Hepatitis B virus.  
 PN US2004063652-A1.  
 XX  
 PD 01-APR-2004.  
 XX  
 PF 29-MAR-2001; 2001US-00821662.  
 XX  
 PR 21-MAR-1988; 88US-00170515.  
 PR 18-AUG-1989; 89US-00395932.  
 PR 10-AUG-1990; 90US-00565606.  
 PR 21-SEP-1990; 90US-00586603.  
 PR 29-NOV-1991; 91US-00800328.  
 PR 04-FEB-1992; 92US-00830417.  
 PR 22-OCT-1992; 92US-00965084.  
 PR 17-MAR-1993; 93US-00032385.  
 PR 04-AUG-1993; 93US-00102132.  
 PR 09-AUG-1993; 93US-00104424.  
 PR 15-SEP-1993; 93US-00122791.  
 PR 18-NOV-1993; 93US-00155944.  
 PR 25-NOV-1997; 97US-00978293.  
 XX  
 PA (JOLL/) JOLLY D J.  
 PA (MONT/) MONTISANO D.  
 XX  
 PI Jolly DJ, Montisano D;  
 XX  
 DR WPI; 2004-282522/26.  
 XX  
 PT Introducing nucleic acid molecules to an animal or human, useful for  
 PT treating diseases including cancer, genetic diseases, arthritis or AIDS  
 PT comprises administering a composition comprising two or more gene  
 PT delivery vehicles.  
 XX  
 PS Disclosure; SEQ ID NO 23; 72pp; English.  
 XX  
 CC The invention relates to a method of introducing nucleic acid molecules  
 CC to an animal which comprises administering a composition comprising two  
 CC or more gene delivery vehicles to an animal at the same time and same  
 CC site via a single administration device. The method is useful for  
 CC introducing nucleic acid molecules to an animal, preferably humans for

CC treating diseases including cancer, genetic diseases, arthritis or AIDS.  
 CC The method can also be administered to plants using traditional methods.  
 CC The introduction of multiple or more than one nucleic acid molecule at  
 CC one time provide significant advantages because multiple nucleic acid  
 CC molecules can provide complementary substances or activities to a single  
 CC organ or joint. The difficulty, cost and time to engineer multiple  
 CC nucleic acid molecules is much less than engineering a single molecule.  
 CC With the use of multiple molecules, there is less chance that one  
 CC substance or activity will sterically hinder or otherwise interfere with  
 CC the expression of activity. The use of multiple molecules also permits  
 CC systems subject to differing activating events, thus permitting better  
 CC control of differential expression of the different substances or  
 CC activities. The present sequence represents the HBV precore/core DNA.  
 XX

SQ Sequence 646 BP; 154 A; 170 C; 137 G; 185 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 12; Length 646;  
 Best Local Similarity 85.0%; Pred. No. 8.5;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUAUAGGCGAGGTT 20  
 |||||:|||||  
 Db 43 AGAGATGATTAGGCGAGGTT 24

RESULT 17  
 AAQ47014/c  
 ID AAQ47014 standard; DNA; 655 BP.  
 XX AC AAQ47014;  
 XX  
 DT 27-AUG-2003 (revised)  
 DT 25-MAR-2003 (revised)  
 DT 31-JAN-1994 (first entry)  
 XX  
 DE HBV (adw) corrected precore/core sequence.  
 XX  
 KW Precore; core; coding region; hepatitis B; virus; HBV; plasmid; KSII+;  
 KW KSII+HBpc/c; pAM6; deletion; frameshift; PCR; overlap extension; SK+ Hbe;  
 KW primers; mutation; hepatocellular carcinomas; class-I;  
 KW cytotoxic T-lymphocyte; CTL; hepatitis C; infection; ss.  
 XX

OS Hepatitis B virus.  
 XX  
 FH Key Location/Qualifiers  
 FT mutation 334  
 FT /\*tag= a  
 FT /note= "Nucleotide which is deleted in plasmid pAM6"  
 XX  
 PN WO9315207-A2.  
 XX  
 PD 05-AUG-1993.  
 XX  
 PF 04-FEB-1993; 93WO-US001009.  
 XX  
 PR 04-FEB-1992; 92US-00830417.  
 XX  
 PA (VIAG-) VIAGENE INC.  
 XX

PI Jolly DJ, Chang SMW, Lee WT, Townsend K, Odeja J;  
 DR WPI; 1993-258682/32.  
 XX  
 PT Treatment of hepatitis B and C, and associated carcinoma(s) - using a  
 PT vector construct directing the expression of part of hepatitis B or C  
 PT antigen.  
 XX  
 PS Example 2; Fig 2; 110pp; English.  
 XX

CC This sequence represents the entire precore/core coding region of  
 CC hepatitis B virus (HBV) isolated from the plasmid KSII+HBpc/c. This  
 CC plasmid was created by ligating a 1.8 kb fragment of plasmid pAM6

CC containing the entire precore/core region, into the BamHI site of KSII+.  
 CC The precore/core region of plasmid KSII+HBpc/p which was sequenced and was  
 CC found to contain a single base pair deletion which causes a frameshift at  
 CC codon 79 which results in two consecutive in-frame TAG codons. This  
 CC deletion was corrected by PCR overlap extension in plasmid SK+ Hbe using  
 CC the primer sequences given in AAQ47015-18 in four separate reactions. The  
 CC mutation may also be corrected using the primers given in AAQ47019-23 in  
 CC a separate series of reactions. The isolated HBV precore/core region may  
 CC be used in a method to induce potent class-I restricted protective and  
 CC therapeutic cytotoxic T-lymphocyte (CTL) response, and a humoral response  
 CC for the treatment of hepatitis B and C infections, as well as a humoral response  
 CC hepatocellular carcinomas. (Updated on 25-MAR-2003 to correct PN field.)  
 XX (Updated on 27-AUG-2003 to correct OS field.)

SQ Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 655;  
 Best Local Similarity 85.0%; Pred. No. 8.5;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUAUAGGCGAGGTT 20  
 |||||:|||||  
 Db 43 AGAGATGATTAGGCGAGGTT 24

RESULT 18  
 AAT35649/c  
 ID AAT35649 standard; cDNA; 655 BP.  
 XX AC AAT35649;  
 XX

DT 27-AUG-2003 (revised)  
 DT 25-FEB-1997 (first entry)  
 XX  
 DE Precore/core region of HBV.  
 XX

KW Precore; core region; HBV; hepatitis B virus; gene delivery vehicle; GDV;  
 KW immunogen; HBV antigen; hepatitis C carcinoma cell; HBV infection;  
 KW gene expression; non-tumorigenic tumour associated antigen; therapy;  
 KW altered ras gene; altered p53 gene; altered mucin; ss.  
 XX

OS Hepatitis B virus.  
 XX

FH Key Location/Qualifiers  
 FT misc\_feature 10..97  
 FT /\*tag= a  
 FT /note= "precure region"  
 FT misc\_feature 98..655  
 FT /\*tag= b  
 FT /note= "core region"  
 XX

PN WO9621015-A2.  
 XX

PD 11-JUL-1996.  
 XX

PF 22-DEC-1995; 95WO-US016964.  
 XX

PR 30-DEC-1994; 94US-00368210.  
 XX

PA (CHIR ) CHIRON VIAGENE INC.  
 XX

PI Jolly DJ, Montisano D;  
 XX

DR WPI; 1996-333990/33.  
 XX

PT Introduction of nucleic acid molecules to an animal - comprises  
 PT administration of two or more gene delivery vehicles comprising  
 PT heterologous nucleic acid.  
 XX

PS Disclosure; Page 131; 161pp; English.  
 XX

CC This sequence represents the precore/core region of the hepatitis B virus  
 CC (HBV) genome. This sequence can be included in a gene delivery vehicle

CC (GDV) of the invention, and is used as an immunogenic portion of a HBV  
CC antigen. The GDVs can be used in the method of the invention, for  
CC introducing nucleic acids into an animal, by administration of a  
CC composition comprising two or more GDVs, in combination with a carrier or  
CC diluent. Each GDV contains a nucleic acid molecule not naturally  
CC contained within the GDV, or directs expression of at least one substance  
CC (or biologically active nucleic acid) in host cells containing the GDV.  
CC The two GDVs collectively direct the expression of at least two different  
CC substances, or direct the expression of at least one substance, where the  
CC GDVs differ in one or more biological functions. The GDVs can be used for  
CC destroying hepatitis C carcinoma cells, for treating HBV (when a GDV  
CC contains an immunogenic HBV fragment such as this sequence). The GDVs can  
CC also be used for directing expression of non-tumorigenic, tumour  
CC associated antigens (such as altered ras gene), altered p53 gene, and  
CC altered mucin. (Updated on 27-AUG-2003 to correct OS field.)  
XX  
SQ Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 655;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
|||||:|||||  
DB 43 AGAGATGATTAGGCAGAGGT 24

RESULT 19  
AAH77569/c  
ID AAH77569 standard; DNA; 655 BP.  
AC AAH77569;  
DT 19-OCT-2001 (first entry)  
XX HBV genotype G strain US1 preCore/Core DNA.

XX Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;  
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBCAg;  
KW HBeAg; ds.

XX Hepatitis B virus.

XX WO200140279-A2.

XX 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.

XX 03-DEC-1999; 99EP-00870252.

XX 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

XX Stuyver L, Van Geyt C, De Gendt S;

XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and  
PT polynucleotide sequences that are phylogenetically different from HBV  
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
PT therapy.

XX Claim 3; Fig 7; 94pp; English.

XX The invention relates to the complete nucleic acid sequence of a new  
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
CC This genotype was found with a high prevalence in patients chronically  
CC infected with HBV and residing in Europe and the USA. The invention  
CC relates to a fully defined sequence of 3248 nucleotides as given in  
CC specification, a sequence with 92% identity to the given sequence, or  
CC sequence that is degenerate to the mentioned sequences. These  
CC polynucleotides are useful for HBV genotyping. The proteins encoded by

CC the polynucleotides are useful for detecting antibodies in a biological  
CC sample. Ligands that bind to the proteins and antibodies directed against  
CC the proteins are useful for detecting the proteins and for detecting  
CC HBCAg and HBeAg (precore precursor proteins). They are also useful for  
CC preparing a vaccine or medicament for treating HBV infections. The  
CC present sequence is provided in an alignment of preCore/Core sequences of  
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,  
CC US6, US7, US9, US10) of HBV genotype G  
XX

SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;

Query Match 100.0%; Score 20; DB 4; Length 655;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
|||||:|||||  
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 20  
AAH77568/c  
ID AAH77568 standard; DNA; 655 BP.  
XX AAH77568;  
AC AAH77568;  
DT 19-OCT-2001 (first entry)  
XX HBV genotype G strain FR2 preCore/Core DNA.

XX Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;  
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBCAg;  
KW HBeAg; ds.

XX Hepatitis B virus.

XX WO200140279-A2.

XX 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.

XX 03-DEC-1999; 99EP-00870252.

XX 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

XX Stuyver L, Van Geyt C, De Gendt S;

XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and  
PT polynucleotide sequences that are phylogenetically different from HBV  
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
PT therapy.

XX Claim 3; Fig 7; 94pp; English.

XX The invention relates to the complete nucleic acid sequence of a new  
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
CC This genotype was found with a high prevalence in patients chronically  
CC infected with HBV and residing in Europe and the USA. The invention  
CC relates to a fully defined sequence of 3248 nucleotides as given in  
CC specification, a sequence with 92% identity to the given sequence, or  
CC sequence that is degenerate to the mentioned sequences. These  
CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
CC the polynucleotides are useful for detecting antibodies in a biological  
CC sample. Ligands that bind to the proteins and antibodies directed against  
CC the proteins are useful for detecting the proteins and for detecting  
CC HBCAg and HBeAg (precore precursor proteins). They are also useful for  
CC preparing a vaccine or medicament for treating HBV infections. The  
CC present sequence is provided in an alignment of preCore/Core sequences of  
CC an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,

CC US6, US7, US9, US10) of HBV genotype G

SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;  
Query Match 100.0%; Score 20; DB 4; Length 655;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUGAUUAGGCAGAGGT 20  
|||||:|||||  
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 21  
AAH77574/c  
ID AAH77574 standard; DNA; 655 BP.  
XX  
AC AAH77574;  
XX  
DT 19-OCT-2001 (first entry)  
XX  
DE HBV genotype G strain US10 preCore/Core DNA.  
XX

KW Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;  
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;  
KW HBeAg; ds.

OS Hepatitis B virus.  
XX  
XX WO200140279-A2.  
PN  
XX  
FD 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.  
XX  
XX 03-DEC-1999; 99EP-00870252.  
PR  
XX 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

XX Stuyver L, Van Geyt C, De Gendt S;  
XX  
XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and  
PT polynucleotide sequences that are phylogenetically different from HBV  
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
PT therapy.

XX Claim 3; Fig 7; 94pp; English.

XX The invention relates to the complete nucleic acid sequence of a new  
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
CC This genotype was found with a high prevalence in patients chronically  
CC infected with HBV and residing in Europe and the USA. The invention  
CC relates to a fully defined sequence of 3248 nucleotides as given in  
CC specification, a sequence with 92% identity to the given sequence, or  
CC sequence that is degenerate to the mentioned sequences. These  
CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
CC the polynucleotides are useful for detecting antibodies in a biological  
CC sample. Ligands that bind to the proteins and antibodies directed against  
CC the proteins are useful for detecting the proteins and for detecting  
CC HBcAg and HBeAg (precursor proteins). They are also useful for  
CC preparing a vaccine or medicament for treating HBV infections. The  
CC present sequence is provided in an alignment of preCore/Core sequences of  
CC an HBV genotype A strain (HBVXCRS) and 7 strains (FR1, FR2, US1, US3,  
CC US6, US7, US9, US10) of HBV genotype G

XX Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;  
Query Match 100.0%; Score 20; DB 4; Length 655;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUGAUUAGGCAGAGGT 20  
|||||:|||||  
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 22  
AAH77573/c  
ID AAH77573 standard; DNA; 655 BP.  
XX  
AC AAH77573;  
XX  
DT 19-OCT-2001 (first entry)  
XX  
DE HBV genotype G strain US7 preCore/Core DNA.  
XX

KW Hepatitis B virus; HBV; preCore; Core; pres1; pres2; HBS; HBX; HBPol;  
KW HBSAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;  
KW HBeAg; ds.

OS Hepatitis B virus.  
XX  
XX WO200140279-A2.  
PN  
XX  
PD 07-JUN-2001.

XX 20-NOV-2000; 2000WO-EP011526.  
XX  
XX 03-DEC-1999; 99EP-00870252.  
PR  
XX 07-DEC-1999; 99US-0169287P.

XX (INNO-) INNOGENETICS NV.

XX Stuyver L, Van Geyt C, De Gendt S;  
XX  
XX WPI; 2001-374785/39.

XX Novel isolated and/or purified hepatitis B virus polypeptide and  
PT polynucleotide sequences that are phylogenetically different from HBV  
PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
PT therapy.

XX Claim 3; Fig 7; 94pp; English.

XX The invention relates to the complete nucleic acid sequence of a new  
CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
CC This genotype was found with a high prevalence in patients chronically  
CC infected with HBV and residing in Europe and the USA. The invention  
CC relates to a fully defined sequence of 3248 nucleotides as given in  
CC specification, a sequence with 92% identity to the given sequence, or  
CC sequence that is degenerate to the mentioned sequences. These  
CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
CC the polynucleotides are useful for detecting antibodies in a biological  
CC sample. Ligands that bind to the proteins and antibodies directed against  
CC the proteins are useful for detecting the proteins and for detecting  
CC HBcAg and HBeAg (precursor proteins). They are also useful for  
CC preparing a vaccine or medicament for treating HBV infections. The  
CC present sequence is provided in an alignment of preCore/Core sequences of  
CC an HBV genotype A strain (HBVXCRS) and 7 strains (FR1, FR2, US1, US3,  
CC US6, US7, US9, US10) of HBV genotype G

SQ Sequence 655 BP; 144 A; 156 C; 143 G; 206 T; 0 U; 6 Other;  
Query Match 100.0%; Score 20; DB 4; Length 655;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGAGAUGAUUAGGCAGAGGT 20  
|||||:|||||  
DB 33 AGAGATGATTAGGCAGAGGT 14

RESULT 23



```

XX FH Key Location/Qualifiers
XX FT misc_feature 11..97
XX FT /*tag= a
XX FT /note= "Precore region"
XX FT misc_feature 98..655
XX FT /*tag= b
XX FT /note= "Core region"
XX FT mutation replace(332..334, CC)
XX FT /*tag= c
XX FT mutation replace(338..340, CAA)
XX FT /*tag= d
XX US6297048-B1.
XX PN
XX XX
XX PD 02-OCT-2001.
XX XX
XX PF 07-JUN-1995; 95US-00483511.
XX PR 04-FEB-1992; 92US-00830417.
XX PR 17-MAR-1993; 93US-00032385.
XX PR 04-AUG-1993; 93US-00102132.
XX PR 05-AUG-1994; 94US-00286829.
XX PR 19-JAN-1995; 95US-00374414.
XX PA (CHIR ) CHIRON CORP.
XX PI
XX PJ Jolly DJ, Chang SMW, Lee WTL, Townsend K, O'dea J;
XX XX WPI; 2001-647290/74.
XX DR
XX XX
XX PT New vectors that direct the (co-)expression of one or more immunogenic
XX PT portions of the hepatitis B or C virus antigen(s), useful in gene
XX PT therapy, e.g. for treating or preventing hepatitis B or C infections, or
XX PT hepatocellular carcinomas.
XX PS Example 2; Fig 2; 64pp; English.
XX CC
XX CC The present invention relates to a method for treating hepatitis B or C
XX CC infections. The method involves administering a vector construct that
XX CC directs the expression of at least one immunogenic portion of hepatitis B
XX CC virus (HBV) antigen, containing HBeAg, HbAg, HsAg, S, Pre-S1, Pre-S2;
XX CC open reading frame (ORF) 5, ORF 6, HBV pol or HxAg or co-expression of
XX CC at least one immunogenic portion of a HBV antigen and at least one
XX CC immunogenic portion of a hepatitis C virus (HCV) antigen. The vectors are
XX CC useful in gene therapy, particularly for treating or preventing hepatitis
XX CC B and hepatitis C infections, as well as hepatocellular carcinomas (HCC).
XX CC The present sequence is a PCR primer used for amplifying Hepatitis B
XX CC virus adw strain precore/core mutant DNA
XX SQ Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 4; Length 655;
XX Best Local Similarity 85.0%; Pred. No. 8.5;
XX Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AGAGAUCATUAGGCAGAGGT 20
XX DB 43 AGAGATGATTAGGCAGAGGT 24
XX
XX RESULT 26
XX ID ABX80077/c
XX XX
XX AC ABX80077;
XX XX
XX XX
XX DT 22-APR-2003 (first entry)
XX XX
XX DE Hepatitis B virus precore/core DNA.
XX KW Hepatitis B virus; hepatitis C virus; hepatitis C infection; poliovirus;
XX KW hepatitis B infection; hepatitis C antigen; polyprotein antigen; SV40;

```

```

KW rhinovirus; pox virus; canary pox virus; vaccinia virus; influenza virus;
KW adenovirus; parvovirus; adeno-associated virus; herpes virus; measles;
KW corona virus; HIV; human immunodeficiency virus; Sindbis virus; virucide;
KW hepatotropic; ds; precore/core DNA.
XX Hepatitis B virus.
XX OS
XX XX
XX PN US2002141974-A1.
XX PD 03-OCT-2002.
XX XX
XX PF 24-JUL-2001; 2001US-00912679.
XX PR 04-FEB-1992; 92US-00830417.
XX PR 17-MAR-1993; 93US-00032385.
XX PR 04-AUG-1993; 93US-00102132.
XX PR 05-AUG-1994; 94US-00286829.
XX PR 19-JAN-1995; 95US-00374414.
XX PR 07-JUN-1995; 95US-00483511.
XX XX
XX PA (JOLLY) JOLLY D J.
XX PA (CHAN/) CHANG S M W.
XX PA (LEEM/) LEE W T L.
XX PA (TOWN/) TOWNSEND K.
XX PA (ODEA/) O'DEA J.
XX PI
XX PJ Jolly DJ, Chang SMW, Lee WTL, Townsend K, O'dea J;
XX XX WPI; 2003-174125/17.
XX DR
XX XX
XX PT Treating hepatitis C infections in a warm-blooded animal by administering
XX PT a vector construct, which directs the expression of an immunogenic
XX PT portion of a hepatitis C antigen, and alternatively, with an
XX PT immunomodulatory cofactor.
XX PS Example 2; Fig 2; 70pp; English.
XX CC
XX CC The invention relates to a method for treating hepatitis C infections in
XX CC a warm-blooded animal comprising administering a vector construct which
XX CC directs the expression of at least one immunogenic portion of a hepatitis
XX CC C antigen, where an immune response is generated, and alternatively, in
XX CC combination with an immunomodulatory cofactor. The invention also relates
XX CC to a vector construct which directs the co-expression of at least one
XX CC immunogenic portion of a hepatitis B antigen and at least one immunogenic
XX CC portion of a hepatitis C antigen, an immunogenic portion of the
XX CC polyprotein antigen, or an immunogenic portion of the polyprotein antigen
XX CC and an immunoregulatory cofactor. A recombinant virus carrying the vector
XX CC construct is selected from poliovirus, rhinovirus, pox virus, canary pox
XX CC virus, vaccinia virus, influenza virus, adenovirus, parvovirus, adeno-
XX CC associated virus, herpes virus, SV40, HIV, measles, corona virus or
XX CC Sindbis virus. This sequence represents hepatitis B virus precore/core
XX CC DNA used in the method of the invention
XX SQ Sequence 655 BP; 156 A; 171 C; 140 G; 188 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 20; DB 9; Length 655;
XX Best Local Similarity 85.0%; Pred. No. 8.5;
XX Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AGAGAUCATUAGGCAGAGGT 20
XX DB 43 AGAGATGATTAGGCAGAGGT 24
XX
XX RESULT 27
XX ID ABX96938/c
XX XX
XX AC ABX96938 standard; DNA; 655 BP.
XX XX
XX AC ABX96938;
XX XX
XX DT 15-MAY-2003 (first entry)
XX XX
XX DE Hepatitis B virus (HBV) DNA.

```



Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 Db 46 AGAGATGATTAGGCAGAGGT 27

RESULT 29  
 AAH77572/c  
 ID AAH77572 standard; DNA; 664 BP.  
 XX AC AAH77572;  
 XX DT 19-OCT-2001 (first entry)  
 XX DE HBV genotype G strain US6 preCore/Core DNA.  
 XX KW Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;  
 XX KW HBeAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBeAg;  
 XX KW HBeAg; ds.  
 XX OS Hepatitis B virus.  
 XX PN WO200140279-A2.  
 XX PD 07-JUN-2001.  
 XX PF 20-NOV-2000; 2000WO-EF011526.  
 XX PR 03-DEC-1999; 99EP-00870252.  
 XX PR 07-DEC-1999; 99US-0169287P.  
 XX PA (INNO-) INNOGENETICS NV.  
 XX PI Stuyver L, Van Geyt C, De Gendt S;  
 XX DR WPI; 2001-374785/39.  
 XX PT Novel isolated and/or purified hepatitis B virus polypeptide and  
 PT polynucleotide sequences that are phylogenetically different from HBV  
 PT genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
 PT therapy.  
 XX PS Claim 3; Fig 7; 94pp; English.  
 CC The invention relates to the complete nucleic acid sequence of a new  
 CC human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
 CC This genotype was found with a high prevalence in patients chronically  
 CC infected with HBV and residing in Europe and the USA. The invention  
 CC relates to a fully defined sequence of 3248 nucleotides as given in  
 CC specification, a sequence with 92% identity to the given sequence, or  
 CC sequence that is degenerate to the mentioned sequences. These  
 CC polynucleotides are useful for HBV genotyping. The proteins encoded by  
 CC the polynucleotides are useful for detecting antibodies in a biological  
 CC sample. Ligands that bind to the proteins and antibodies directed against  
 CC the proteins are useful for detecting the proteins and for detecting  
 CC HBeAg and HBeAg (precursor proteins). They are also useful for  
 CC preparing a vaccine or medicament for treating HBV infections. The  
 CC present sequence is provided in an alignment of preCore/Core sequences of  
 CC an HBV genotype A strain (HBVXCP5) and 7 strains (FR1, FR2, US1, US3,  
 CC US6, US7, US9, US10) of HBV genotype G  
 XX SQ Sequence 664 BP; 146 A; 160 C; 144 G; 208 T; 0 U; 6 Other;

Query Match 100.0%; Score 20; DB 4; Length 664;  
 Best Local Similarity 85.0%; Pred. No. 8.5;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 Db 33 AGAGATGATTAGGCAGAGGT 14

RESULT 30  
 ADO07220/c  
 ID ADO07220 standard; DNA; 669 BP.  
 XX AC ADO07220;  
 XX DT 15-JUL-2004 (first entry)  
 XX DE Hepatitis B virus core antigen DNA.  
 XX KW HBeAg; immunomodulator; vaccine; gene; ss.  
 XX OS Hepatitis B virus.  
 XX PH Key Location/Qualifiers  
 FT CDS 10..669  
 FT /\*tag= a  
 FT /product= "HBcAg"  
 FT /partial  
 FT /note= "No start codon"  
 XX PN WO2004035007-A2.  
 XX PD 29-APR-2004.  
 XX PF 17-OCT-2003; 2003WO-US033178.  
 XX PR 17-OCT-2002; 2002US-0419279P.  
 XX PA (ORAG-) ORAGEN CORP.  
 XX PI Michaels F;  
 XX DR WPI; 2004-348329/32.  
 XX DR P-PSDB; ADO07221.  
 XX PT Modulating a systemic immune response to a peptide in a mammal comprises  
 XX transmuscosally administering a macromolecular aggregate of the peptide.  
 XX PS Disclosure; SEQ ID NO 1; 81pp; English.  
 CC The present sequence is the DNA sequence of the hepatitis B virus core  
 CC antigen (HBcAg) gene from HBV serotype ayw. A peptide comprising a HBV  
 CC protein can be used in claimed methods of the invention for modulating an  
 CC immune response in a mammal. A method of inducing a systemic immune  
 CC response to a peptide in a mammal comprises transmuscosally administering  
 CC to the mammal a macromolecular aggregate of the peptide. The  
 CC macromolecular aggregate comprises at least 10 peptide subunits, may have  
 CC a molecular weight of over 1,000 kDa, and is preferably at least 5 nm in  
 CC diameter. It is resistant to digestive degradation, being stabilised in  
 CC aggregate form by chemical treatment and/or by recombinant protein  
 CC engineering of the peptide. The peptide preferably comprises a HBV  
 CC protein selected from HBV surface protein, nucleocapsid protein or  
 CC envelope protein. Transmuscosal administration to a mammal of a  
 CC macromolecular aggregate of a HBV surface protein engenders a systemic  
 CC immune response in the mammal. A method of suppressing an immune response  
 CC in a mammal involves transmuscosally administering a monomolecular peptide  
 CC that is resistant to digestive degradation and which may be stabilised by  
 CC chemical treatment or protein engineering, and which may be derived from  
 CC a HBV protein. A monomolecular peptide is useful for the induction of  
 CC oral tolerance when induction of systemic immunity is undesirable, e.g.  
 CC in cases of chronic infections.

SQ Sequence 669 BP; 155 A; 170 C; 148 G; 196 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 12; Length 669;  
 Best Local Similarity 85.0%; Pred. No. 8.5;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUAUAGGCAGAGGT 20  
 |||||:|||||  
 Db 63 AGAGATGATTAGGCAGAGGT 44



RESULT 31  
AAD09092/c  
ID AAD09092 standard; DNA; 673 BP.  
XX  
AC AAD09092;  
XX  
DT 04-SEP-2001 (first entry)  
XX  
DE Hepatitis B virus FRI strain genotype G PreCore/HBcAg DNA.  
XX  
KW HBV genotype G; preCore; HBp; polymerase; envelope protein; preS1;  
KW preS2; surface antigen; HBsAg; HBx protein; vaccine; liver disease;  
KW hepatitis; liver cancer; HBcAg; core antigen; ds.  
XX  
OS Hepatitis B virus.  
XX  
PH Key Location/Qualifiers  
FT CDS 1..672  
FT /tag= a  
FT /product= "PreCore/HBcAg core protein"  
FT /transl\_except= (pos:4..6, aa:Xaa)  
FT /transl\_except= (pos:82..84, aa:Xaa)  
FT /note= "Xaa corresponds to in-frame stop codon; Does not  
FT include stop codon"  
FT /partial  
FT misc\_feature 1..87  
FT /tag= b  
FT /note= "PreCore protein DNA"  
FT misc\_feature 88..672  
FT /tag= c  
FT /note= "HBcAg core protein DNA"  
FT misc\_feature 94..129  
FT /tag= d  
FT /note= "Core insert peptide DNA"  
XX  
PN WO200138498-A2.  
XX  
XX 31-MAY-2001.  
XX  
XX 21-NOV-2000; 2000WO-US032108.  
XX  
XX 24-NOV-1999; 99US-0167206P.  
XX  
XX (PHAR-) PHARMASSET INC.  
XX PA (INNO-) INNOGENETICS NV.  
XX  
XX Stuyver L, Schinazi R, De Gendt S, Van Geyt C, Zoulim F, Fried M;  
XX Rosseau R;  
XX  
XX WPI; 2001-367676/38.  
XX P-PSDB; AAE04707.  
XX  
XX Novel hepatitis B virus genotype G, nucleic acids encoding virus,  
XX polypeptides encoded by nucleic acids, useful for preparing vaccine to  
XX treat or prevent the hepatitis B virus genotype G infection in a subject.  
XX  
XX Claim 4; Page 56-57; 84pp; English.  
XX  
XX The present invention relates to hepatitis B virus (HBV) strain FRI,  
XX genotype G DNA encoding PreCore/Core protein, HBp, envelope (PreS1,  
XX PreS2 and surface antigen HBsAg) and HBx proteins. HBV genotype G nucleic  
XX acids and polypeptides are useful for diagnosing, prognosing and treating  
XX infections caused by HBV genotype G. They can be used in a vaccine to  
XX treat or prevent HBV genotype G infection. The HBV genotype G derived  
XX nucleic acids and antibodies are useful for detecting HBV genotype G in a  
XX sample or diagnosis of HBV genotype G infection. The presence of HBV  
XX genotype G statistically correlates with the presence of liver damage  
XX and/or liver cancer in the subject. The HBV genotype G core insert  
XX peptide encoding nucleic acid is useful for designing monitoring assays  
XX to study and predict the evolution of anti-HBe and anti-HBc antibodies  
XX and HBsAg (genotype G e antigen) in patients infected with HBV. The  
XX antibodies or antigens of HBV genotype G are useful for identifying a

CC stage of liver disease caused by HBV genotype G. The present sequence is  
CC hepatitis B virus (HBV) strain FRI, genotype G DNA fragment encoding  
CC PreCore/Core antigen (HBcAg) protein  
XX  
SQ Sequence 673 BP; 148 A; 165 C; 146 G; 214 T; 0 U; 0 Other;  
Query Match 100.0%; Score 20; DB 4; Length 673;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGAGAUGAUAGGCGCAGGCT 20  
DB 33 AGAGATGATTAGCGCAGGCT 14  
RESULT 32  
AAH77563/c  
ID AAH77563 standard; DNA; 675 BP.  
XX  
AC AAH77563;  
XX  
DT 19-OCT-2001 (first entry)  
XX  
DE HBV preCore/Core gene.  
XX  
KW Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBs; HBx; HBp;  
KW HBsAg; antiviral; vaccine; genotype G; genotyping; HBcAg; HBsAg; ds.  
XX  
OS Hepatitis B virus.  
XX  
PN WO200140279-A2.  
XX  
PD 07-JUN-2001.  
XX  
XX 20-NOV-2000; 2000WO-EP011526.  
XX  
XX 03-DEC-1999; 99EP-00870252.  
XX PR 07-DEC-1999; 99US-0169287P.  
XX  
XX (INNO-) INNOGENETICS NV.  
XX  
XX Stuyver L, Van Geyt C, De Gendt S;  
XX WPI; 2001-374785/39.  
XX  
XX Novel isolated and/or purified hepatitis B virus polypeptide and  
XX polynucleotide sequences that are phylogenetically different from HBV  
XX genotype A-F molecules, useful for HBV diagnosis, prophylaxis and  
XX therapy.  
XX  
XX Claim 4; Fig 2; 94pp; English.  
XX  
XX The invention relates to the complete nucleic acid sequence of a new  
XX human hepatitis B virus (HBV) genotype, provisionally named genotype G.  
XX This genotype was found with a high prevalence in patient chronically  
XX infected with HBV and residing in Europe and the USA. The invention  
XX relates to a fully defined sequence of 3248 nucleotides as given in  
XX specification, a sequence with 92% identity to the given sequence, or  
XX sequence that is degenerate to the mentioned sequences. These  
XX polynucleotides are useful for HBV genotyping. The proteins encoded by  
XX the polynucleotides are useful for detecting antibodies in a biological  
XX sample. Ligands that bind to the proteins and antibodies directed against  
XX the proteins are useful for detecting the proteins and for detecting  
XX HBcAg and HBsAg (precore precursor proteins). They are also useful for  
XX preparing a vaccine or medicament for treating HBV infections. The  
XX present sequence is the complete coding sequence of the HBV preCore/Core  
XX gene  
SQ Sequence 675 BP; 149 A; 165 C; 147 G; 214 T; 0 U; 0 Other;  
Query Match 100.0%; Score 20; DB 4; Length 675;  
Best Local Similarity 85.0%; Pred. No. 8.5;  
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```

QY      1 AGAGAUGAUUAGGCAGAGGT 20
      |||||:|:|:|:|:|:|:|:|:|
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 33
AAH77566/c
ID      AAH77566 standard; DNA; 681 BP.
XX
AC      AAH77566;
XX
DT      19-OCT-2001 (first entry)
XX
DE      HBV genotype A strain HBVXCPs preCore/Core DNA.
XX
KW      Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;
KW      HBsAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW      HBeAg; ds.
XX
OS      Hepatitis B virus.
XX
FN      WO200140279-A2.
XX
PD      07-JUN-2001.
XX
PF      20-NOV-2000; 2000WO-EP011526.
XX
PR      03-DEC-1999; 99EP-00870252.
PR      07-DEC-1999; 99US-0169287P.
XX
PA      (INNO-) INNOGENETICS NV.
XX
PI      Stuyver L, Van Geyt C, De Gendt S;
XX      WPI; 2001-374785/39.
XX
PT      Novel isolated and/or purified hepatitis B virus polypeptide and
PT      polynucleotide sequences that are phylogenetically different from HBV
PT      genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT      therapy.
XX
PS      Example 2; Fig 7; 94pp; English.
XX
CC      The invention relates to the complete nucleic acid sequence of a new
CC      human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC      This genotype was found with a high prevalence in patients chronically
CC      infected with HBV and residing in Europe and the USA. The invention
CC      relates to a fully defined sequence of 3248 nucleotides as given in
CC      specification, a sequence with 92% identity to the given sequence, or
CC      sequence that is degenerate to the mentioned sequences. These
CC      polynucleotides are useful for HBV genotyping. The proteins encoded by
CC      the polynucleotides are useful for detecting antibodies in a biological
CC      sample. Ligands that bind to the proteins and antibodies directed against
CC      the proteins are useful for detecting the proteins and for detecting
CC      HBcAg and HBeAg (precursor proteins). They are also useful for
CC      preparing a vaccine or medicament for treating HBV infections. The
CC      present sequence is provided in an alignment of preCore/Core sequences of
CC      an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC      US6, US7, US9, US10) of HBV genotype G
XX
SQ      Sequence 681 BP; 151 A; 166 C; 139 G; 189 T; 0 U; 36 Other;

Query Match      100.0%; Score 20; DB 4; Length 681;
Best Local Similarity 85.0%; Pred. No. 8.5;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGAGAUGAUUAGGCAGAGGT 20
      |||||:|:|:|:|:|:|:|:|:|
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 34
AAH77567/c
ID      AAH77567 standard; DNA; 681 BP.
XX
AC      AAH77567;
XX
DT      19-OCT-2001 (first entry)
XX
DE      HBV genotype G strain FR1 preCore/Core DNA.
XX
KW      Hepatitis B virus; HBV; preCore; Core; preS1; preS2; HBS; HBX; HBPol;
KW      HBsAg; antiviral; vaccine; genotype G; genotype A; genotyping; HBcAg;
KW      HBeAg; ds.
XX
OS      Hepatitis B virus.
XX
FN      WO200140279-A2.
XX
PD      07-JUN-2001.
XX
PF      20-NOV-2000; 2000WO-EP011526.
XX
PR      03-DEC-1999; 99EP-00870252.
PR      07-DEC-1999; 99US-0169287P.
XX
PA      (INNO-) INNOGENETICS NV.
XX
PI      Stuyver L, Van Geyt C, De Gendt S;
XX      WPI; 2001-374785/39.
XX
PT      Novel isolated and/or purified hepatitis B virus polypeptide and
PT      polynucleotide sequences that are phylogenetically different from HBV
PT      genotype A-F molecules, useful for HBV diagnosis, prophylaxis and
PT      therapy.
XX
PS      Claim 3; Fig 7; 94pp; English.
XX
CC      The invention relates to the complete nucleic acid sequence of a new
CC      human hepatitis B virus (HBV) genotype, provisionally named genotype G.
CC      This genotype was found with a high prevalence in patients chronically
CC      infected with HBV and residing in Europe and the USA. The invention
CC      relates to a fully defined sequence of 3248 nucleotides as given in
CC      specification, a sequence with 92% identity to the given sequence, or
CC      sequence that is degenerate to the mentioned sequences. These
CC      polynucleotides are useful for HBV genotyping. The proteins encoded by
CC      the polynucleotides are useful for detecting antibodies in a biological
CC      sample. Ligands that bind to the proteins and antibodies directed against
CC      the proteins are useful for detecting the proteins and for detecting
CC      HBcAg and HBeAg (precursor proteins). They are also useful for
CC      preparing a vaccine or medicament for treating HBV infections. The
CC      present sequence is provided in an alignment of preCore/Core sequences of
CC      an HBV genotype A strain (HBVXCPs) and 7 strains (FR1, FR2, US1, US3,
CC      US6, US7, US9, US10) of HBV genotype G
XX
SQ      Sequence 681 BP; 149 A; 165 C; 147 G; 214 T; 0 U; 6 Other;

Query Match      100.0%; Score 20; DB 4; Length 681;
Best Local Similarity 85.0%; Pred. No. 8.5;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGAGAUGAUUAGGCAGAGGT 20
      |||||:|:~|:|:|:|:|:|:|
Db      33 AGAGATGATTAGGCAGAGGT 14

RESULT 35
AAH80943/c
ID      AAH80943 standard; DNA; 750 BP.
XX
AC      AAH80943;
XX
DT      25-MAR-2003 (revised)
DT      19-NOV-1990 (first entry)

```



XX WPI; 1999-009329/01.  
 XX New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1334 BP; 288 A; 363 C; 311 G; 372 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1334;  
 Best Local Similarity 85.0%; Pred. No. 9.2;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 |||||:|||||  
 Db 735 AGAGATGATTAGGCAGAGGT 716  
 RESULT 38  
 AAV82688/c  
 ID AAV82688 standard; DNA; 1395 BP.  
 XX AAV82688;  
 AC AAV82688;  
 DT 16-FEB-1999 (first entry)  
 XX Fulminant hepatitis B virus genotype D variant FHBV5 sequence.  
 DE Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX Hepatitis B virus.  
 OS Hepatitis B virus.  
 PN WO9845421-A2.  
 XX 15-OCT-1998.  
 PD 08-APR-1998; 98WO-EP002048.  
 PP 09-APR-1997; 97GB-00007221.  
 PR (UNIU ) UNIV GLASGOW.  
 XX Carman B;  
 PN WO9845421-A2.  
 XX 15-OCT-1998.  
 PD 08-APR-1998; 98WO-EP002048.  
 PP 09-APR-1997; 97GB-00007221.  
 PR (UNIU ) UNIV GLASGOW.  
 XX Carman B;  
 PI WPI; 1999-009329/01.  
 XX New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.

CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1395 BP; 277 A; 387 C; 331 G; 398 T; 0 U; 2 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1395;  
 Best Local Similarity 85.0%; Pred. No. 9.2;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUUAGGCAGAGGT 20  
 |||||:|||||  
 Db 846 AGAGATGATTAGGCAGAGGT 827  
 RESULT 39  
 AAV82687/c  
 ID AAV82687 standard; DNA; 1400 BP.  
 XX AAV82687;  
 AC AAV82687;  
 DT 16-FEB-1999 (first entry)  
 XX Fulminant hepatitis B virus genotype D variant FHBV4 sequence.  
 DE Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX Hepatitis B virus.  
 OS Hepatitis B virus.  
 PN WO9845421-A2.  
 XX 15-OCT-1998.  
 PD 08-APR-1998; 98WO-EP002048.  
 PP 09-APR-1997; 97GB-00007221.  
 PR (UNIU ) UNIV GLASGOW.  
 XX Carman B;  
 PI WPI; 1999-009329/01.  
 XX New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified

CC mutations are associated with fulminant infections, probably because they  
XX reduce the ability to bind inhibitory proteins in the host cell

SQ Sequence 1400 BP; 287 A; 388 C; 332 G; 393 T; 0 U; 0 Other;

Query Match 100.0%; Score 20; DB 2; Length 1400;

Best Local Similarity 85.0%; Pred. No. 9.2;

Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20

|||||:|:|:|:|:|:|

Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 40

AAV82692/c

ID AAV82692 standard; DNA; 1445 BP.

XX

AC AAV82692;

XX

DT 16-FEB-1999 (first entry)

XX

DE Fulminant hepatitis B virus genotype D variant FHBV13 sequence.

XX

KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;

XX HBV-related disease; ss.

XX

OS Hepatitis B virus.

XX

PN WO9845421-A2.

XX

PD 15-OCT-1998.

XX

PF 08-APR-1998; 98WO-EP002048.

XX

PR 09-APR-1997; 97GB-00007221.

XX

PA (UNITU ) UNIV GLASGOW.

XX

PI Carman B;

XX

DR WPI; 1999-009329/01.

XX

PT New hepatitis B virus nucleic acid with combination of specific mutations

XX - useful for, e.g. detection of binding interactions between host or

XX viral proteins and HBV nucleic.

XX

PS Disclosure; Fig 5; 85pp; English.

XX

CC The present sequence represents part of the genome of a fulminant

XX Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.

CC The specification describes Hepatitis B virus (HBV) nucleic acid that has

XX a mutation (i.e. alteration from the normal nucleotide in any of the

XX genotypes A to F) in at least two of the enhancer I region, the negative

XX regulatory element region, the enhancer II/ core upstream regulatory

XX sequence/ basal core promoter region, or a mutation which leads to an X-

XX peptide amino acid change to Cys or Met. The HBV variants of the

XX invention are used to detect binding interactions between host or viral

XX proteins and HBV nucleic acid. Probes that hybridise to any of the

XX specified mutated regions are used to detect HBV-related disease,

XX especially fulminant infection, but also severe chronic infection or

XX serologically unusual forms of disease. Combinations of the specified

XX mutations are associated with fulminant infections, probably because they

XX reduce the ability to bind inhibitory proteins in the host cell

XX

SQ Sequence 1445 BP; 297 A; 406 C; 338 G; 404 T; 0 U; 0 Other;

Query Match

Best Local Similarity 100.0%; Score 20; DB 2; Length 1445;

Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20

|||||:|:|:|:|:|:|

Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 41

AAV82685/c

ID AAV82685 standard; DNA; 1445 BP.

XX

AC AAV82685;

XX

DT 16-FEB-1999 (first entry)

XX

DE Fulminant hepatitis B virus genotype D variant FHBV2 sequence.

XX

KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;

XX HBV-related disease; ss.

XX

OS Hepatitis B virus.

XX

PN WO9845421-A2.

XX

PD 15-OCT-1998.

XX

PF 08-APR-1998; 98WO-EP002048.

XX

PR 09-APR-1997; 97GB-00007221.

XX

PA (UNITU ) UNIV GLASGOW.

XX

PI Carman B;

XX

DR WPI; 1999-009329/01.

XX

PT New hepatitis B virus nucleic acid with combination of specific mutations  
XX - useful for, e.g. detection of binding interactions between host or  
XX viral proteins and HBV nucleic.

XX

PS Disclosure; Fig 5; 85pp; English.

XX

CC The present sequence represents part of the genome of a fulminant

XX Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.

CC The specification describes Hepatitis B virus (HBV) nucleic acid that has

XX a mutation (i.e. alteration from the normal nucleotide in any of the

XX genotypes A to F) in at least two of the enhancer I region, the negative

XX regulatory element region, the enhancer II/ core upstream regulatory

XX sequence/ basal core promoter region, or a mutation which leads to an X-

XX peptide amino acid change to Cys or Met. The HBV variants of the

XX invention are used to detect binding interactions between host or viral

XX proteins and HBV nucleic acid. Probes that hybridise to any of the

XX specified mutated regions are used to detect HBV-related disease,

XX especially fulminant infection, but also severe chronic infection or

XX serologically unusual forms of disease. Combinations of the specified

XX mutations are associated with fulminant infections, probably because they

XX reduce the ability to bind inhibitory proteins in the host cell

XX

SQ Sequence 1445 BP; 298 A; 393 C; 340 G; 414 T; 0 U; 0 Other;

Query Match

Best Local Similarity 100.0%; Score 20; DB 2; Length 1445;

Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGGCAGAGGT 20

|||||:|:|:|:|:|:|

Db 846 AGAGATGATTAGGCAGAGGT 827

RESULT 42

AAV82690/c

ID AAV82690 standard; DNA; 1445 BP.

XX

AC AAV82690;

XX

DT 16-FEB-1999 (first entry)

XX

DE Fulminant hepatitis B virus genotype D variant FHBV7 sequence.  
 XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX Hepatitis B virus.  
 OS WO9845421-A2.  
 XX 15-OCT-1998.  
 XX 08-APR-1998; 98WO-EP002048.  
 XX 09-APR-1997; 97GB-00007221.  
 XX (UNIU ) UNIV GLASGOW.  
 XX Carman B;  
 XX WPI; 1999-009329/01.  
 XX New hepatitis B virus nucleic acid with combination of specific mutations  
 - useful for, e.g. detection of binding interactions between host or  
 viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX SQ Sequence 1445 BP; 293 A; 402 C; 340 G; 410 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1445;  
 Best Local Similarity 85.0%; Pred. No. 9.2;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 AGAGAUGAUUAGGCAGAGGT 20  
 DB 846 AGAGATGATTAGGCAGAGGT 827  
 RESULT 43  
 AAV82684/c  
 ID AAV82684 standard; DNA; 1445 BP.  
 XX AAV82684;  
 XX 16-FEB-1999 (first entry)  
 XX Fulminant hepatitis B virus genotype D variant FHBV1 sequence.  
 XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX Hepatitis B virus.  
 OS WO9845421-A2.  
 XX 15-OCT-1998.

PF 08-APR-1998; 98WO-EP002048.  
 XX 09-APR-1997; 97GB-00007221.  
 XX (UNIU ) UNIV GLASGOW.  
 XX Carman B;  
 XX WPI; 1999-009329/01.  
 XX New hepatitis B virus nucleic acid with combination of specific mutations  
 - useful for, e.g. detection of binding interactions between host or  
 viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX SQ Sequence 1445 BP; 298 A; 400 C; 336 G; 411 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1445;  
 Best Local Similarity 85.0%; Pred. No. 9.2;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 AGAGAUGAUUAGGCAGAGGT 20  
 DB 846 AGAGATGATTAGGCAGAGGT 827  
 RESULT 44  
 AAV82695/c  
 ID AAV82695 standard; DNA; 1500 BP.  
 XX AAV82695;  
 XX 16-FEB-1999 (first entry)  
 XX Fulminant hepatitis B virus genotype D variant CHBV2 sequence.  
 XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX Hepatitis B virus.  
 OS WO9845421-A2.  
 XX 15-OCT-1998.  
 XX 08-APR-1998; 98WO-EP002048.  
 XX 09-APR-1997; 97GB-00007221.  
 XX (UNIU ) UNIV GLASGOW.  
 XX Carman B;  
 XX WPI; 1999-009329/01.  
 XX New hepatitis B virus nucleic acid with combination of specific mutations

PT - useful for, e.g. detection of binding interactions between host or  
 XX viral proteins and HBV nucleic.  
 PS Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1500 BP; 308 A; 412 C; 347 G; 433 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 85.0%; Pred. No. 9.3;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUAGGCAGAGGT 20  
 DB 846 AGAGATGATTAGGCAGAGGT 827  
 |||||:|||||  
 RESULT 45  
 AAV82683/C  
 ID AAV82683 standard; DNA; 1500 BP.  
 XX  
 AC AAV82683;  
 XX  
 DT 16-FEB-1999 (first entry)  
 XX  
 DE Fulminant hepatitis B virus genotype D variant AHBV1 sequence.  
 XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO9845421-A2.  
 XX  
 PD 15-OCT-1998.  
 XX  
 DE Fulminant hepatitis B virus genotype D variant AHBV1 sequence.  
 XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO9845421-A2.  
 XX  
 PD 15-OCT-1998.  
 XX  
 PF 08-APR-1998; 98WO-EP002048.  
 XX  
 PR 09-APR-1997; 97GB-00007221.  
 XX  
 PA (UNITU ) UNIV GLASGOW.  
 XX  
 PI Carman B;  
 XX  
 DR WO9845421-A2.  
 XX  
 PD 15-OCT-1998.  
 XX  
 PF 08-APR-1998; 98WO-EP002048.  
 XX  
 PR 09-APR-1997; 97GB-00007221.  
 XX  
 PA (UNITU ) UNIV GLASGOW.  
 XX  
 PI Carman B;  
 XX  
 DR WPI; 1999-009329/01.  
 XX  
 PT New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX

CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1500 BP; 305 A; 411 C; 354 G; 430 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 20; DB 2; Length 1500;  
 Best Local Similarity 85.0%; Pred. No. 9.3;  
 Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AGAGAUGAUAGGCAGAGGT 20  
 DB 846 AGAGATGATTAGGCAGAGGT 827  
 |||||:|||||  
 RESULT 46  
 AAV82694/C  
 ID AAV82694 standard; DNA; 1500 BP.  
 XX  
 AC AAV82694;  
 XX  
 DT 16-FEB-1999 (first entry)  
 XX  
 DE Fulminant hepatitis B virus genotype D variant HBVP2CSX sequence.  
 XX  
 KW Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;  
 KW HBV-related disease; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO9845421-A2.  
 XX  
 PD 15-OCT-1998.  
 XX  
 PF 08-APR-1998; 98WO-EP002048.  
 XX  
 PR 09-APR-1997; 97GB-00007221.  
 XX  
 PA (UNITU ) UNIV GLASGOW.  
 XX  
 PI Carman B;  
 XX  
 DR WPI; 1999-009329/01.  
 XX  
 PT New hepatitis B virus nucleic acid with combination of specific mutations  
 PT - useful for, e.g. detection of binding interactions between host or  
 PT viral proteins and HBV nucleic.  
 XX Disclosure; Fig 5; 85pp; English.  
 XX The present sequence represents part of the genome of a fulminant  
 CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.  
 CC The specification describes Hepatitis B virus (HBV) nucleic acid that has  
 CC a mutation (i.e. alteration from the normal nucleotide in any of the  
 CC genotypes A to F) in at least two of the enhancer I region, the negative  
 CC regulatory element region, the enhancer II/ core upstream regulatory  
 CC sequence/ basal core promoter region, or a mutation which leads to an X-  
 CC peptide amino acid change to Cys or Met. The HBV variants of the  
 CC invention are used to detect binding interactions between host or viral  
 CC proteins and HBV nucleic acid. Probes that hybridise to any of the  
 CC specified mutated regions are used to detect HBV-related disease,  
 CC especially fulminant infection, but also severe chronic infection or  
 CC serologically unusual forms of disease. Combinations of the specified  
 CC mutations are associated with fulminant infections, probably because they  
 CC reduce the ability to bind inhibitory proteins in the host cell  
 XX  
 SQ Sequence 1500 BP; 305 A; 408 C; 349 G; 438 T; 0 U; 0 Other;





```
KW HBV-related disease; ss.
XX
OS Hepatitis B virus.
XX
PN W09845421-A2.
XX
PD 15-OCT-1998.
XX
XX 08-APR-1998; 98WO-EF002048.
XX
XX 09-APR-1997; 97GB-00007221.
XX
PA (UNITU ) UNIV GLASGOW.
XX
XX Carman B;
XX
XX WPI; 1999-009329/01.
XX
XX New hepatitis B virus nucleic acid with combination of specific mutations
PT - useful for, e.g. detection of binding interactions between host or
PT viral proteins and HBV nucleic.
XX
XX Disclosure; Fig 5; 85pp; English.
XX
XX The present sequence represents part of the genome of a fulminant
CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.
CC The specification describes Hepatitis B virus (HBV) nucleic acid that has
CC a mutation (i.e. alteration from the normal nucleotide in any of the
CC genotypes A to F) in at least two of the enhancer I region, the negative
CC regulatory element region, the enhancer II/ core upstream regulatory
CC sequence/ basal core promoter region, or a mutation which leads to an X-
CC peptide amino acid change to Cys or Met. The HBV variants of the
CC invention are used to detect binding interactions between host or viral
CC proteins and HBV nucleic acid. Probes that hybridise to any of the
CC specified mutated regions are used to detect HBV-related disease,
CC especially fulminant infection, but also severe chronic infection or
CC serologically unusual forms of disease. Combinations of the specified
CC mutations are associated with fulminant infections, probably because they
CC reduce the ability to bind inhibitory proteins in the host cell
XX
XX Sequence 1500 BP; 302 A; 416 C; 353 G; 427 T; 0 U; 2 Other;
SQ
Query Match 100.0%; Score 20; DB 2; Length 1500;
Best Local Similarity 85.0%; Pred. No. 9.3;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGCGCAGAGGT 20
DB 846 AGAGATGATTAGCGCAGAGGT 827

RESULT 50
AAV82693/c
ID AAV82693 standard; DNA; 1500 BP.
XX
XX AAV82693;
XX
XX 16-FEB-1999 (first entry)
XX
XX Fulminant hepatitis B virus genotype D variant HBVP3CSX sequence.
XX
XX Fulminant hepatitis B virus; variant; FHBV; HBV; binding interaction;
KW HBV-related disease; ss.
XX
XX Hepatitis B virus.
OS
XX W09845421-A2.
XX
XX 15-OCT-1998.
XX
XX 08-APR-1998; 98WO-EF002048.
XX
XX 09-APR-1997; 97GB-00007221.
```

```
XX (UNITU ) UNIV GLASGOW.
PA Carman B;
PI
XX WPI; 1999-009329/01.
XX
XX New hepatitis B virus nucleic acid with combination of specific mutations
PT - useful for, e.g. detection of binding interactions between host or
PT viral proteins and HBV nucleic.
XX
XX Disclosure; Fig 5; 85pp; English.
XX
XX The present sequence represents part of the genome of a fulminant
CC Hepatitis B virus (FHBV) genotype D variant, nucleotides 1000 to 2500.
CC The specification describes Hepatitis B virus (HBV) nucleic acid that has
CC a mutation (i.e. alteration from the normal nucleotide in any of the
CC genotypes A to F) in at least two of the enhancer I region, the negative
CC regulatory element region, the enhancer II/ core upstream regulatory
CC sequence/ basal core promoter region, or a mutation which leads to an X-
CC peptide amino acid change to Cys or Met. The HBV variants of the
CC invention are used to detect binding interactions between host or viral
CC proteins and HBV nucleic acid. Probes that hybridise to any of the
CC specified mutated regions are used to detect HBV-related disease,
CC especially fulminant infection, but also severe chronic infection or
CC serologically unusual forms of disease. Combinations of the specified
CC mutations are associated with fulminant infections, probably because they
CC reduce the ability to bind inhibitory proteins in the host cell
XX
XX Sequence 1500 BP; 314 A; 403 C; 343 G; 440 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 20; DB 2; Length 1500;
Best Local Similarity 85.0%; Pred. No. 9.3;
Matches 17; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGAGAUGAUUAGCGCAGAGGT 20
DB 846 AGAGATGATTAGCGCAGAGGT 827

Search completed: December 15, 2004, 15:38:58
Job time : 182 secs
```

**THIS PAGE LEFT BLANK**